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GBS Guillain–Barré syndrome NK Natural killer
GDP-Fuc Guanosine 5’ diphospho-fucose PDH Pyruvate dehydrogenase
GOS Galactooligosaccharide PDMS Polydimethylsiloxane
HCC Hepatocellular carcinoma PLA2 Phospholipase A2







HRP Horseradish peroxidase SCFA Short chain fatty acids
IBD Irritable bowel disease T1D Type 1 diabetes




Since the turn of the millennium, we have witnessed the emergence of synthetic biology as a field
which set the stage for transforming biotechnology and medicine. The tools developed have enabled
us to apply general engineering approaches to manipulate biological systems towards achieving
desired functions. In this work, we harness the programmability of microbes to understand the role
of prebiotic oligosaccharides.
Prebiotics are important glycans that shape the human gut microbiota from as early as, shortly
after birth. Human milk oligosaccharides (HMOs), found in breast milk, are naturally occurring
chemicals that selectively promote growth or activity in a microbial community. Given the ben-
efits of prebiotics, especially HMOs, there has been a lot of interest in replicating their function
by synthesizing them. Numerous approaches have been developed for their large-scale synthesis,
however, the structural analysis of glycans is challenging and is under steadily increasing demand.
The range of analytical techniques currently accessible to analyze glycans is limited by a lack of
suitable high-throughput techniques, relying mostly on chromatographic methods. Biological sys-
tems have enormous potential to solve many engineering problems, and synthetic biology provides
an attractive approach to harness this potential.
In this work, I first describe two platforms for the development of high-throughput, linkage-
specific screening of glycans. The first is based on a genetically engineered whole-cell biosensor,
which produces a response to lactose. I created a library of specific glycosidases that can trim com-
plex HMOs down to lactose and trigger a response. The second platform is based on an enzymatic,
paper-based assay for determination of the type of fucosylation and sialylation in glycans. The pa-
per device was developed with immobilized enzymes that was coupled to a colorimetric, redox assay
for rapid screening. This part of the work provides new techniques to enable a streamlined synthesis
process for HMOs with a significant reduction in analysis time of new producer strains. The second
xvi
platform paves the way for development of a glyco-barcode assay for rapid analysis of key glycosy-
lation patterns not only in biosynthesis platforms but also for diagnosis or monitoring disease states
in different biomarkers. The other focus of my thesis is directed towards manipulating engineered
microbial communities. Targeted biochemical modulation of microbiota can utilize prebiotics that
are designed to modulate microbial function or growth. Here, I demonstrated engineered bacte-
rial strains that, owing to selective utilization of HMOs, enabled growth-based selection in mixed
cultures. The dynamic regulation of growth and protein production in mixed culture models is
also demonstrated. We also illustrate chemical synthesis of bio-inspired novel inducer molecules for
orthogonal control of protein expression
With this work, the goal was to contribute towards expanding the glycobiology toolbox and help
elucidate the staggering complexity of glycans. The promises of the ability to engineer microbial
populations are immense in that we are living in symbiosis with bacteria, and their interactions
play roles that heavily impact human health. Taken together, these projects demonstrate a variety
of approaches for glycan analysis and utilization, taking inspiration from the denizens of the human
gut microbiome and suggests multiple avenues forward towards clinical and health impact.
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CHAPTER 1. INTRODUCTION
We have over 100 trillion microbial organisms living on and inside our bodies, working in concert
to maintain an ecosystem. The human gut represents a thriving ecosystem and the overarching
goal of my PhD work was to develop ways to deliberately manipulate this gut microbiome to en-
hance health using synthetic biology which has enormous potential to address challenges in health.
The first chapter of the dissertation introduces the concept of prebiotics and highlights some key
advantages, their mechanisms of action and the roles they play towards human health. Chapter
two covers genetically encoded whole cell biosensors that enable high-throughput, linkage-specific
detection of HMOs and enable dynamic regulation of growth and protein expression in mixed
populations. We leverage the unique specificity of glycosidase enzymes to create a synthetic in
vivo genetic circuit that allows non-chromatographic, high-throughput, glycosidic linkage-specific,
sensitive, and orthogonal detection of lactose-based HMOs. The third and fourth chapters look
at paper-based sensing for fucosylation and sialylation, keeping rapid, simple, low-cost real-time
detection, in mind. The assay platform allows analysis of hundreds of samples in minutes and
we anticipate that this rapid and simple analytical method will be extended towards developing
a universal glyco-barcoding platform for high throughput screening of glycosylation. The rest of
the thesis sheds light on the dynamics of microbial communities by studying properties of simpler
social interactions. Chapters four and five describe approaches for microbiome manipulations, a
shift towards understanding and engineering community-level interactions in mixed populations.
Finally, chapter six introduces chemically synthesized novel inducer molecules that were inspired by
biological mimics which can allow greater control over gene/protein expression and make orthog-
onal control more amenable in mixed populations. These studies can further allow us to exploit
interspecific interactions to optimize synthesis of chemicals or repurpose natural communities.
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2.1 Abstract
The human gut is an ecosystem comprising trillions of microbes interacting with the host. The
composition of the microbiota and their interactions play roles in different biological processes
and in the development of human diseases. Close relationships between dietary modifications,
microbiota composition and health status have been established. This chapter focuses on prebiotics,
or compounds which selectively encourage the growth of beneficial bacteria, their mechanisms of
action and benefits to human hosts. Synthesis technology for human milk oligosaccharides, part of
one of the most well-characterized prebiotic-probiotic relationships, is also reviewed here. Current
and future research in this area points to greater use of prebiotics as tools to manipulate the
microbial and metabolic diversity of the gut for the benefit of human health.
2.2 Introduction
The human gastrointestinal tract hosts an enormous population of microorganisms, bacteria,
archaea, and eukarya [1] (roughly 40 trillion cells [2, 3]. Although the gut microbiota has been
explored for centuries, only recently have correlations been made between the population of the
gut and human diseases [4], including Crohn’s disease [5], inflammatory bowel disease [6], cardio-
vascular disease [7, 8] and cancer [9, 10]. In addition to host genetics, the composition of the gut
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microbiome is influenced to a large extent by environmental factors including diet [11–16], espe-
cially in early life [17]. Given the connection between gut population dynamics and disease states,
strategies to alter microbiome composition have been developed including fecal transplants [18, 19],
introduction of consortia of or single beneficial microorganisms (also known as probiotics) [20, 21]
and purveyal of substrates to support growth of commensal microorganisms [22]. Metagenomic
approaches have revealed cosmic genetic diversity [14, 23–25], that gets colonized at birth [26],
gradually adjusting to a stable adult microbiome, albeit some perturbations [27, 28]. The tremen-
dous influence of the gut microbiota on human health and disease [4], in addition to the emergence
of high-throughput and low-cost sequencing [29–31], has prompted an ever-increasing number of
studies to improve understanding of the gut microbiome. The number of academic articles focusing
on gut microbiome/microbiota has increased from approximately 600/9,000 in 2008, to more than
19,000/160,000 in 2018 (Figure 2.1).
While it may not be surprising that the overall diet can affect the composition of the microbiome,
certain compounds, known as prebiotics, have been found to uniquely influence the growth of
beneficial microbes [32]. Prebiotic enrichment is not a new concept. The term ”bifidus factor” was
coined in the 1950s to account for the enrichment of beneficial Lactobacillus bifidus in infants [33].
Recently, a consensus definition was recently proposed by the International Scientific Association of
Probiotics and Prebiotics (ISAPP) as “a substrate that is selectively utilized by host microorganisms
conferring a health benefit.” [34]
The mechanisms of the benefit of prebiotics are manifold, but are essentially either direct (e.g.,
carbohydrate structures similar to host glycans can block adhesion to host cells [35]) or downstream,
encouraging the proliferation of bacteria whose metabolites directly affect the gut environment or
host gene expression (e.g., the effect of short-chain fatty acids on both gut pH and modulation
of immune function [36]). In this review, we describe the most common prebiotics, their role in
manipulating the microbiome and their downstream effects on human health, as well as strategies
for chemical and biotechnological synthesis of these important compounds.
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Figure 2.1 Accelerating progress in the study of the gut microbiota/microbiome. The
graph shows the cumulative number of journal articles with “Gut Microbiota”
or “Gut Microbiome” in the last 30 years from 1989 to 2019. Data obtained
from Google Scholar
2.3 Carbohydrate prebiotics
The accessibility of a carbon source is a major contributor to a microbe’s ability to produce
biomass [37, 38]. It follows, then, that microbial populations might change in response to changing
carbon sources based on each species’ ability to use those sources. Species from the two major bac-
terial phyla, Bacteroidetes and Firmicutes, have been identified that break down polysaccharides
and complex oligosaccharides [39, 40] including Bacteriodes thetaiotaomicron [41], Bacteroides cel-
lulolyticus [42] and Roseburia intestinalis [43]. Other mechanisms besides carbohydrate utilization,
like cross feeding [44] allow homogeneous bacterial populations to give rise to more diverse popula-
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tions where metabolites from one strain provide a niche for the other [45, 46]. Beneficial outcomes
from consumption of prebiotics are listed in table 2.1.
2.3.1 Human milk oligosaccharides (HMO)
Evidence from as early as the 1930s showed lower risk of morbidity or mortality due to enteric
disease in breast-fed infants [47]. In addition to lipids and sugars such as lactose that directly pro-
vide nutrition to infants, human breast milk is rich in biologically active compounds that exhibit
antimicrobial and immunomodulatory activities [48]. It also contains human milk oligosaccha-
rides (HMOs), carbohydrates which are not digestible by the infant but instead influence the gut
microbiome, which will be the main focus of this review.
The symbiotic relationship between human milk and beneficial bacteria is the result of 200
million years of co-evolution [49] and represents nature’s strategy for establishing a healthy human
infant microbiome. With the growing evidence of the beneficial functions that HMOs offer to
infants, various methods of synthesis have been devised. Before the advent of current synthesis
technology,alternative complex oligosaccharides such as fructans, galactans and phytochemicals
which can be sourced more readily and economically, from relatively more abundant resources.The
structures of prebiotics discussed in this review have been illustrated in Figure 2.1. Beneficial
outcomes from consumption of prebiotics listed in Table 2.1.
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Figure 2.2 Structural diversity of carbohydrate prebiotics. (A) Fructans: inulin is com-
posed of fructose units linked to each other by β-(2,1) bonds, found in many
plants (B) Galactans: GOS are composed of β-(1,6) linked galactose residues
with a terminal glu.cose or galactose at the reducing end that are produced
by enzymatic transgalactosylation of glucose, galactose, or lactose (C) Xy-
looligosaccharides, XOS are produced from xylan-rich lignocellulosic materi-
als, consisting of xylose residues linked via β-(1,4) linkages. Side groups such
as α-D-glucopyranosyl uronic acid, acetyl groups, or arabinofuranosyl residues
leads to branched XOS. (D) Mannan-oligosaccharides, MOS are composed of
β-1,4-linked mannose residues, derived from many plants and yeast cell walls.
(E) HMO blueprint and simple HMOs, all composed of a lactose core at the
reducing end. Lactose can be fucosylated or sialylated terminally or elongated
by lacto-N-biose (β-1,3-linked, type I) or N-acetyllactosamine (β-1,4-linked,
type II) structures. The structures pictured are (i) basic structure of HMOs,
(ii) 2′-fucosyllactose, (iii) 3-fucosyllactose, (iv) 6′-sialyllactose, (v) Lacto-N-te-
traose, (vi) Lacto-N-neotetraose.
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HMOs are the third most abundant component in human milk, after lactose and lipids, and
constitute a family of structurally diverse unconjugated glycans with a core lactose residue at the
reducing end, a backbone of alternating N-acetyl glucosamine and galactose, and/or other moieties
including fucose (α-1,2, α-1,3, or α-1,4 linked) or sialic acid (α-2,3 or α-2,6 linked) [50] (Figure 2.2E).
Human breast milk contains about 5–15 g/L of free oligosaccharides [35, 50]. Genome sequencing
of bifidobacteria such as Bifidobacterium longum subsp. infantis and other isolates revealed gene
clusters encoding glycosyl hydrolases and transporters [49] that allow them to consume HMOs as a
primary carbon source [82]. B. longum subsp. infantis, B. longum subsp. longum, B. breve and B.
pseudocatenulatum, internalize HMOs via ATP-binding cassette (ABC) transporters and hydrolyze
these oligosaccharides using intracellular glycosyl hydrolases [83]. This strategy protects the in-
fant by giving an ecological advantage to these bifidobacteria, preventing potential pathogens from
colonizing the gut [84]. Other species including B. bifidum and Bacteroides species secrete extra-
cellular hydrolases that break down oligosaccharides before the sugars are internalized. Sugars are
fermented to acetate, which can be converted to butyrate by obligate anaerobes [85] and is found
in higher concentrations in infants with healthy guts [86]. There are a few reported mechanisms
by which the proliferation of bifidobacteria helps in protecting infants from diseases like diarrhea
and necrotizing enterocolitis. Their unique mechanism of metabolizing HMOs is also accompanied
by improved binding to the intestinal mucosal layer [51]. A recent metagenomic study, The En-
vironmental Determinants of Diabetes in the Young (TEDDY), showed an overrepresentation of
bifidobacteria and the presence of HMO utilization genes in breastfed infants [87]. This data also
supported the protective effects of SCFAs in early-onset Type 1 diabetes (T1D), as was seen in
mice [88].
A major challenge in developing and utilizing HMOs for therapeutic purposes is the limited
supply of human milk and difficulty in isolation from other milk sources [89]. Thus, chemical and
biotechnological synthesis of HMOs has become a field of great interest, as outlined below.
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2.3.1.1 Chemical synthesis
The construction of complex carbohydrates is challenging due to the combined demands of elab-
orate procedures for glycosyl donor and acceptor preparation and the requirements of regio-and
stereoselectivity in glycosylation. They involve the preparation of selectively protected monosac-
charide units, one with a strategically positioned free hydroxyl group (a nucleophilic acceptor) and
one bearing a labile leaving group at the anomeric carbon that acts as a glycosyl donor in the
ensuing glycosylation reaction. The remaining hydroxyl groups need to be protected (1) to tune
the overall electronic properties of the donors and acceptors so that the donor–acceptor pair can
be matched and (2) for further deprotection and glycosylation or functional-group modifications
[90]. Chemoselective, orthogonal and iterative glycosylation strategies, which exploit differential
reactivities of anomeric leaving groups, allow several selected glycosyl donors to react in a specific
order resulting in a single oligosaccharide product [91]. Plante et al. devised a solid-phase synthesis
method that allows automated synthesis by framing the repetitive glycosylation and deprotection
into a coupling cycle [92]. By exposing the nucleophilic acceptor hydroxyl group on the solid
support to the glycosylating agent in solution, support-bound oligosaccharides can be produced.
Solid-phase synthesis eases purification but the complexity of protection-deprotection remains the
same and is accompanied by steric hindrance [93].
One-pot synthesis methods have been developed that involve multistep reactions performed in
a single setup, thus eliminating the need to isolate intermediates and shortening the experimental
time frame. Wang et al. developed a highly regioselective, combinatorial, orthogonal and one-pot
protection method that can aid in glycan synthesis using a single catalyst, which gives selectively
one isomer at each step [90]. The complex and dynamic nature of the glycans makes their syn-
thesis via traditional chemical methods challenging [94] and the numerous selective protection and
deprotection steps makes it tedious. This is exacerbated by the formation of a mixture of anomers
which would involve an additional separation step [95].
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2.3.1.2 Enzymatic/chemoenzymatic synthesis
Biocatalytic approaches avoid some of the challenges faced in chemical synthesis. The use of
enzymes as catalysts means regioselectivity and stereospecificity are better controlled and there
are fewer steps involved, making the process cost effective and less time consuming [94, 95]. Two
different enzymatic approaches can be taken: (1) Glycosyltransferase catalyzed synthesis, which
requires sugar nucleotides or sugar-1-phosphates as donors, and (2) Glycosidase-catalyzed synthesis.
These enzymatic methods for synthesis involve either isolation or recombinant production the
synthesis enzymes [96]. The substrates for the glycosyltransferasesare nucleotide sugars (e.g., UDP-
glucose) and require an acceptor for the transfer of the glycosyl residue. The glycosidase-catalyzed
pathway involves the transfer of an enzyme-bound glycosyl residue to an acceptor (water, in the
absence of an organic compound). Enzymatic solid-phase synthesis combines advantages of enzy-
matic synthesis with the ease of purification that comes with solid-phase methods [97]. One-pot
synthesis methods require protection of groups only during building block synthesis which is in the
order of increasing reactivity [98].
To build more complex HMO structures of varying lengths, linkages or branching, a chemoen-
zymatic strategy is more desirable, in which a chemically synthesized acceptor is further modified
via enzymatic steps. A one-pot multienzyme approach was used to synthesize lacto-N-neotetraose
in two steps via azido alkyl-lactoside using glycosyltransferases and this strategy was reiterated
to synthesize sialyl-and fucosyl-derivatives [99]. Another approach is to synthesize an acceptor
with a cleavable anomeric linker to allow for purification of reaction intermediates [100]. After the
enzymatic extension is complete, the linker can be hydrolyzed to give oligosaccharides with a free
reducing end. A solid phase strategy was used to synthesize sialylated HMOs, which is generally
challenging due to steric hindrance and reduced reactivity of the position. Fair et al. overcame this
using automated solid phase assembly of the glycan backbone followed by enzymatic sialylation




New strategies for oligosaccharide production have been developed using metabolically engi-
neered microbes. This approach has brought down the cost of synthesis of glycans significantly
since they do not require the overproduction and isolation of the glycosyltransferases and ex-
pensive precursors and have high production titers [102]. Several workhorse microbes have been
used as hosts, mainly dependent on the commercially availability of the expression vector and the
ease of manipulation. Escherichia coli has been the host of choice but species that are naturally
evolved to regenerate sugar nucleotides reduces a number of steps taken to genetically modify cer-
tain pathways. Lactose has commonly been used as the sugar acceptor. Saccharomyces cerevisiae,
carrying plasmids expressing the human β-1,4-galactosyltransferase gene, were used to success-
fully produce LacNAc from GlcNAc and UDP-Gal [103]. Ruffing et al. successfully engineered
Agrobacterium sp. to synthesize galactose-core oligosaccharides by exploitingthe UDP-galactose
regeneration system [104]. E. coli and Corynebacterium ammoniagenes strains have been used
to synthesize N-acetyllactosamine, 3′-sialyllactose and Lewisx structures. E. coli strains over-
expressing CMP-NeuAc synthetase and CTP synthetase genes were used to produce cytidine 5’
monophospho-N-acetylneuraminic acid (CMP-NeuAc). The production of this nucleotide sugar
donor coupled with the overexpression of the α-(2,3)-sialyltransferase gene of Neisseria gonor-
rhoeae and coupling with C. ammoniagenes that forms UTP from orotic acid resulted in high titer
production of 3′-sialyllactose [105].
2′-Fucosyllactose (2′-FL) is the most abundant oligosaccharide in human milk [106] and has
been shown to offer protection against pathogens including Campylobacter jejuni [107]. Scientists
have developed different biosynthetic pathways in E. coli to produce 2′-FL [108, 109]. The de
novo pathway transforms mannose-6-phosphate to GDP-L-fucose. They cloned and chromosomally
integrated recombinant α-(1,2)-fucosyltransferase (FutC) from Helicobacter pylori and genes from
the GDP-L-fucose de novo pathway into E. coli. With the addition of the salvage pathway, the
intracellular GDP-L-fucose concentration was controlled via FucP using extracellularly added L-
fucose. This resulted in a 10 times higher yield and a final 2′-FL concentration of 20 g/L. Earlier,
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another group produced 2′-FL using two expression plasmids where glycosylation was achieved
by the N. meningitidis lgtAB genes [110]. Recently, Yu et al. demonstrated production of 2′-FL
in engineered S. cerevisiae via the salvage pathway to produce 2′-FL using L-fucose and lactose
[111]. Although 3-FL can be synthesized by a similar approach using α-1,3-fucosyltransferase, its
poor expression results in very low titers. Yu et al. engineered it by removing the membrane-
binding region and elongating the heptad repeats to achieve a 10–20-fold increase in 3-FL titer
[111]. Priem et al. expressed the β-1,3 N-acetylglucosaminyltransferase lgtA gene and the β-1,4
galactosyltransferase lgtB gene of N. meningitidis in E. coli and by sequential reactions produced
Lacto-N-triose (GlcNAcβ-1-3Galβ-1-4Glc) and Lacto-N-neotetraose (Galβ-1-4GlcNAcβ-1-3Galβ-1-
4Glc). They also produced 3′ sialyllactose by inactivating the nanA gene which encodes an aldolase
and by exogenous addition of sialic acid [112].
More recently, Guo et al. demonstrated synthesis of 6′-sialyllactose, using a unique trans-
sialidase to transfer a sialyl residue to lactose by transglycosylation, with high transglycosylation
activity and strict regioselectivity [113]. In glycosidase-catalyzed synthesis, there is typically com-
petition between transglycosylation and hydrolysis, which can be improved by employing higher
acceptor/donor ratios that increase the probability of nucleophilic attack by the acceptor on the
enzyme to form a glycosyl-enzyme intermediate. Zeuner et al. engineered an α-1,3/4-L-fucosidase
to completely remove its hydrolytic activity and improved the transfucosylation activity to achieve
3-fold higher yields in their fucosylated product [114].
Excellent reviews covering the recent developments in synthesizing galactose-containing oligosac-
charides [115] and regarding commercialization and regulatory framework [116] can be found. Figure
2.3 exemplifies engineered metabolic pathways for synthesis of common HMOs.
2.3.2 Fructans: Inulin and Fructooligosaccharide (FOS)
Inulin, a polysaccharide abundant in commercial plant sources such as chicory and agave, is
a polydisperse β-(2,1) fructan with the fructose units linked to each other by β-(2,1) bonds, with
a degree of polymerization (DP) ranging from 2 to 60 [117] (Figure 2.2A). Each fructose chain is
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capped by a terminal α-(1,2) linked glucose molecule. Fructooligosaccharide (FOS) is composed of
shorter-chain oligomers, with a DP between 2-10, which can be produced by hydrolysis of inulin
using endoinulinase. The prebiotic property of inulin is derived from its β-(2,1) linkages that remain
indigestible. Their selective fermentation by bifidobacteria that produce an intracellular inulinase
to hydrolyse the β-(2,1) fructose linkages, allows for the modulation of the composition of the gut
microbiota [118]. Fructans are widely used as additives in food for their health boosting properties,
especially in conjunction with probiotics, for a synergistic “synbiotic” effect [119]. Their physio-
logical effects are dictated by their chain length, as shown by a study where FOS was fermented
more rapidly and produced more butyrate compared to inulin [120]. In a simulated microbial en-
vironment seeded with fecal samples, supplementation of inulin resulted in increased Bacterioides
uniformis or Bacterioides caccae [121].
2.3.3 Galactans: Galactooligosaccharide (GOS)
GOS are composed of galactose residues with a terminal glucose or galactose at the reducing
end (Figure 2.2B). Commercially, GOS are produced by enzymatic transgalactosylation of glucose,
galactose, or lactose attached via β-(1, 2, 3, 4, or 6) linkages, with a DP of 2-8. GOS utilization is
dependent on the linkage specificity of the β-galactosidases. Studies have shown the dose-dependent
increase in fecal bifidobacteria infants and increased SCFA levels upon fermentation [122–124].
GOS has been widely used in infant formula and other confectioneries and beverages [125, 126] and
together with commercially available probiotic bifidobacteria and lactobacilli [127].
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Table 2.1 Prebiotic effects on health
Prebiotic Effect on health References
Oligosaccharides HMO Anti-inflammatory effect, regulation of
permeability of host cells, protection
from diarrhea, necrotizing enterocolitis
andrespiratory tract infections
(Bode, 2012[50];
Chichlowski et al., 2012[51];
Newburg and Walker,
2007[52]; Weng et al.,
2014[53]; Zenhom et al.,
2011[54])
FOS Anti-inflammatory effect, improve IBS
symptoms, lower blood glucose level,
anti-cancer, diarrhea treatment, re-
duces atopic dermatitis
(Lewis et al., 2005[55]; Moro
et al., 2006[56]; Paineau
et al., 2008[57]; Pourghas-
sem Gargari et al., 2013[58];
Zenhom et al., 2011[54])
Inulin Improves bowel function, increased bi-
fidobacteria population, lower serum
lipopolysaccharide level, immunomod-
ulatory action, increased mineral ab-
sorption, cardiovascular effects, anti-
cancer
(Costabile et al., 2010[59];
Dewulf et al., 2013[60]; Fer-
nandes et al., 2017[61]; Klin-
der et al., 2004[62]; Propst
et al., 2003[63]; Trautwein
et al., 1998[64]; Vandeputte
et al., 2017[65]; Vogt et al.,
2015[66])
GOS Immunomodulatory action, pathogen
adherence inhibition, improve IBS
symptoms, reduces atopic dermatitis
(Fernandes et al., 2017[61];
Moro et al., 2006[56]; Quin-
tero et al., 2011[67]; Silk et
al., 2009[68])
MOS Lowers IBS, increased expression of
pro-inflammatory mediators, lower
proinflammatory cytokines, prevent
binding of pathogenic bacteria to host
cells
(Ferenczi et al., 2016[69];
Ofek and Beachey, 1978[70])
XOS Immunomodulatory action, increased
plasma HDL concentration, anti in-
flammatory effect, reduction in triglyc-
erides, lower dose requirement for clin-
ical efficacy, anti-cancer
(Hansen et al., 2013[71];
Hsu et al., 2004[72]; Rastall
and Gibson, 2015[73]; Sav-
ille and Saville, 2018[74];
Whistler et al., 1976[75])
Phytochemicals Phenolics Decreased visceral obesity, improve in-
sulin sensitivity, anti-inflammatory ef-
fect, pathogen inhibition, anticancer
properties, antioxidant activity, in-
creased fatty acid oxidation
(Anhê et al., 2015[76];
Huang et al., 2008[77];
Mahady et al., 2003[78];
Shimoda et al., 2009[79];
Thilakarathna et al.,
2018[80]; Youn et al.,
2005[81];)
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Figure 2.3 Engineered metabolic pathways for the production of fucosyllactose, sialyllactose
and lacto-N-triose. Lactose, L-fucose and sialic acid are transported into the
cell by specific permeases LacY, FucP and NanT. Glycerol serves as the car-
bon/energy source. Molecules and enzymes have been abbreviated as: Glc,
D-glucose; Gal, D-galactose; L-Fuc, L-fucose; Neu5Ac, sialic acid; Lac, Lac-
tose; GDP-4k-6d-Man, GDP-4-keto-6-deoxymannose; GDP-Man, GDP-D-mannose;
ManNAc, N-Acetylmannosamine; UDP-GlcNAc, Uridine diphosphate N-acetylglu-
cosamine; 2′-FL, 2′-fucosyllactose; 6′-SL, 6′-sialyllactose; LNT2; lacto-N-triose II;
Lacy, lactose permease; LacZ, β-galactosidase; FucP, fucose permease; WcaG,
GDP-fucose synthase; GlpF, glycerol MIP channel; ManB, phosphomannomutase;
ManC, mannose-1-phosphate guanylyltransferase; Gmd, GDP-mannose 4,6-dehy-
dratase; FutC, α-1,2-fucosyltransferase; ST6Gal, β-galactoside α-2,6-sialyltransferase;
lgtA, N-acetylglucosaminyltransferase; glmS, glutamine-fructose-6-phosphate amino-
transferase; glmM, phosphoglucosamine mutase; glmU, N-acetylglucosamine 1-phos-
phate uridyltransferase; neuC, UDP-N-acetylglucosamine 2-epimerase; neuB, N-acetyl




XOS are produced from xylan-rich lignocellulosic materials, consisting of xylose residues linked
via β-(1,4) linkages with a DP between 2-10 (Figure 2.2C). Depending on the source, XOS are
usually accompanied by other side groups such as α–D–glucopyranosyl uronic acid, acetyl groups,
or arabinofuranosyl residues, whose presence results in branched structures [128]. Studies showed
the selective ability of certain probiotic strains, Bifidobacterium adolescentis and Lactobacillus
plantarum to utilize XOS owing to the presence of xylanolytic enzyme systems [129, 130]. Compared
to other prebiotic substrates, including FOS, GOS and MOS, XOS produced the largest amount
of SCFA upon degradation by fecal microbiota of pigs [131]. There is direct experimental evidence
for the prebiotic efficacy of XOS in humans, including increased proportion of bifidobacteria [132]
and SCFA levels [133].
2.3.5 Mannan-oligosaccharide (MOS)
MOS are oligomers composed of mannose residues, linked together by β-1,4 glycosidic bonds,
with a DP in the range 2-10 (Figure 2.2D). Derived from yeast cell walls, MOS has been widely used
to improve growth and health performance of livestock and aquaculture [134]. Supplementation
of MOS to chicken feed reduced Clostridium perfringens and E. coli, and increased the relative
population of Lactobacillus [135]. Bacterial genera such as Bacteroides and Bacillus produce man-
nanases that can cleave β-1,4 mannopyranoside in mannan products. MOS has been shown to
bind to mannose specific lectins expressed in bacteria with fimbriae and hence, reduces bacterial
adhesion to mannose-containing glycoprotein receptors on intestinal epithelial cells [70].
2.4 Mechanism of action of prebiotics
While prebiotics can manipulate the bacterial population, they can also benefit the host via
gut environment through direct interactions with potential pathogens and/or the immune system.
Figure 2.4 summarizes the proposed mechanisms of prebiotic action.
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Prebiotics are capable of interacting with the carbohydrate receptors on immune cells. Receptors
on phagocytes and natural killer (NK) cells can be activated by binding of β-glucans that triggers
neutrophil phagocytosis [136]. Glucans are a heterogeneous group of glucose polymers, composed
of a backbone of β-(1,3)-linked β-D-glucopyranosyl units with β-(1,6)-linked side chains. Dectin-1,
a NK-cell-receptor-like C-type lectin [137], was identified as a macrophage receptor for β-glucans,
eliciting antitumor and antimicrobial activity [138]. Inulin-type fructans are also receptors for gut
dendritic cells (DCs), via Toll-like receptors, C-type lectin receptors, and galectins, that induce
anti-inflammatory cytokines [66]. The activity of HMOs against bacterial and viral infections can
be explained by their absorption from the GI tract into the system and serving as receptors for
bacterial or viral adhesion molecules [139].
Another mechanism by which prebiotics promote health is by promoting the production of
metabolites, e.g., folate, indoles, secondary bile acids, trimethylamine-N-oxide (TMAO) and short
chain fatty acids (SCFAs), through fermentation of the prebiotic compounds [4]. The gut microbiota
are endowed with plethora of glycoside hydrolases and polysaccharide lysases that are capable of
breaking down the indigestible carbohydrates that traverse intact all the way to the distal gut
[140]. It is the fermentation of these carbohydrates that produces SCFAs. These SCFAs can be
transported across the intestine and into the systemic compartments, affecting the immune system.
The SCFAs, acetate, propionate and butyrate in particular, showcase antimicrobial activity, lead to
the lowering of pH in the gut, and heavily impacting the host metabolism and immunity, including
from food and self-antigens [32, 141–143]. SCFAs also inhibit histone-deacetylase (HDAC) activity
that affects gene transcription [144]. SCFAs can also bind to G-coupled protein receptors on
leukocytes. Butyrate serves not only as a carbon source for colonic cells and hence helping to
maintain a healthy gut barrier but also aids in maintaining the anaerobic conditions inside the gut
[145, 146]. One study reported downregulation of inflammatory cytokines upon treatment with
propionate but no effect with XOS indicating the indirect SCFA-mediated anti inflammatory effect
[71].
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Another outcome of prebiotic treatment is the selective increase/decrease in specific intestinal
bacteria that in turn, can induce health benefits. Early studies showed the growth advantage of
bifidobacteria over E. coli and Clostridium spp. that cannot utilize XOS, leading to the predom-
inance of bifidobacteria population [129]. Treatment with FOS was also associated with higher
intestinal bifidobacteria counts in another study [72]. These bifidobacteria can digest XOS and
FOS to produce lactate and SCFAs. One study showed that the gut microbial composition is
a key player in energy homeostasis and hence towards obesity [147]. It was hypothesized that
the Firmicutes-enriched cecal microbiota (relative to Bacteroidetes-enriched microbiota) promoted
obesity by limiting energy uptake/storage.
2.5 Role of prebiotics in human health
The gut microbiota has been considered as an organ, constituting multitudes of cells and per-
forming various functions in the human body. Prebiotics have a profound effect in modulating
the gut microbiota, and hence a concomitant effect on human health. With increasing number of
pre-clinical studies underway supporting the benefits of prebiotics, they are becoming an attractive
therapeutic target for the prevention and treatment of human diseases.
2.5.1 Immunomodulation
Prebiotics may affect the immune system, either directly or indirectly via metabolites produced
through fermentation or probiotic-mediated modulation of gene expression. β-glucans interact with
cell surface receptors to induce macrophages and NK cells which can also lead to inhibition of
tumor growth in its promotion stage [148]. HMOs have shown to directly affect the development
of the neonatal immune system. They stimulate production of cytokines and proliferation of im-
mune cellular population [149]. In elderly adults, GOS was shown to increase phagocytosis, NK
cell activity and production of anti-inflammatory cytokines and a decrease in the production of
proinflammatory cytokines [150]. HMOs containing sialic acid moieties were shown to inhibit the
binding of rotavirus to host cells, directly affecting immune activity in rotavirus-infected neonates
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[151]. Several studies showed that mice exposed to inulin enriched with oligofructose, raffinose or
FOS had enhanced production of cytokines [152–154]. HMOs also exhibit anti-adhesive properties
against pathogenic bacteria and toxins, preventing attachment to epithelial cells [155].
2.5.2 Irritable bowel syndrome (IBS)
Irritable bowel syndrome (IBS) is a common functional disorder characterized by abdominal
discomfort and pain, bloating and an alteration in bowel habit [156]. Studies have shown that
soluble fibers in partially hydrolyzed guar gum can alleviate abdominal pain and improve bowel
habits [157]. Another study showed a decrease in digestive discomfort in patients given FOS [57].
GOS was also shown to significantly improve IBS symptoms [68].
2.5.3 Irritable bowel disease (IBD)
The two main types of IBD being ulcerative colitis and Crohn’s disease. Crohn’s disease usually
affects the intestine and causes inflammation that affects the body’s ability to digest food, absorb
nutrients and eliminate waste. Ulcerative colitis mainly affects the lining of the large intestine and
rectum and chronic colitis can lead to colon cancer. IBD is associated with increased levels of the
proinflammatory cytokines interleukin-1 (IL-1), IL-6, IL-8, and tumor necrosis factor α(TNF-α)
[158]. Treatment with inulin and oligofructose was shown to reduce inflammation in rat models
with colitis [159]. Reduced severity of DSS-induced colitis was also observed by another study
under treatment with a combination of inulin/oligofructose and B. infantis [160]. Consumption of






















































































































































































































































































































2.5.4 Mental health or neurological disease
The gut-brain axis has emerged as an exciting concept in science. This crosstalk between the
gut and brain is mediated by the vagus nerve [161]. There has been evidence that shows the ability
of the gut microbiota to communicate with the brain and modulate behavior by activating neural
pathways and central nervous system (CNS) signaling systems [162]. Treatment with XOS was
shown to reduce effects from pro-inflammatory cytokines in the brain [163]. Long-term consumption
of XOS diminished activation of microglia and restored cognitive function in obese rats [164].
Chronic supplementation of FOS/GOS exhibited both antidepressant and anxiolytic effects and also
reduced stress-induced corticosterone release by modifying gene expression in the hippocampus and
hypothalamus in mice [165]. Similarly, significant decrease in anxiety was observed in in animals
treated with MOS [69].
2.5.5 Cardiovascular disease
Cardiovascular diseases are associated with high levels of cholesterol and/or triglycerides [166].
Studies in rats with prebiotic fiber demonstrated a significant decrease in serum cholesterol levels
[167]. Consumption of XOS by rats also showed a decline in the level of triglycerides [72]. Other
studies have reported the reduction in cholesterol on consumption of FOS in diabetic subjects [168]
and improvement in lipid profiles with inulin [169]. Propionate, produced by prebiotic fermentation,
also lowers serum cholesterol levels and inhibits expression of the genes associated with intestinal
cholesterol biosynthesis [170].
2.5.6 Cancer
Numerous studies have identified prebiotics exhibiting anticancer properties [80, 171, 172]. Pre-
biotics can achieve this owing to their mechanisms of actions described earlier. Non-digestible
polyphenols have the ability to alter the gut microbiota population, favoring strains capable of
breaking down polyphenols, e.g., Bifidobacterium and Lactobacillus spp., and producing simple
phenolic metabolites. These metabolites can modulate enzyme and gene expression, e.g., phenolic
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residues like coumaric and caffeic acid produced by degradation of polyphenolics suppressed the
histone-deacetylase activity in human colon cancer cells [173]. Butyrate was also reported to sup-
press cancer by inducing apoptosis in cancer cells and limiting histone deacetylase activity [174].
Microbial metabolites of quercetin and caffeic acid lowered the DNA damage in human adenoma
cells by regulating enzymes involved in detoxification and inflammation [175]. XOS and FOS were
shown to inhibit colonic aberrant crypt foci in rats by lowering cecal pH and serum triglyceride
levels [176]. It has also been proposed that absorption of micronutrients helped alleviate cancer
risks. Consumption of inulin, FOS, GOS was shown to increase the solubility of minerals and hence
enhance their absorption [177].
2.6 Conclusions
Significant progress has been made over the past few decades in recognizing the importance
of gut microbiota to overall health. Going forward, armed with new tools and innovative ap-
proaches, opportunities still exist to allow scientists to further elucidate the mechanisms involved.
Realization of the properties and benefits of prebiotics offer a new dimension for the development
of functional foods and new treatment strategies for therapeutic targeting of the gut microbiota.
However, further investigations are needed to elucidate the mechanisms involved in the treatment
of diseases and confirmed with experimental models and clinical trials before prebiotics can be used
as a potential therapeutic. In this review, we focused only on carbohydrate-based prebiotics but
more recent studies have shown the prebiotic effects of other molecules including phytochemicals.
Phytochemicals are bioactive non-nutrient plant compounds shown to exhibit selective stimula-
tion of the gut microbiota [178]. Polyphenols, for example, are not absorbed and reach the colon
where they undergo metabolic transformations through the gut microbiota: fission of cyclic rings,
deglycosylation, ester hydrolysis, and these metabolites are absorbed by the body [179]. These
phytochemicals have been reported to lower risks of major chronic diseases, including hyperten-
sion, diabetes, neurodegenerative diseases and cancer [180]. Further studies need to be carried out
to better understand their mechanisms and elucidate their benefits to host health.
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Engineering strategies to develop tools for the enrichment of the gut microbiota are evolving
and custom-designed prebiotics is another area that needs further exploration, to better understand
their effects on immunomodulation and interactions with pathogenic microbes. With the current
large-scale synthesis routes, elaborate biological investigations can be carried out. We still need to
understand the effects all components of the microbiota including the spectrum of fungi, archaea,
bacteriophages and viruses. The approach of coupling prebiotics and probiotics (as synbiotics), still
has untapped capabilities toward influencing and improving human health.
Another exciting development in this area is the creation of engineered bacteria capable of pro-
ducing metabolites, peptides, or proteins that benefit the host, i.e., live biotherapeutics [181–184].
As development of these engineered probiotic organisms continues, it follows that strategies for
controlling their population dynamics will be essential for optimizing their efficacy. Two recent
studies have approached this topic by creating orthogonal niches for bacteria via diet-based inter-
vention [185, 186]. Essentially, prebiotics that can only be consumed by the species of interest can
uniquely and reversibly upregulate that species in the gut. As we understand more fully the biology
of prebiotics and their relationship to the dynamics of the gut microbiome and metabolome and
workings of the human body, we will be better positioned to take more sophisticated approaches
to shaping the microbiota for better health.
The first chapter of the dissertation introduces the concept of prebiotics and highlights some
key advantages and their mechanisms of action. Chapter two covers genetically encoded whole cell
biosensors that enable high-throughput, linkage-specific detection of HMOs and enable dynamic
regulation of growth and protein expression in mixed populations. The third and fourth chapters
look at paper-based sensing, keeping rapid, simple, low-cost real-time detection, in mind. Chapters
four and five describe approaches for microbiome manipulations, a shift towards understanding
and engineering community-level interactions in mixed populations. Finally, chapter six introduces
chemically synthesized novel inducer molecules that were inspired by biological mimics.
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Quintana, Federico Argüelles, Katharina E Scholz-Ahrens, Günther Sawatzki, Richard Ze-
lenka, Jürgen Schrezenmeir, Michael de Vrese, and Enrico Bertino. Galacto-oligosaccharides
are bifidogenic and safe at weaning: a double-blind randomized multicenter study. J. Pediatr.
Gastroenterol. Nutr., 48(1):82–88, January 2009.
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CHAPTER 3. LINKAGE-SPECIFIC DETECTION AND METABOLISM OF
HUMAN MILK OLIGOSACCHARIDES IN ESCHERICHIA COLI
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3.1 Abstract
Human milk oligosaccharides (HMOs) are important prebiotic complex carbohydrates with
demonstrated beneficial effects on the microbiota of neonates. However, optimization of their
biotechnological synthesis is limited by the relatively low throughput of monosaccharide and link-
age analysis. To enable high-throughput screening of HMO structures, we constructed a whole-cell
biosensor which uses heterologous expression of glycosidases to generate linkage-specific, quantita-
tive fluorescent readout for a range of HMOs at detection limits down to 20 µM in approximately 6
hours. We also demonstrate the use of this system for orthogonal control of growth rate or protein
expression of particular strains in mixed populations. This work enables rapid non-chromatographic
linkage analysis and lays the groundwork for the application of directed evolution to biosynthesis
of complex carbohydrates as well as the prebiotic manipulation of population dynamics in natural
and engineered microbial communities.
3.2 Introduction
Human milk is the initial sole source of nutrition for many infants. In addition to its nutri-
tive protein, fat, and carbohydrate content, it is highly abundant in unique oligosaccharides that
comprise 5 to 15 g/L [1] or 20% of its carbohydrate content [2]. These human milk oligosaccha-
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rides (HMOs) are indigestible by the infant but play many roles in the infant gut. For example,
gut bacteria capable of cleaving glycosidic linkages [3, 4] can metabolize these carbohydrates into
organic acids such as butyrate and acetate which lowers the intestinal pH, providing important
energy sources for colonocytes [5]. In addition, HMOs bind pathogens by acting as decoys and
inhibit adhesion to the intestinal epithelial surface, protecting breast-fed infants against diarrhea-
causing pathogens [6–9]. HMOs have recently been shown to affect infant body mass [10], Candida
albicans invasion in the infant gut [11], attenuation of inflammation in the intestine [12], and the
overall microbial makeup in the gut environment [13]. Given the interesting benefits that these
oligosaccharides confer on infants, especially preterm [14], a plentiful and inexpensive supply of
these carbohydrates would be of great benefit to neonatal health. However, the nature of sugars,
especially the prevalence of multiple hydroxyl groups, makes synthesis of these compounds difficult.
HMOs typically have a degree of polymerization from 3 to 10 monosaccharides with a lactose
(Gal-β-1,4-Glc) core at the reducing end. They are generally modified by the addition of fucose (α-
1,2-, α-1,3- or α-1,4- Fuc), sialic acid (N-acetylneuraminic acid) (α-2,3- or α-2,6- Sia), or glycosidic
linkages (β-1,3- or β-1,6-) to other lactose or N-acetyllactosamine precursors. The most abundant
HMOs are 2’-fucosyllactose, 3-fucosyllactose, lacto-n-fucopentaose I, and, 3’-sialyllactose [15–17].
Examples of some HMO trisaccharides can be found in Figure 3.1A.
Various chemical and chemoenzymatic synthesis methods of HMOs have been reported [18–
23]. However, these approaches often require rigorous protection-deprotection schemes or purified
components such as activated nucleotide sugars and robust enzymes, both of which can be rather
expensive to produce. Because of these limitations, biotechnological approaches for in vivo pro-
duction of HMOs in microbes has garnered attention owing to its scalability and cost effectiveness
[24].
Metabolic engineering of microbial strains has been used to produce complex carbohydrates in
vivo [25]. Successful examples of this approach are the production of various human milk oligosac-
charides [26, 27], blood groups [28], eukaryotic N-glycans [29–31], and pathogen-mimicking glycans
[32–34]. While metabolic engineering in microbes [1, 26, 35, 36] has shown promise, optimization
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of glycan production is limited by the low throughput of detection. These glycan structures can be
extremely diverse because glycosidic bonds between monosaccharides can form at many different
points on the sugar, leading to branching based on glycosidic linkage, and identifying these linkages
is not straightforward, especially α- or β-anomeric configuration. NMR [37, 38], mass spectrometric
methods (reviewed in [39]) or profiling of enzyme digests which leverages the specific affinity of en-
zymes for particular sugars and linkages, breaking down the glycan followed by a chromatography
step for quantification [40]. An even more coarse-grained method of detecting sugar composition is
acid hydrolysis of glycans with trifluoroacetic acid followed by quantitation by LC/MS [41]. More
recently, high pH anion-exchange chromatography (HPAEC-PAD) [42, 43], polysaccharide analysis
by carbohydrate gel electrophoresis (PACE) [44] and capillary electrophoresis with laser-induced
fluorescence (CE-LIF) [45] have become well established. While recent interest in glycomics has
led to improvements in throughput of chromatographic/mass spectrometric methods [46], their
maximum throughput is on the order of hundreds of samples per day without automation [47]. In
addition, they also often require specialized equipment and expertise in analysis as well as sample
derivatization. Substantially increased throughput of detection of these glycan moieties and link-
ages would enable approaches such as directed evolution [48–50] towards improved production of
glycans.
In the synthetic biology community, engineering of genetic circuits has generated cellular de-
vices that can sense and translate to a quantifiable biological response, with practical applications in
biosensing, therapeutics and production of small molecules and biofuels [51, 52]. Bacterial biosen-
sors have been successfully developed for the detection of toxic chemicals, pollutants, drugs, and
antibiotics [53–61].
Here, we present the construction of a synthetic in vivo genetic circuit that can serve as a
platform for detecting lactose-based HMOs. Briefly, the method uses heterologous expression of
glycosidases highly specific to human milk oligosaccharide carbohydrate linkages to generate lactose,
the presence of which is detected by the lac operon. We demonstrate non-chromatographic, linkage-
specific, sensitive, and orthogonal detection of ten of the most abundant trisaccharide HMOs using
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this engineered Escherichia coli biosensor. We also show that HMOs can be quantitatively detected
in the context of biotechnological production. In addition, we show that our engineered cells can
utilize HMOs as sole carbon sources, mimicking their prebiotic effect and serving as a growth-based
selection. We also demonstrate that crosstalk between strains expressing different glycosidases is
minimal, demonstrating the capacity to detect distinct HMOs in parallel. Finally, we demonstrate
the regulation of growth and protein expression of engineered strains in mixed culture using HMOs
as inducers. Taken in total, this work represents a robust system for massively parallel optimization
of biotechnological production of human milk oligosaccharides and HMO-based dynamic regulation
of growth and protein production in mixed cultures.
3.3 Experimental Methods
A more detailed methodology can found in Appendix B which was adapted from a protocol
published in the Journal of Visualized Experiments (JoVE) [62].
3.3.1 Bacterial strains and plasmids
The plasmids and strains used in this study are listed in Table 3.1. E. coli NEB 5-alpha
and NEB 10-beta (New England Biolabs Inc., Ipswich, MA) were used for routine cloning and
E. coli BL21 (DE3) was used for oligosaccharide detection and growth experiments. The plasmid
pET28:GFP was a gift from Matthew Bennett (Addgene plasmid # 60733). pET28:GFP is the
pET28b expression vector with GFP downstream of the T7-specific promoter PT7/LacO, which
contains binding sites for the lactose repressor, LacI [63]. Plasmid pET28:mCherry was constructed
via Gibson Assembly using mCherry DNA amplified from plasmid pHL1277. The plasmid pHL 1277



































































































































































































































































































































Table 3.1 Plasmids and strains in this study
REAGENT or RESOURCE SOURCE IDENTIFIER
Bacterial and Virus Strains
NEB 5-alpha Competent E.coli New England Bi-
olabs
Catalog #C2987I
NEB 10-beta E.coli New England Bi-
olabs
Catalog #C3019I
BL21 (DE3) E.coli New England Bi-
olabs
Catalog #C2527I






JM109 gwBC-F2 (Baumgärtner et
al., 2013a)
N/A
JM109 gwBC (Baumgärtner et
al., 2013a)
N/A
Chemicals, Peptides, and Recombinant Proteins
2’-Fucosyllactose Carbosynth CAS #41263-94-9
3-Fucosyllactose Carbosynth CAS #41312-47-4
3’-Sialyllactose sodium salt Carbosynth CAS #128596-80-5
6’-Sialyllactose sodium salt Carbosynth CAS #157574-76-0





Neuraminidase Assay Kit Sigma-Aldrich MAK121-1KT
L-Fucose Assay Kit Megazyme K-FUCOSE
Oligonucleotides
See Table S.2.4 This study N/A
Recombinant DNA
pET28:GFP donated by Matthew
Bennett
Addgene Plasmid #60733
pHL 1277 donated by Han Lim Addgene Plasmid #53017
pET28:mCherry This study N/A
pAfcA This study N/A
pAfcB This study N/A
pNanH This study N/A
pNanH2 This study N/A
pYebF-NanH2 This study N/A
pBnaG This study N/A
Software and Algorithms
SAS version 9.4 SAS institute https://www.sas.com/en us/home.html
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Plasmid pAfcA was constructed by DNA synthesis of an operon comprising a promoter, ri-
bosome binding site, signal sequence, and glycosidase open reading frame which was cloned into
plasmid pG9m-2 by Gen9 (Cambridge, MA). Promoter J23110 from the Anderson promoter col-
lection and Shine-Dalgarno sequence (BBa J34801) were chosen as a strong constitutive promoter
and ribosome binding site from the Registry of Standard Biological Parts (http://parts.igem.org).
To facilitate periplasmic export of the glycosidase, the 22 amino acid signal sequence of pelB from
Dickeya dadantii was encoded immediately upstream of the 1,2-α-L-fucosidase domain (residues
577-1,474) of gene afcA from Bifidobacterium bifidum, which was codon-optimized for E. coli (IDT
DNA Codon Optimization Tool). Plasmid pAfcB was constructed by replacement of the AfcA fu-
cosidase domain with the 1,3-α-L-fucosidase domain (residues 19-471) of the afcB gene. This gene
was amplified by PCR from the genomic DNA of Bifidobacterium longum subsp. infantis ATCC
15697TM (American Type Culture Collection, Manassas, VA). The afcB fragment was assembled
into the same vector using NEBuilderr HiFi DNA Assembly Master Mix (New England Biolabs
Inc., Ipswich, MA) with the amplicons digested with DpnI before PCR purification. The genes
encoding NanH (P. multocida) and BnaG (L. casei) were similarly synthesized by Gen9 (residues
29-778 and 32-533 respectively). The gene encoding NanH2 (B. longum sp. infantis), composed of
394 residues, was amplified from genomic DNA (ATCC 15697) and cloned into pAfcA using NEB
Hifi Assembly. The bicistronic elements were constructed by cloning two glycosidases with their re-
spective promoters in a casette. The gene encoding LnbB (B. bifidum), composed of 1201 residues,
BbgIII (B. bifidum), composed of 1877 residues and BbhI (B. infantis), composed of 1572 residues,
were amplified from respective genomic DNA. The oligonucleotide primers for the construction of
the plasmids are listed in Supplementary Table ??.
3.3.1.1 Cell culture and induction
Competent BL21 (DE3) cells were co-transformed with pET28:GFP and either pAfcA or pAfcB
by electroporation. After transformation and recovery, single colonies of the transformed cells were
grown in Luria-Bertani (LB) media (1% tryptone, 0.5% yeast extract, and 1% NaCl) containing
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appropriate antibiotics at 37 °C in a shaking incubator. Media was supplemented with antibiotics
at the following final concentrations: 50 µg/mL carbenicillin and/or 30 µg/mL kanamycin. Cells
were grown to mid-exponential phase (OD600 of approximately 0.6) before addition of carbohydrate
inducer. Cultures were induced by adding 2’-FL, and 3-FL to a final concentration of 0.3% or 3’-SL
and 6’-SL to a final concentration of 0.4% or lacto-N-triose II to a final concentration of 0.32%.
All oligosaccharides were sourced from Carbosynth (Carbosynth, Berkshire, UK). Isopropyl β-D-1-
thiogalactopyranoside (IPTG; Invitrogen, Carlsbad, CA) and lactose were added to a final concen-
tration of 0.1mM and 0.2% respectively. All oligosaccharide concentrations are molar equivalents
to 0.2% lactose. These cultures were then incubated at 37 °C in a rotary shaker (250rpm) for 16h.
In cultures with supplemented exogenous fucosidase, 0.012 units of α-1,2-fucosidase (Megazyme)
were added to growth media before induction.
3.3.2 Method details
3.3.2.1 Measurement of GFP Fluorescence
To quantify the green fluorescence intensity of the GFP, 150 µL of the overnight culture of GFP
expressing bacterial cells was harvested, washed and re-suspended in 500 µL 1X PBS (phosphate
buffered saline). Standard curves were prepared in the range from 0 mg/L to 3000 mg/L. Expression
data of the resuspended cells were collected the Iowa State Flow Cytometry Facility (Ames, IA)
using a BD FACSCanto Plus RUO (San Jose, CA) flow cytometer with a solid state 488 nm/20 mW
(nanometer/milliWatt) blue laser and a 505 nm-long pass and 525/50 nm-band pass filter set. Cells
were gated for forward and side scatter to avoid aggregated cells and debris. All measurements of
fluorescence were obtained from three independent biological replicates maintained under identical
conditions. For each culture, 25,000-40,000 events were collected.
3.3.2.2 Production of 2’-FL
The 2’-FL producing strain, JM109 gwBC-F2, obtained from G. Sprenger (Universität Stuttgart)
was cultivated in a shake flask. JM109 gwBC strain without fucosyltransferase futC genes was used
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as control. The shake flask experiments were carried out in 1 L shake flasks with 250 mL minimal
media and 1% glycerol as the carbon source, according to the protocol listed in the paper [26]. At
mid log phase IPTG (0.5 mM) and lactose (2%) were added and the cultures were grown for 24 h
before pelleting and washing them. All culture and growth conditions for the control were identical
to the 2’-FL producing strain. Cell lysis was carried out by sonication. Oligosaccharide concentra-
tions in the lysates were determined by LC-MS before testing with the biosensor. Serial dilutions of
30% commercial 2’-FL with added lysate from the non 2’-FL producing strain, was used to generate
a calibration curve for absolute quantitation of 2’-FL in the lysate (Supplementary Figure S.2.9D).
The same volume of control lysate was added as the 2’-FL producing strain lysate. The run order
of samples was randomized to ensure that any biological variation is independent of systematic bias
in the analytical process.
3.3.2.3 Validation with LC-MS
2’-FL concentrations from cell lysates were verified by HPLC-MS. HPLC analysis was performed
on Agilent Technologies 1100 Series HPLC system coupled to an Agilent Technologies Mass Selec-
tive Trap SL detector (Agilent Technologies, Santa Clara, CA) equipped with an electrospray ion
source (ESI) and controlled by ChemStation A.10.02, including data acquisition and processing.
Products were analyzed on a Luna C18 reversed phase column (150 mm× 2 mm, 5 , Phenomenex,
Germany) detected by electrospray ionization (positive ion mode). Mobile phase consisted of sol-
vent 1 (aqueous solution containing formic acid 0.1% (v/v)) and solvent 2 (acetonitrile containing
formic acid 0.1% (v/v)). The LC gradient was delivered at 0.4 ml/min, and consisted of an initial
linear increase from 100% solvent 1/0% solvent 2 to 0% solvent 1/100% solvent 2 over 15 min,
followed by a linear decrease to starting conditions for 5 min, allowing a sample injection every 30
minutes. 5 µL of sample was injected and the column temperature kept at 40 °C. Standards and
samples were analyzed in triplicates and standard curves were created from six different concen-
trations. Identification of 2’-FL by mass spectrometry was completed by comparison with 2’-FL
standard (Supplementary Figure S.2.9C).
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3.3.2.4 Growth of strain with a sole carbon source
Cells were cultured in M9 minimal media (M9 salts, MgSO4, CaCl2 and 0.1% thiamine) which
was supplemented with glucose, lactose, 2’-FL or 3-FL. 200 µL of the media was inoculated with
cells in mid-log phase after the cells were washed with the minimal media in a clear bottom 96-well
plate (Corning). The growth of the cells was monitored by measuring the optical density at 600
nm at 37 °C on a Synergy neo2 plate reader (BioTek, Winooski, VT).
3.3.2.5 Coculture experiments in defined media
Single colonies harboring pAfcA and pAfcB were picked from agar plates and incubated with 5
mL of LB at 37 °C. The cells were cultivated at 37 °C to mid-log phase, washed with distilled water
and inoculated at 1% into 300 µL of M9 minimal media supplemented with 2 mM MgSO4, 0.1 mM
CaCl2 and 0.1% thiamine at ratios of 1:1, 1:10, and 1:100 with a single carbon source: lactose,
2’-FL or 3-FL and allowed to grow for 72h. After enrichment, cells from the co-culture were then
diluted and plated on agar plates and incubated at 37 °C overnight. Thirty to fifty of the single
colonies were randomly selected and subjected to multiplex colony PCR with primers corresponding
to afcA and afcB to determine the proportion of specific plasmids in the mixed population. For
colony PCR, OneTaq 2x Master Mix (New England Biolabs Inc., Ipswich, MA) were used according
to the protocols supplied by the manufacturer. The products were visualized in agarose gels. All
enrichments were cultured in triplicate. The GFP/RFP reporter assays were conducted in the
same way with a coculture at 1:1 ratio in a defined media with a single carbohydrate source and
the fluorescence analyzed on a plate reader (200 µL in each well). The plate was sealed with
a Breathe Easy sealing membrane (Millipore Sigma, St. Louis, MO) and subjected to continuous
orbital shaking. Measurements were made every 10 minutes. Once the cells reached their stationary
phase, the cells were pelleted and washed twice in PBS before inoculating at 0.1% into fresh media
with the second carbohydrate source. This was repeated for another cycle and reverting to the first
carbohydrate source. Excitation and emission wavelengths were 485 nm and 528 nm respectively
for GFP and 590 nm and 645 nm for mCherry respectively. Statistical analysis was done using
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SAS (version 9.4; SAS Institute Inc, Cary, NC). The proportions of cells expressing either plasmid
were modeled using a binomial distribution with the replicates as the random variable and the
carbon source, starting inoculation ratio and respective genes as independent variables. Statistical
signicance was set at P <0.0001 for all analyses. To determine crosstalk between the two strains,
the experiments were carried out identically, but in LB with a single carbohydrate source.
3.3.2.6 Selective lactose removal
Cells harboring pAfcA were grown to mid-log phase in LB. The inocula were supplemented
with lactose (0.2%) or 2’-FL (0.3%) and varying levels of β-galactosidase (Millipore Sigma, St.
Louis, MO). The β-galactosidase was reconstituted by dissolving in 1 mM magnesium chloride.
Here, one unit hydrolyzes 1.0 of o-nitrophenyl β-D-galactoside to o-nitrophenol and D-galactose
per minute. The cultures were grown overnight at 37 °C and analyzed on a flow cytometer. For
pre-treatment with cells that consume lactose, BL21 (DE3) cells were grown to mid-log phase in
LB and spiked with equimolar lactose (0.003%), 2’-FL (0.005%) or a mixture of lactose and 2’-FL.
After incubating for 1, 2 or 3h, they were spun down and the supernatant added to the biosensing
cells. These cultures were similarly analyzed on a flow cytometer. For lactose precipitation and cell
lysis with ethanol, two volumes of ethanol were added to the culture and incubated for 4 h before
being spun down and the supernatant collected. This lysate was incubated overnight at 4 °C and
the precipitated lactose was removed by filtration. Different concentrations of lysate were added
to a final volume of 300 µL. The final ethanol concentrations in the cultures ranged from 0 to 2%
(v/v), not considering the losses due to evaporation.
3.3.2.7 Enzymatic assays
To quantify the α-2,3-sialidase enzymes, a commercial enzymatic assay was carried out on
supernatant and lysates of NanH and NanH2 biosensing cells. The sialidase activity was measured
using Neuraminidase Assay Kit (Sigma-Aldrich, St. Louis, MO) according to the protocols supplied
by the manufacturer. The samples were diluted 100-fold before testing. One unit of neuraminidase
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activity was defined as the amount of enzyme that generates 1.0 of sialic acid per minute at pH 7.4
at 37 °C.
To quantify the α-1,2-L-fucosidase and α-1,3-L-fucosidase, 5 mL of pAfcA/pAfcB expressing
cells were grown in LB, washed and concentrated ten-fold before lysing via sonication. The pAfcA
lysate was incubated with varying concentrations of 2’-FL in 10 mM sodium phosphate buffer (pH
7.0) at 30 °C. The reaction mixtures were boiled for 3 minutes before using the L-Fucose Assay Kit
(Megazyme) to determine the amount of fucose released. One unit of α-1,2-L-fucosidase activity was
defined as the amount of enzyme required to release one of α-L-fucose per minute from 2’-FL (2 mM)
in sodium phosphate buffer (10 mM), pH 7 at 30 °C. The pAfcB lysate was incubated with varying
concentrations of 2-chloro-4-nitrophenyl-α-L-fucopyranoside (CNP-fucose; Carbosynth, Berkshire,
UK) in McIlvaine buffer, pH 5.6 (citric acid/disodium hydrogen phosphate) at 37 °C for 10 minutes
and the reactions were stopped by addition of 1 M Na2CO3. Absorbance at 405 nm was measured
on a Synergy neo2 plate reader (BioTek, Winooski, VT). One unit of α-1,3-L-fucosidase activity was
defined as the amount of enzyme required to hydrolyze one of CNP-fucose to 2-chloro-4-nitrophenol
per minute in McIlvaine buffer, pH 6 at 37 °C. All enzyme concentrations in were estimated by
calculation of the [E]total from Vmax using cited Michaelis-Menten parameters with respect to the
observed velocity in the assay of interest.
3.3.2.8 Quantification and Statistical Analysis
Non-linear regression was used for statistical analysis and the calibration curve was analyzed
using the Four Parameter Logistic (4PL) model:
y = d+
(a− d)




a = Minimum asymptote representing minimum reporter activity; b = Hill’s slope; c = Inflection
midpoint, or the concentration of analyte where y=(d-a)/2, representative of the position of linear
region; d = Maximum asymptote representing maximum reporter activity. MATLAB (MathWorks,
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Natick, MA) was used to fit the 4PL model using the built-in fit function to determine estimates
of the parameters using a nonlinear least-squares method. All statistical analysis and associated
error bars have been identified in the figure captions.
3.4 Results and Discussion
3.4.1 A fluorescent reporter of 2’-fucosyllactose
We hypothesized that since all HMOs contain lactose, specific enzymatic cleavage of modifying
sugars would generate lactose, activating the lac operon and leading to expression of a reporter
protein (in this case, GFP) in proportion to the quantity of the HMO of interest (Figure 3.1B). 2-
fucosyllactose (Fuc-α-1,2-Gal-β-1,4-Glc, 2-FL) is the most abundant oligosaccharide in human milk.
As proof of concept, we sought to design a biosensor specific to 2’-FL to be used in conjunction
with the biotechnological production of the oligosaccharide. To defucosylate 2’-FL, we chose the
1,2-α-L-fucosidase domain of the AfcA protein from Bifidobacterium bifidum, which is known to be
highly specific for α-1,2 fucose linkages [65] and is implicated in the ability of B. bifidum to grow
on 2’-FL [66]. The gene was codon-optimized for E. coli (synthesized by Gen9, Cambridge, MA)
and synthesized in a cassette downstream of the constitutive J23110 promoter. Because we were
not certain that the trisaccharides of interest would be transported across the inner membrane, we
directed the glycosidase to the E. coli periplasm via N-terminal fusion of the pelB signal sequence
(ssPelB). This plasmid was named pAfcA. On a second plasmid, we provided GFP under control of
the T7 promoter (pET28:GFP). The plasmids were co-transformed into E. coli BL21 (DE3), which
contains the T7 RNA polymerase under control of the the lacUV5 promoter (the strain containing
both plasmids is referred to as pAfcA/GFP). When lactose (Galβ1,4Glc) enters the system, it
induces the lac operon, allowing transcription of T7 RNAP. We hypothesized that by monitoring
expression of GFP, we could detect the level of 2’-FL which had been defucosylated by the AfcA
fucosidase domain (Figure 3.1B). To determine the effect of 2’-FL addition on GFP expression, cells
containing pAfcA or an empty vector control were grown to mid-log phase and incubated overnight
(16 h) with either no inducer, lactose, 2’-FL, 3-FL (3-fucosyllactose, (Gal-β-1,4-(Fuc-α-1,3)-Glc, a
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trisaccharide isomer of 2’-FL with a different glycosidic linkage). Oligosaccharides were added as
molar equivalents to 0.2% w/v lactose. All cultures were then analyzed for GFP fluorescence by flow
cytometry. Figure 3.2A shows the mean fluorescence from each induction condition. As expected,
lactose induction led to high fluorescence with and without expression of AfcA. In contrast, cells
harboring the pAfcA plasmid induced with only 2’-FL had over 100-fold higher fluorescence than
cells not expressing pAfcA. In addition, no significant increase in fluorescence was noted when
cells were induced with the trisaccharide isomer 3-FL, indicating that the α-1,2 linkage was favored
for defucosylation over the α-1,3 linkage. To determine whether this difference was due to the
defucosylation of 2’-FL, cells were induced with 2’-FL in media containing exogenous commercial
α-1,2-fucosidase (Megazyme), which also led to activation of the lac operon (Figure 3.2A).
3.4.2 A fluorescent reporter of 3-fucosyllactose
In a similar way, we reasoned that expression of an α-1,3-fucosidase would allow for cleavage
and detection of 3-FL. A search of fucosidases in Bifidobacterium longum subsp. infantis ATCC
15697 (B. infantis) revealed the glycosidase Blon 0426 (which we hereafter refer to as AfcB), which
hydrolyzes α-1,3-linked L-fucose [67]. We amplified the fucosidase domain of the Blon 0426 gene
from the genomic DNA of B. infantis and replaced the afcA gene in the pAfcA plasmid, creating
pAfcB. pAfcB and pET28:GFP were co-transformed into BL21 (DE3) cells as above. Cultures were
induced as above and incubated for 16 h. In the case of induction with 0.3% 3-FL, we observed
a roughly 150-fold higher mean fluorescence than that in cells expressing pAfcA or no glycosidase
(Figure 3.2A). Importantly, no change in fluorescence was noted on induction with 0.3% 2’-FL.
Thus cells expressing the α-1,2-fucosidase AfcA were responsive to 2’-FL and not 3-FL and cells
expressing α-1,3-fucosidase AfcB were responsive to 3-FL and not 2’-FL, demonstrating the linkage
specificity of the sensor and the ability to distinguish between isomeric trisaccharides.
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Figure 3.2 Characterization of biosensor for 2’-FL and 3-FL detection. (A) Fluorescent detection of
2’-FL and 3-FL. Cells containing pET28:GFP and either pAfcA (green), pAfcB (magenta),
or an empty vector control (blue) were induced for 16h with no sugar, 2’-FL, 2’-FL with
exogenously added α-1,2-fucosidase, 3-FL, or lactose. (B) Limits of detection and transfer
functions of biosensors after 16h incubation. Response curves depicting mean fluorescence
(measured in triplicate by flow cytometry) for pAfcA/2’FL (green circle) and pAfcB/3-FL
(magenta square) or empty control vector (blue diamond) at varying amounts of trisac-
charide cultured as in (A). The dose-response curve was fit with a 4PL model, shown by
the lines. (C) Time course of reporter expression. Strains pAfcA or pAfcB were incubated
with 2’-FL (green square) or 3-FL (magenta diamond) respectively and fluorescence was
monitored over 8 h of induction. Strain pAfcA incubated with lactose is included as a
control.
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Biosensor use in the context of biotechnology. Figure continued on the next page.
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Figure 3.3 Biosensor use in the context of biotechnology. (A) Workflow demonstrating the use of the
biosensor in a simple protocol. (B) Lactose removal by enzymatic digestion. Cultures con-
taining 2’-FL or lactose were incubated with biosensor cultures containing varying amounts
of exogenous β-galactosidase at induction time were assayed for fluorescence after 16h in-
cubation. (C) Lactose removal by incubation with wild-type cells. LB containing 2’-FL,
lactose, or a 50:50 mixture (0.2% lactose equivalent) was incubated for various times with
BL21 (DE3) cells then tested with biosensor cultures. (D) Lactose removal and cell lysis by
ethanol pretreatment. Fermentations of JM109 gwBC-F2 or JM109 gwBC cells were incu-
bated with two volumes of ethanol and filtered before incubation with fluorescent biosensor
cells and compared with fluorescence from untreated JM109 gwBC-F2 culture. (E) Quan-
tification of 2’-FL in cell lysate. The biosensor was evaluated for its ability to detect 2’-FL
from a producer strain. All fluorescence values represent mean fluorescence from flow cytom-
etry experiments averaged between three biological replicates. Vertical error bars represent
standard deviations of mean fluorescence from triplicate measurements and horizontal error
bars represent the variation in 2’-FL measured by HPLC in the three replicates.
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3.4.3 Limits of detection of fucosylated trisaccharides
To evaluate the sensitivity of this assay, we characterized the fluorescent response to varying
levels of 2’-FL and 3-FL to estimate the dynamic range and limits of detection. For pAfcA and
2’-FL, the dynamic linear range of detection was found to be between 40 and 400 mg/L and the
limit of detection at 4 mg/L (Figure 3.2B). To put this level in context, E. coli strains have been
engineered to synthesize 2’-FL at concentrations upto 21.1 g/L [26] and the concentration of 2’-FL
in human milk of secretor mothers ranges from 649-3880 mg/L [68] which upon dilution prior to
analysis can be measured well within the linear range. The experimental data were fitted into a
4-parameter logistic model (4PL) using MATLAB (Figure 3.2B). The resulting transfer functions
revealed the dynamic range and the minimum/maximum expression levels (Supplementary Table
S.2.2). For pAfcB and 3-FL, the dynamic range of detection was more narrow, between 400 and 600
mg/L and the limit of detection at 350 mg/L. Interestingly, 2’-FL with AfcA had a lower detection
limit and more extended dynamic range than 3-FL with AfcB. We speculated that this difference
may be due to differences in the activities of these enzymes. Quantification of the enzyme activities
revealed the intracellular enzyme concentration to be at 0.6 U/L for the AfcA and 3.5 U/L for
AfcB. Given the respective kcat values of these enzymes: 160 s
−1 for AfcA and 4.48 s−1 for AfcB
[67], we estimated periplasmic protein concentrations as 62.5 pM for AfcA and 13 nM for AfcB.
Thus, we attribute the difference in transfer functions to the roughly 200-fold higher expression of
AfcB. We note that the constitutive promoter J23110 is quite strong and that substitution for a
weaker promoter may improve the dynamic range of the 3-FL assay.
While in initial experiments we induced with trisaccharide overnight (ca. 16 h), we sought to
determine the induction time required to obtain a usable fluorescent signal. To quantify this more
precisely, we used flow cytometry at specific time points to generate snapshot measurements of
the dynamics of reporter expression (Supplementary Figure S.2.9). Figure 3.2C shows fluorescent
output from cells containing plasmids pAfcA/pAfcB and pET28:GFP at various time points after
induction with either lactose, 2’-FL or 3-FL. The signal was found to saturate after approximately
5 h, meaning this technique can be used within the span of a normal workday. There is a notable
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lag phase for pAfcA/GFP cultures incubated with 2’-FL, which we attribute to the time taken to
defucosylate 2’-FL and transport lactose into the cell for induction of the reporter protein. The lag
phase is considerably shorter for pAfcB/GFP cultures grown in 3-FL.
3.4.4 Detection of 2’-FL from cell lysate of a producing strain
Having established that the biosensor can specifically and sensitively detect 2’-FL we next sought
to adapt this platform for use in a biotechnological context. Recently, Baumgärtner et al. developed
a strain capable of producing 2’-FL at levels of up to 21 g/L [26] using lactose as a substrate. We
cultured this producer strain (JM109 gwBC-F2) and quantified 2’-FL production using LC-MS from
a standard curve made by adding defined amounts of 2’-FL to lysate from a non-producer strain
(JM109-gwBC) grown under identical conditions (Supplementary Figure S.2.10A-C). We added cell
lysate from the producer strain to cultures containing the pAfcA/GFP cells and assayed the GFP
expression from these cultures. Figure 3.3E shows the fluorescent readout for 2’-FL containing cell
lysate vs. the established standard curve, along with the 4PL model. The models are in good
agreement, as seen from the Hill coefficients under the two conditions (Supplementary Table S.2.2).
Higher variability between the signals was observed as more lysate was added to the system, which
we attribute to inhibition of either glycosidase activity or GFP expression by unknown components
of cell lysate.
3.4.5 Reducing signal from lactose as false positive
The presence of lactose in milk or in biotechnological processes could lead to false positives, so
it is desirable for the sensor to be selective for HMOs over lactose. To remove the residual lactose,
the cultures may be pelleted and washed, as seen in the control in Figure 3.3E. However, this
step can be time consuming, and so we hypothesized that for applications containing lactose, the
lactose could instead be selectively enzymatically degraded. To this end, we incubated pAfcA/GFP
cells with 0.2% lactose or 0.3% 2’-FL in the presence of varying amounts of exogenous commercial
β-galactosidase (Figure 3.3B). For cells induced with lactose for 16h, the fluorescence signal was
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20% of the original signal, while with 2’-FL, the signal was at 80% when treated with 12 units of
β-galactosidase.
Although this strategy effectively reduces signal from lactose, the requirement for purified en-
zyme is somewhat restrictive. With the same strategy in mind, we hypothesized that wild type
BL21 (DE3) cells added in a pre-incubation step would metabolize residual lactose, leaving behind
the 2’-FL, which these cells cannot use as a carbon source. In addition, these cells would also
be incapable of proliferating in the downstream assay which uses antibiotics for plasmid selection.
When incubated with lactose (0.2%) for 3h, the signal dropped to its background level whereas
the signal stayed the same when incubated with 0.3% 2’-FL (Figure 3.3C). Interestingly, when
spiked with equimolar lactose and 2’-FL (0.1% and 0.15%, respectively), the signal dropped to
levels comparable to what was observed with the same concentration of 2’-FL.
Finally, we hypothesized that addition of ethanol would simultaneously selectively precipitate
lactose [69] and lyse cells. We incubated the producer strain and the control in two volumes
of ethanol for four hours and the lysate obtained was kept at 4 °C overnight for the lactose to
precipitate. Upon filtration, they were tested at different concentrations with the biosensing cells
(Figure 3.3D). A two-fold drop in fluorescence was observed compared to cells not treated with
ethanol and roughly three-fold higher signal compared to the non 2’-FL producing control cells.
Despite being a simple extraction process, the recovery of the 2’-FL is lower compared to other
methods, possibly from losses due to some crystallization of 2’-FL. No significant inhibition of
growth of the biosensor cells was observed, owing to the low final ethanol concentrations (< 2%)
in the cultures. Optimization of this protocol could minimize losses and greatly simplify the assay
by eliminating the need for a lysis step. Having demonstrated that the biosensor can be used to
detect 2’-FL in strains engineered for production, these strategies of lactose removal can greatly
improve the throughput and selectivity of the biosensor. In summary, we have demonstrated
several techniques for the selective removal of lactose from the assayed sample. First, washing
cells before lysis reduces background significantly (Figure 3.3E). Next, lactose can be degraded
selectively by incubation with either commercial β-galactosidase (Figure 3.3B) or cells capable
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of consuming lactose (e.g., BL21) (Figure 3.3C). While these strategies effectively remove most
background lactose, they require an incubation period. Finally, ethanol can be added to the
culture to selectively precipitate lactose, which is also effective but reduces overall signal and
requires filtration or decanting (Figure 3.3D). The optimal lactose removal strategy will vary by
user priorities including cost, time, and throughput, and equipment availability. Overall, for most
applications, removal using BL21 cells is inexpensive and high-throughput as it can be performed
on many cultures in parallel, however it adds 3 h to the detection process. Figure 3.3A summarizes
a general workflow for detection of 2’-FL in a producer strain with strategies to fill the gap for
reducing false positives.
3.4.6 Detection of sialylated and N- acetylglucosaminylated trisaccharides
The demonstrated ability to differentiate between fucosylated isomers of different linkages in-
spired us to expand the capability of our biosensor to other modifications of lactose present in
HMOs. To accomplish this, we synthesized and codon-optimized or amplified from genomic DNA
three more genes, as with afcA, and incorporated them into our secretion and expression plasmid.
The glycosidases chosen were (1) nanH2 from B. infantis, a sialidase which is known to hydrolyze
both α-2,3 and α-2,6 sialic acid linkages [70] (2) nanH from Pasteurella multocida, an α-2,3 sialidase
with activity on 3’-SL [71] , and (3) the lacto-N-biosidase domain (corresponding to residues 32 to
533) of the bnaG gene from Lactobacillus casei, previously demonstrated to be essential for hydrol-
ysis of lacto-N-triose II (GlcNAc-β-1,3-Gal-β-1,4-Glc, LNT II) in this organism and other related
lactobacilli [72]. First, we measured the fluorescent response of the biosensor to 3’-SL using B.
infantis NanH2 as the glycosidase. When incubated with 0.4% 6’-SL, we observed an over 100-fold
increase in mean fluorescence compared to cells not expressing the sialidase. The mean fluorescence
also increased in response to the addition of 3’-SL, in accordance with previously observed broader
substrate specificity of this enzyme [70] (Figure 3.4A) but the overall response to sialylated HMOs
was not as robust as that of the fucosylated HMOs. We hypothesized that this was a result of
negatively charged siayllactose facing electrostatic mass transfer resistance across the E. coli outer
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membrane. To overcome this barrier, we created an N-terminal fusion of NanH2 to the E. coli YebF
protein, which has been shown to direct extracellular protein secretion in E. coli [73, 74]. We used a
commercially available neuraminidase assay kit (Millipore Sigma) to determine the sialidase activity
in the extracellular media when fused with the YebF protein. Only trace levels of sialidase activity
were observed for the periplasmic NanH2 construct compared to the YebF-NanH2 fusion where the
majority accumulated in the extracellular medium (Supplementary Figure S.2.11A). When NanH2
was fused with YebF and secreted extracellularly, the fluorescent response was roughly 3-fold higher
and comparable to that of fucosylated HMOs with their respective fucosidases (Figure 3.4A). As
NanH2 has been shown to have activity on both 3’-SL and 6’-SL, we noted a similar qualitative
trend in the fluorescent response of NanH2-producing cells to 6’-SL (Figure 3.4B). In cells expressing
the YebF-NanH2 fusion protein, the fluorescent response was again higher than with periplasmi-
cally expressed NanH2. However, while the limits of detection for 3’-SL and 6’-SL were similar,
the overall fluorescent response to 0.4% 6’-SL was lower compared to 0.4% 3’-SL. Kinetic data ob-
served by Sela et al. (Sela et al., 2011) showed a 2-fold lower catalytic efficiency (attributable to a
2-fold higher KM with comparable kcat values) for a 3’-sialylated substrate (KM : 7.8 mM) than its
6’-sialylated counterpart (KM : 3.8 mM). This difference would suggest an approximately 1.4-fold
higher activity on 6’-SL at the amounts assayed (approximately 6.3 mM in the media). While the
reason for this slight discrepancy is not clear, we demonstrate that sialic acid-containing HMOs
can be detected reliably in our system. To test if a highly specific sialidase could be used to detect
a specific sialic acid linkage, we expressed P. multocida NanH, which has a 50-fold higher activity
on an α-2,3 linked (4-methylumbelliferyl-3’-SL) to a 6’-sialylated substrate (4-MU-6’-SL) (Mizan et
al., 2000), in both the periplasmic (ssPelB fusion) and extracellular (YebF fusion) spaces. In the
case of periplasmic expression, we saw very low fluorescence even at 0.4% 3’-SL. However, the YebF
fusion to this protein contributed a measurable signal. Comparison of sialidase activity of the su-
pernatant for YebF-NanH and YebF-NanH2 variants using 3’-SL as a substrate revealed a roughly
900-fold lower activity for NanH compared to NanH2 (0.036 U/L in supernatant of YebF-NanH
vs. 32 U/L in supernatant of YebF-NanH2). Using available kinetic parameters on 4-MU-3’-SL
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for both enzymes as a proxy for activity, we estimate that the difference in activity corresponds
to a roughly 380-fold lower (2.2 pM vs. 840 pM) enzyme expression, suggesting that functional
expression and/or translocation of P. multocida NanH is limited in this system and is a target for
further optimization of expression. Even so, we were still able to observe fluorescence well above
background for 3’-SL in the NanH case, while no fluorescent signal was observable when NanH
cells were incubated with 6’-SL (Figure 3.4C). Finally, we tested the N-acetylgalactosaminidase
domain of BnaG from L. casei, known to hydrolyze LNT II. Cells expressing this glycosidase had
a moderate fluorescent response at 0.3% LNT II (Figure 3.4C). BnaG, although specific towards
GlcNAc-β-1,3-glycosidic linkage, only possesses exoglycosidase activity (Bidart et al., 2016). This
was demonstrated by the lack of signal, when tested with lacto-N-neotetraose which contains the
same but non-terminal β-1,3- linked GlcNAc (Supplementary Figure S.2.11B).
3.4.7 Detection of higher order HMOs using combinatorial expression of glycosidases
As the functional roles of more complex HMOs are being elucidated, interest in synthesizing
them is growing [75]. The tetrasaccharides lacto-N-tetraose (LNT) and lacto-N-neotetraose (LNnT)
are highly abundant oligosaccharides in human milk [16, 17] and associated with anti-inflammatory
and anti-bacterial properties [76, 77]. There have been several reports of using different approaches
to synthesize these tetrasaccharides and their derivatives [78–80]. LNT (Galβ1-3GlcNAcβ1-3Galβ1-
4Glc) is classified as a type I HMO and LNnT (Galβ1-4GlcNAcβ1-3Galβ1-4Glc) is an isomer of
LNT and classified as a type II oligosaccharide. These isomers can be distinguished by the single
glycosidic linkage (i.e., β1-3 vs. β1-4). To detect these complex oligosaccharides we took our strategy
a step further by using a combinatorial expression of glycosidases. By creating combinatorial
libraries of glycosidases, we were able to screen all of the top ten HMOs as identified by the food
and biotechnology industry (Table 3.1).
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Figure 3.4 Substrate specificity of glycosidases. (A) Dose-response curve of biosensor for detection of
3’-SL. Two variants pNanH2 (blue) and pYebF-NanH2 (magenta) were induced with 3’-SL.
Cells lacking the plasmid (green) were used as a control. (B) Dose-response curve of biosensor
for detection of 6’-SL. Similarly, two variants pNanH2 (teal), pYebF-NanH2 (pink), and the
control (lavender) were induced with 6’-SL as in Figure 3.4A. (C) Heat map showing the range
of biosensors created and tested for orthogonality. Heat map represents mean fluorescence
of cell cultures expressing the indicated glycosidase induced with equivalent of 0.2% lactose
of indicated sugars. All cultures were induced overnight.
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Our search for glycosidsases to trim the tetrasaccharides down to lactose started with studying
the degradation pathway of these oligosaccharides in bifidobacteria. We turned to bifidobacteria
based on previous studies that show their unique metabolic pathways comprising of glycosidases
that give them the nutritional advantage over other microbes. We scanned the array of enzymes
that includes various types of intra- and extracellular glycosidases that have been characterized.
Table 3.1 lists the glycosidases that we used to construct our biosensors. To generate lactose from
more complex oligosaccharides, we took a combinatorial approach that provides a mechanism of
hydrolyzing specific linkages via linkage-specific glycosidases. Figure 3.5 shows a schematic of the
genetic circuits for difucosyllactose (DFL) and 3’-sialyl-3-fucosyllactose (3’-S-3-FL). The bicistronic
elements consisted of two glycosidases targeting the terminal fucose and sialic acid moieties. In the
case of 3’-S-3-FL, no signal was observed with the biosensor construct. We hypothesized that it
was the same mass transfer limitation that we had encountered earlier with 3’-SL and 6’-SL. We
integrated the yebF signal peptide to secrete the glycosidases to the extracellular media and were
ultimately able to detect this HMO.
Bifidobacteria bifidum are capable of hydrolyzing lacto-N-tetraose into Galβ1-3GlcNAc (lacto-
N-biose I; LNB I) and lactose via the extracellular lacto-N-biosidase, LnbB (Wada et al. 2008).
This glycosidase is specific to type 1 chains only (Galβ1-3GlcNAc). We isolated the lnbB gene
from B. bifidum JCM1254 and integrated it into our biosensing plasmid. Upon incubating LNT
and LNnT with the whole cell biosensing cells, a signal was only observed with LNT, as expected
(Figure 3.6A). Here, we were able to cleave the tetrasaccharide to liberate lactose with a single
enzyme.
Another study investigated the degradation pathway of LNnT, revealing a sequential breakdown
from the non-reducing terminus by extracellular exo-glycosidases [81]. The genes encode an extra-
cellular β-galactosidase, BbgIII, and a β-N-acetylhexosaminidase, BBhI. The study also found that
BbgIII nor BbhI had any hydrolytic activity on LNT. This suggested that BbhI had neither endo-
type nor disaccharide-releasing activities like LnbB. We constructed biosensors expressing each of
these single glycosidases. Contrary to what was reported by Miwa et al., we observed a signal with
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LNT. This suggested that they do cleave LNT to lactose. No signal was observed with LNnT. We
went on to build the bicistronic construct and were able to detect LNnT (Figure 3.6A). We tested
a few other combinations of β-galactosidases and β-N-acetylhexosaminidases from B. bifidum and
B. infantis but were unable to detect LNnT. Normalized GFP expression for each biosensor was
fitted to the 4PL model to derive biosensor performance (Figure 3.6B).
Figure 3.5 Bicistronic constructs for detection of tetrasaccharides. (A) L- Schematic illustration of
genetic construct for detection of difucosyllactose. R- Heatmap showing fluorescent readout
from biosensor constructs. (B) Same as in (A) for detection of 3’-sialyl-3-fucosyllactose.
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We finally applied the same concept to detect a pentaose, lacto-N-fucopentaose I (Fucα1-2Galβ1-
3GlcNAcβ1-3Galβ1-4Glc; LNFP I) which is a type I blood group H antigen pentaose sugar. Here,
we expressed LnbB and AfcA that cleaved the pentasaccharide to liberate lacto-N-biose I, fucose
and lactose which showed a signal with LNFP I.
Taken together, we demonstrated the action of different glycosidase enzymes and their combi-
nations on 10 different HMOs. As a final proof of the orthogonality of detection in our system,
we tested each of the substrates individually with cells expressing each of the enzymes or their
combinations (Figure 3.7). Very little mean fluorescence was detected for the non-target trisac-
charides (off diagonal), except for the case of NanH2, which is known to hydrolyze both 6’-SL and
3’-SL and behaved accordingly. With the higher-order HMOs, we can detect the oligosaccharides
but cannot distinguish them from the trisaccharides. Thus, we conclude that our assay facilitates
quantitative fluorescent detection of ten different human milk oligosaccharides in a manner specific
to the glycosidic linkage associated with the chosen enzymes.
Figure 3.6 Characterization of biosensor for LNT and LNnT detection. (A) Fluorescent detection of
LNT and LNnT. Cells containing pET28:GFP and either pLNbB (blue) or pBbgIII+BBhI
(red) were induced for 16 hr. (B) Limits of detection and transfer functions of biosensors
after 16 hr incubation. Response curves depicting mean fluorescence (measured in triplicate
by flow cytometry) at varying amounts of tetrasaccharide cultured as in (A).
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Figure 3.7 Heat map showing the range of biosensors created and tested for orthogonality. Heat map
represents mean fluorescence of cell cultures expressing the indicated glycosidase induced
with equivalent of 0.2% lactose of indicated sugars.
3.4.8 HMOs can be used as a sole carbon source in engineered strains
Previous studies have reported that bifidobacteria thrive by consuming oligosaccharides in the
infant gut [82, 83]. This prompted us to assess the ability of our engineered E. coli to utilize
HMOs as a carbon source. E. coli BL21(DE3) containing pAfcA were cultured in M9 minimal
media containing 0.2% lactose, 0.3% 2’-FL or 0.3% 3-FL as a sole carbon source. The strain
demonstrated growth on both carbohydrate substrates (Figure 3.8A). During growth on lactose,
there was a lag phase of approximately 1 h followed by normal exponential growth with a specific
growth rate of 0.09 h-1. Interestingly, the lag phase increases by 20-fold when using 2’-FL as the
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carbon source compared to lactose, which we suggest represents the time component of hydrolysis
of 2’-FL into lactose in the LacZ+ strain BL21(DE3). The specific growth rate, however, remains
comparable to that observed in lactose. They are also comparable to the specific growth rate in
glucose, 0.1 h−1. We also cultured biosensing cells harboring the pAfcB plasmid with 2’/3-FL.
These cells demonstrated a similar specific growth rate but a considerably shorter lag phase (15 h)
compared to pAfcA. No growth was observed for either cells in the absence of a carbon source or
for cells expressing AfcB in media containing 2’-FL.
3.4.9 Prebiotic enrichment of strains in mixed culture
The ability to hydrolyze complex carbohydrates is a key determining factor in the proliferation
of individual strains in complex microbial environments [84]. Competition among the strains re-
sults in the dominance of the population expressing the carbohydrate hydrolyzing phenotype. Since
we had established growth on HMOs in E. coli, we tested whether we could control the relative
abundance of a particular strain in a mixed culture by varying the carbohydrate source. To exam-
ine the dynamics of HMO-utilizing E. coli strains in a mixed culture environment, we co-cultured
two BL21 (DE3) strains harboring either pAfcA or pAfcB in minimal media with HMOs as a sole
carbon source and evaluated their relative abundance. Mixtures with relative abundances varying
from 1:1 to 1:100 of pAfcA and pAfcB cells were inoculated into M9 media containing either 2’-FL,
3-FL, or lactose. After culturing for 36 hours, approximately 500 CFU were plated on non-selective
media and grown overnight at 37 °C. From these plates, approximately 50 colonies were used as
templates for colony PCR amplification with primers specific for either the afcA or afcB genes.
The results of these colony PCR characterizations are shown in Figure 3.8B and Supplementary
Table S.2.10. As expected, when cells were grown on lactose with a 1:1 inoculum ratio, the ratio of
AfcA:AfcB colonies was approximately 50% (14/26 AfcA). However, in the presence of 2’-FL, cells
expressing pAfcA were much more abundant (>90%) than the original inoculum ratios, demon-
strating enrichment at a level far greater than chance (p <0.0001). Similarly, in the presence of
3-FL, pAfcB cells were greatly enriched as well (>95%). This result demonstrates growth-based
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selection for glycosidase activity or HMO utilization in mixed culture providing a selection-based
option for directed evolution studies in addition to the already established fluorescent screen.
A mixed population of biosensors designed to respond to different inputs must be able to
distinguish between them. To monitor for crosstalk between microbial strains (e.g., growth of a
strain not engineered to use the substrate of interest), we transformed cells expressing AfcA with
pET28:GFP and cells expressing AfcB with a pET28 vector containing the red fluorescent protein
mCherry. We expected that during growth on minimal media, only cells able to use a particular
HMO as a carbon source would grow and that fluorescent protein expression would be induced in
those cells, allowing red or green fluorescence to serve as a proxy for real-time analysis of population
dynamics. Cells expressing AfcA/GFP and AfcB/mCherry were mixed at a 1:1 ratio and cultured
in M9 with 0.3% 2’-FL. In agreement with the colony PCR results from Figure 3.8B, cells with
green fluorescence dominated the population during culture and virtually no red fluorescence was
detected. On the other hand, the same population cultured in lactose displayed roughly equal
relative fluorescence throughout the course of growth (Supplementary Figure S.2.12A). When this
culture reached the end of exponential phase, the cells were washed and diluted at a ratio of
1:100 into M9 media with 3-FL. This time, a red fluorescent population dominated, indicative of
the abundance of the AfcB-producing strain. Notably, near the end of the exponential phase, a
relatively small amount of green fluorescence began to appear. We believe this is indicative of
extracellular hydrolysis of 3-FL by AfcB via leakage or some other mechanism [85, 86] and is a
small source of crosstalk. However, we note that the red fluorescent signal is still significantly
higher (roughly 9-fold) and only appears after a few hours of growth. Finally, after reaching the
end of exponential phase, the population was washed again and diluted 1:100 in M9 with 2’-FL.
Green fluorescence again dominated the population with very little red fluorescent background.
We repeated the enrichment cycle in 2’-FL to determine if a similar high red fluorescence signal
was observed. It is unclear why some crosstalk seems to occur in the 3-FL cultures but not 2’-FL
cultures. However, leakage of enzymes from the periplasmic space is common, especially in the case
of heterologous expression [85] and is often inversely proportional to protein size [87]. The expressed
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AfcB protein is approximately half the molecular weight of the AfcA protein (50.36 kDa vs. 96.76
kDa), making it more likely to leak into the extracellular milieu and hydrolyze 3-FL to lactose in
the media. We also speculate that the 13-fold higher catalytic efficiency of AfcB relative to AfcA
[67] enables increased hydrolytic activity extracellularly. We thus demonstrated that the selective
pressure exerted by the single carbon source promotes controlled colonization which mirrors natural
strategies exhibited by probiotic bacteria.
3.4.10 Dynamic control of protein expression in mixed culture with HMOs
Recently, engineered microbial consortia have been used to divide tasks between constituent
strains or to change enzymatic expression as substrates are depleted [88–90]. As proof of principle,
we sought to demonstrate our ability to control expression of different proteins in mixed cultures of
E. coli strains using HMOs as inducers. We hypothesized that only in strains equipped to hydrolyze
a particular HMO to lactose would the lac operon be induced, thus providing orthogonal control
over protein expression in mixed cultures. To accomplish this, we inoculated 1:1 cultures of the
AfcA/GFP and AfcB/mCherry strains mentioned above, this time culturing them in rich media
(LB). Our results from the lactose spiked trials indicate that all cells are capable of growing and
expressing fluorescence, irrespective of the glycosidase expressed (Supplementary Figure S.2.12B).
These results stimulated additional experiments similar to that detailed in Figure 3.5B, using
LB media instead of M9 to ensure growth of both strains, to determine crosstalk between mixed
cultures. When cultured in rich media with 2’-FL, we observed high green fluorescent protein
expression but little mCherry expression (Figure 3.8D). When cells were washed and diluted into
3-FL, the mCherry signal dominated, and similarly the GFP signal dominated when the media was
switched back to 2’-FL. We found that the population distribution is altered, favorably towards
one with very minimal crosstalk. We thus demonstrate orthogonal, dynamic control of protein
expression in an unbiased mixed culture via induction using HMOs.
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Prebiotic enrichment and dynamic control of mixed culture. Figure continued on the next page.
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Figure 3.8 Prebiotic enrichment and dynamic control of mixed culture. (A) Growth kinetics of pAfcA
on glucose (orange pentagram), lactose (blue square), 2’-FL (green circle), 3-FL (turquoise
asterisk) and no carbon source (purple star) and of pAfcB on 3-FL (magenta diamond) or
2’-FL (yellow cross). (B) Population distribution after growth in lactose, 2’-FL or 3-FL.
Measurements were made by plating the enriched cultures on non-selective media and per-
forming colony PCR for afcA or afcB genes. Colonies were selected from three independent
plates (technical replicates) from two biological replicates. For statistical analysis, we mod-
eled the population using a binomial distribution to conclude for each dilution ratio, that the
enrichment of the strain was not due to chance but dependent on the carbon source. The
triple asterisk (***) represents a probability of <0.0001 that the result followed a binomial
distribution with respect to the observed lactose control. (C) GFP and mCherry fluorescence
readings from the enrichment procedure with three rounds of enrichment. 1:1 mixtures of
pAfcA/GFP (green circle) and pAfcB/mCherry (magenta square) biosensors were grown
minimal media with the indicated substrates. After the end of log-phase, cultures were di-
luted 100:1 and incubated in fresh minimal media containing the HMO of interest as the
carbon source. (D) GFP and mCherry fluorescence measurements of pAfcA/GFP (green
circle) and pAfcB/mCherry(magenta square) biosensors cocultured in rich media with the
HMO of interest as inducer.
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3.5 Conclusions
In this work, we developed a rapid, non-chromatographic, whole-cell biosensor for quantifica-
tion and linkage analysis of five different human milk oligosaccharides, covering three of the major
modifications to the lactose core: the addition of fucose, sialic acid, and GlcNAc. Since all HMOs
contain a lactose core, we submit that this method can be easily expanded to higher order human
milk oligosaccharides such as lacto-N-fucopentaose or 3-fucosyl-3’-sialyllactose by combinatorial ex-
pression of glycosidases. The throughput of this technique will allow optimization of both synthetic
and biotechnological processes for manufacture of HMOs, as many reaction conditions or bioreac-
tor parameters could be assayed at once (in multi-well format) in a matter of hours. We also
demonstrate the growth of E. coli on HMOs as a single carbon source, providing a growth selection
to complement the established fluorescent screening. In addition to optimization of bioprocess-
ing, this technology lays the groundwork for the use of directed evolution to engineer improved
linkage-specific glycosidases, enabling the expansion of a burgeoning glycobiology toolbox.
We also established the use of HMOs as a modulator of bacterial population in mixed culture,
selectively favoring the growth of the strain with the ability to metabolize the HMO of interest.
This phenomenon closely mirrors the relationship between prebiotic HMOs and bifidobacteria in
the infant gut [91] and serves as a springboard for the use of these prebiotics to manipulate popula-
tion dynamics and protein expression in engineered microbial communities. Taken together, these
applications have broad implications in, e.g., mechanistic studies of the microbiome and the use of
microbial consortia in metabolic engineering of complex high-value products [88]. Methods such as
these will help to expand our knowledge of the synergistic interplay of prebiotics and probiotics in
both the natural holobiont and synthetic microbial communities.
3.6 Significance
In this work, we developed a whole cell biosensor for the high-throughput detection of human
milk oligosaccharides (HMO), which are important prebiotic complex carbohydrate components
of human breast milk. With growing interest in biotechnology for HMO synthesis, owing to its
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beneficial effects on the infant gut microbiota, high-throughput screening is key to optimization of
biosynthesis. Current detection technology is limited by its throughput, cost and complexity and
determination of glycosidic linkage is particularly difficult.
We leverage the unique specificity of glycosidase enzymes to create a synthetic in vivo genetic
circuit that allows non-chromatographic, high-throughput, glycosidic linkage-specific, sensitive, and
orthogonal detection of lactose-based HMOs. We also demonstrated orthogonal, dynamic regulation
of growth and protein expression of selected strains in mixed cultures, mimicking the prebiotic effect
of these compounds. This biosensor platform has the potential to be used as a basis for directed
evolution of enzymes in the biosynthesis pathway and as a tool to modulate the population dynamics
of natural and engineered microbial communities.
Taken together, these results demonstrate that our whole cell biosensor can be leveraged toward
a broad range of biological applications including but not limited to (1) optimization of synthetic,
chemoenzymatic, and biotechnological synthesis of HMOs, (2) dynamic manipulation of microbial
populations and protein expression in those populations, and (3) increasing the availability of HMO
molecules to broaden the scope of research on these important biomolecules.
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3.7 Supporting Information
Figure S.2.9 Dynamic change in population with lactose and 2’-FL induction. Dynamics
of the reporter expression as shown by a set of representative flow cytometry
profiles. On the left (in blue) is the control population induced with lactose,
measured every hour. On the right (in green) is the population induced with
2’-FL.
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Figure S.2.10 Quantification of 2’-FL from producer strain, related to Figure 2.3E. (A)
Extracted ion chromatograms of 2’-FL (m/z 511), same as the commercial
standard shown on top. Chromatogram of 2’-FL from the JM109gwBC-F2
strain (10-fold dilution) is shown at the bottom. The peak at 511 m/z units
is the sodium adduct. (B) An enlargement of mass spectrum m/z from
300-800, where the most abundant signals were concentrated is shown for the
commercial standard (top) and the 2’-FL from the producer strain (bottom).
(C) A standard curve was created by LC-MS analysis with varying levels of
commercial 2’-FL. Error bars represent standard deviations from triplicate
measurements.
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Figure S.2.11 Characterization of glycosidases, related to Figure 2.4. (A) Sialidase activity
of periplasmic (pink) and YebF (purple) variants of NanH2 as quantified in
the periplasm and extracellular medium. (B) Fluorescent detection of LNT
II. Cells containing pET28:GFP and pBnaG (green), or an empty vector
control (blue) were induced for 16h with no sugar, lactose, LNT II or LNnT.
Error bars represent standard deviations from triplicate measurements.
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Figure S.2.12 Crosstalk and enrichment in lactose, related to Figure 2.8C and 2.8D. (A)
Mixed culture population dynamics with lactose in minimal media with
pAfcA and pAfcB in a 1:1 ratio. (B) Mixed culture population dynamics
with lactose in rich media with pAfcA and pAfcB in a 1:1 ratio. Error bars
represent standard deviations derived from three wells in a 96-well plate as
measured on a fluorescent plate reader.
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Table S.2.2 Parameters obtained from mathematical model.
Parameter Plasmid a b c d
2′-FL standard pafcA 44.33 1.74 103.8 2978






3′-SL standard pnanH2 58.62 3.85 984.3 2708
6′-SL standard pnanH2 3.15 1.46 5494 7029
3′-SL standard pyebF-nanH2 2.37E-
6
1.44 1499 10440
6′-SL standard pyebF-nanH2 15.73 1.68 1145 5189
Table S.2.3 Distribution of colonies following enrichment in defined media.
No. of colonies
Carbon source Inoculation ratio Distribution
afcA afcB afcA afcB
Lactose 1 1 14 12
2′-fucosyllactose 1 1 44 4
1 10 47 1
1 100 25 23
3-fucosyllactose 1 1 31 1
10 1 46 4
100 1 24 20
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Table S.2.4 Primers used in this study.
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4.1 Abstract
Advances in sensing technology have enabled analysis of different molecules including complex
carbohydrates. However, glycan analysis is limited by the throughput and complexity of assays for
quantifying them. We describe a simple, low-cost enzymatic assay for the rapid analysis of fucosy-
lation, down to linkage specificity, and its application to high-throughput screening of biologically
relevant fucosylated compounds, to facilitate the need for simple and straightforward analytical
techniques. Paper-based devices have started to integrate into biosensor platforms and other di-
agnostic assays and fusing them with wax printing technology makes their fabrication even more
inexpensive and simple. The specificity of the assay is established by linkage-specific glycosidic
enzymes and the colorimetric output is visible to the naked eye, with costs that are lower than
fluorescence/luminescence-based assays (0.2c/reaction). This platform was further improved by
enhancing storage stability to retain analytical performance over time using desiccation and freeze-
drying techniques. The assay platform allows analysis of hundreds of samples in minutes and we
anticipate that this rapid and simple analytical method will be extended towards developing a
universal glyco-barcoding platform for high throughput screening of glycosylation.
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4.2 Introduction
L-fucose is a common terminal sugar in glycans and oligosaccharides that has been attributed
to several key metabolic and structural functions [1, 2]. It is found as a terminal modification on
N-, O- or lipid-linked oligosaccharides and as a core modification on N-glycans or linked to serine
(Ser) or threonine (Thr) on proteins. It is also the second most abundant terminal monosaccharide
moiety, after sialic acid [3], found in mammalian carbohydrates to form various recognition motifs
on many glycoproteins and glycolipids. Most notably, fucose has important roles as a component
of ABO blood group antigens [4], a key modulator of interactions in the immune system and in
human breast milk. Breastfeeding is associated with a lower risk of infection in babies and the
underlying mechanism has been linked to the diverse range of complex sugars [5, 6], the human
milk oligosaccharides (HMOs) [7]. A large majority of these HMOs are fucosylated [8, 9], with
2’-fucosyllactose (2’-FL) being the most abundant HMO comprising approximately 2 g/L. Notably,
fucosylated HMOs inhibit binding and colonization of pathogens [10, 11] and provide protection
against diarrhea associated with stable toxin of Escherichia coli [12, 13], 2004). Supplementation
of 2’-FL to infant diet showed improved outcomes on innate and adaptive immune profiles [14], and
increasing evidence of the health benefits has led to its commercialization as a supplement in infant
formula. Similarly, the lipopolysaccharide (LPS) of Helicobacter pylori expresses Lewis antigens
(Lex, Ley, H type I blood group structures) resembling the surface of host gastric epithelial cells
[15] and upon H. pylori infection, this may cause antibodies to bind not only to the bacteria but
also the host epithelium resulting in tissue destruction. This antigen mimicry, being analogous to
ABO blood group antigens, may also provide persistence through immune evasion [16]. Fucosy-
lation is also an important oligosaccharide modification involved in cancer and inflammation [17].
The majority of human immunoglobulins (IgG) contain core fucosylation of the N-glycan in the Fc
region, the absence of which has shown to have enhanced antibody-dependent cellular cytotoxicity
(ADCC) activity due to increased binding affinity [18, 19]. Despite the biological importance of fu-
cose, a critical obstacle in elucidating its biochemical roles lies in the technical difficulties associated
with detection and analysis, especially with determining carbohydrate linkage positions. Current
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state-of-the-art methods for determining fucosylation include capillary electrophoresis (CE), mass
spectrometry (MS), HPAEC-PAD [20], NMR [21] or glycan sequencing, which are laborious meth-
ods requiring specialized equipment and sample preparation. Another established method with
higher throughput is the spectrophotometric detection of free L-fucose following defucosylation
by measuring the formation of NADH [22]. Seydametova et al. demonstrated quantitative as-
says for 2’-FL, utilizing hydrolysis by fucosidases [23, 24]. Their efforts, however, focused on a
single biological molecule and by spectrophotometrically measuring the end-point nicotinamide
adenine dinucleotide phosphate (NADP+) formed after an hour. Advances in synthetic biology
have enabled high-throughput screening via biological components that have been standardized,
for example, whole cell biosensors allow for the transduction of analyte concentrations to changes
in gene expression that facilitate high-throughput assaying [25–27]. We previously demonstrated a
genetically encoded whole cell biosensor to facilitate metabolic engineering by enabling the linkage-
specific high-throughput detection of 2’-FL and four other HMOs [28, 29]. The study demonstrated
orthogonal screening of HMO structures, but entails culturing bacterial strains relatively expensive
equipment to read fluorescence, e.g., flow cytometer or microplate reader.
To improve upon this assay, we sought to transfer the underlying detection mechanism to a
paper-based assay. Paper based devices have garnered attention, owing to their simplicity, low-
cost and portability and the minimum resources, time and equipment required in their fabrication
[30]. These devices also allow for rapid analysis of multiple samples in parallel. Colorimetric
assays producing a visual readout are a common choice for paper-based devices [31–33], with their
usefulness lying in the formation of brightly colored formazan products upon reduction. Notably,
they can be particularly useful in point-of-use or low-resource settings.
Here, we demonstrate a standard colorimetric assay for a simple, rapid, low-cost linkage-specific
sensing system for fucosylated biomolecules (Figure S.3.5A). To create this device, we expressed
enzymes specific for three different fucose linkages heterologously in E. coli and immobilized them
on to the paper device. Using a formazan reduction assay coupled with fucose dehydrogenase, we
then assay for the release of free L-fucose. The assay can detect many types of fucosylated molecule,
93
including HMOs, Lewis structures, and N-glycans. Finally, the assay can detect fucosylated com-
pounds in complex body fluid matrices such as human milk and simulated urine.
4.3 Experimental Methods
4.3.1 Chemicals and reagents
All reagents used were of analytical grade. Tris-HCl buffer (pH 9.5) was used as the buffer so-
lution. 2-(p-iodophenyl)-3-(p-nitrophenyl)-5-phenyltetrazolium chloride (INT), phenazine metho-
sulfate (PMS), NADP+ and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (Mil-
lipore Sigma, St. Louis, MO). Luria-Bertani (LB) culture medium, kanamycin and carbenicillin
were obtained from Sigma-Aldrich. Isopropyl β-D-1-thiogalactopyranoside (IPTG) was purchased
from Invitrogen (Invitrogen, Carlsbad, CA). 2’-Fucosyllactose and 3-fucosyllactose were a kind do-
nation by Glycom (Glycom A/S, Denmark). L-fucose, GDP-fucose, A1F-Glycan and 2-Acetamido-
2-deoxy-6-O-(6-deoxy-α-L-galactopyranosyl)-D-glucopyranose (Fuc-α-1,6-GlcNAc) were purchased
from Carbosynth (Carbosynth, Berkshire, UK). Phospholipase A2 (Apis mellifera) was purchased
from Enzo (Enzo Life Sciences Inc., Farmingdale, NY) and horseradish peroxidase from Sigma.
L-Fucose Assay Kit was purchased from Megazyme. All assay reagents were stored at -20 °C. The
assays were carried out at room temperature.
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Figure 4.1 Strategy for paper-based sensing of fucosylation. (A) Schematic illustrating
the immobilization of the enzymes on to the paper device and development
of colorimetric signal upon addition of analyte. (B) Reaction mechanism for
detection of fucose using a linkage specific fucosidase coupled to a colorimetric
assay based on INT tetrazolium dye, 2’-FL shown here. (C) Images of reaction
with free fucose (left) and 2’-FL (right) at 300 mg/L.
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4.3.2 Bacterial strains and plasmids
E. coli NEB 5-alpha (New England Biolabs Inc., Ipswich, MA) was used for routine cloning
and E. coli BL21 (DE3) was used for protein overexpression. Primers and synthetic DNA were
purchased from Integrated DNA Technologies (IDT). Construction of plasmid pAfcA and pAfcB
is reported in our previous work [28]. Plasmids pAfcA and pAfcB comprises of a constitutive pro-
moter and the fucosidase gene cloned onto a G9m-2 vector. Plasmid pET28:FDH was constructed
by replacement of GFP in the pET28:GFP plasmid with the fucose dehydrogenase (FDH) gene with
a His-tag fusion at the N-terminal. The FDH gene was amplified by PCR from the genomic DNA of
Bifidobacterium longum subsp. infantis ATCC 15697™ (American Type Culture Collection, Manas-
sas, VA). The FDH fragment was assembled into the pET28b vector, downstream of a T7 promoter,
using NEBuilder® HiFi DNA Assembly Master Mix (New England Biolabs Inc., Ipswich, MA).
The alfA gene from L. casei was constructed by DNA synthesis (IDT) after codon-optimization for
E. coli (IDT DNA Codon Optimization Tool). The gBlock was amplified and assembled into the
G9m-2 vector, downstream of the constitutive promoter. Bacterial transformations were carried
out using electroporation. The authenticity and orientation of the inserts was confirmed by DNA
sequencing at the Iowa State DNA Facility (Ames, IA).
4.3.3 Proof of concept using commercial kit
To test for the viability of using INT/PMS for a colorimetric readout for assaying free fucose,
we used a L-Fucose Assay Kit (Megazyme Inc., Chicago, IL). Different concentrations of L-fucose
were prepared and the assay carried out in a 96-well plate, according to the protocol supplied by
the manufacturer. 2 µL of the dye mix was added to the reaction mixes and allowed to react for
5 mins. To test for the release of fucose from 2’-FL and 3-FL, a range of concentrations of the
oligosaccharides were incubated with lysate from cells expressing pAfcA and pAfcB respectively,
and followed by the kit protocol. The absorbance at 500 nm was monitored throughout the reaction.
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4.3.4 Enzyme isolation
The fucosidase and FDH expressing strains were cultured in 50 mL of LB medium at 37 °C at
250 rpm, overnight with appropriate antibiotics (carbenicillin, 50 µg/ml and 30 µg/ml kanamycin,
respectively). The pET28:FDH was induced with IPTG (0.5 mM) at mid-log phase. These cultures
were then incubated at 37 °C in a rotary shaker (250 rpm) for 16 hr. The overnight cultures were
washed and resuspended in 2 mL water, and lysed by sonication (10 min, 30 s pulse, 30 s off, 30%
amplitude). Debris was removed from lysates by centrifugation at 5000 xg for 30 mins and the
supernatant stored at 4 °C. One unit of α-1,2-L-fucosidase activity was defined as the amount of
enzyme required to release one mmol of L-fucose per minute from 2’-FL (2 mM) in sodium phosphate
buffer (10 mM), pH 7 at 30 °C. The N-terminally His-tagged FDH was purified from the lysate
under native conditions using the QIAexpress Ni-NTA Fast Start Kit (Qiagen, Vallencia, CA). 5
µl of each fraction was mixed with 5 µl of 2x Laemmli Sample Buffer (Bio-Rad, Hercules, CA).
Each sample was heated at 95 °C for 5 minutes and resolved on SDS-PAGE. The gel was visualized
by Coomassie brilliant blue staining. The apparent molecular weight of FDH was approximately
32 kDa. The protein expression yields were calculated using a NanoDrop One Spectrophotometer
(Thermo Scientific, Waltham, MA).
4.3.5 Fabrication of paper-based sensor
The patterns for this study were printed on Whatman® grade 3 filter papers via wax-printing.
They were purchased as sheets measuring 460 mm x 570 mm and cut to letter-size. Filter paper
(Whatman 3) was chosen for its wicking properties and sturdiness, compared to filter papers of
other thicknesses.The detection zone patterns were designed as circles with 7mm inner diameter and
1 mm thickness on Adobe Illustrator (Adobe, San Jose, CA). The detection zones were printed with
a Xerox Color Qube 8570DN™ (Xerox, Norwalk, CT) printer using black hydrophobic wax-based
ink.
The printed paper was placed in an oven set at 180 °C for 5 mins. To assess if the hydrophobic
barriers fully penetrated the paper, water was spotted onto the detection zones to identify any
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bleeding and cross contamination between zones. If the water bled through, the paper was reheated
and tested again till no bleedthrough was observed. The paper was used once cooled to room
temperature. A layer of single-sided tape was used to seal the bottom side of the paper to contain
the liquid within the barrier and prevent leakage.
4.3.6 Performing paper-based assay
The lysates containing the enzymes were spotted at the center of the detection zones and allowed
to dry. A 20 µL reaction system contained 2.5 µM NADP+, 1.25 mM INT (in DMSO) and 0.5 mM
PMS (in DMSO). Table 4.1 shows a full listing of volumes of reagents required per reaction. A
mastermix containing all the reagents excluding the enzymes and the dye was made and added to
each well. The reactions were initiated by addition of the samples/standards, immediately followed
by the addition of the dye reagent. Reactions were set up under low-light conditions. A color
change was observed within 5 mins. All measurements were performed in triplicate. The paper was
left to incubate in the dark till dry. Once dry, the paper was scanned using an Epson Perfection
V800 Photo Scanner. To evaluate the limit of detection and generate a standard curve, a series of
dilutions of 2’-FL/3-FL were made and analyzed. Data were fit via non-linear regression analysis
using MATLAB.
Table 4.1 Procedure for running assay for determination of fucosylation
Reagent Standard Blank Sample
Distilled water 10 µL 11 µL 10 µL
Buffer 2 µL 2 µL 2 µL
NADP+ 0.5 µL 0.5 µL 0.5 µL
FDH 0.1 µL 0.1 µL 0.1 µL
Fucosidase 1 µL 1 µL 1 µL
Sample/standard 5 µL - 5 µL
INT/PMS dye 2 µL 2 µL 2 µL
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4.3.7 Image and statistical analysis
The scanned images were analyzed on ImageJ that provided intensity data for each reaction.
The MicroArray plugin was used that uses internally controlled regions of interest (ROI) and can
measure microarray image stacks. The RGB channels were split and intensities were analyzed
in the green channel and the mean values recorded. The background from the control with no
analyte was calculated for each measurement. Calibration curves (Figure 4.3C, 4.3D) were built
to get a quantitative readout from the measured transmittance. Comparison of our assay against
a commercial microplate-reader was also carried out. We defined the LoD as the lowest fucose
concentration that gave a colorimetric signal significantly above the control (no fucosylated analyte)
sample (P 0.01). P values were determined by performing a paired parametric t test on Origin. To
compare the analytical performance of our assay on biological fluids, we analyzed 6 random trials,
with one half of the experimental data set allocated toward blind testing.
4.3.8 Long term stability of the paper-based assay
To assess the stability of the paper assay, the AfcA enzyme lysates were spotted onto the
detection zones and left to air-dry in the fume hood for an hour at room temperature. Another
batch of spotted paper was subjected to lyophilization overnight. The papers were either stored
at room temperature or at 4 °C in plastic bags with silica pouches in the dark. To determine the
enzymatic activity after specific storage time, the assays for detection of 2’-FL were carried out over
a period of 45 days by rehydration with standard solutions. The colorimetric output was analyzed
as described earlier. All measurements were carried out at room temperature and in triplicates.
4.3.9 Analysis of biological samples
Pooled human breast milk samples were purchased from BioIVT (Westbury, NY). Surine™
Negative Urine Control was purchased from Cerilliant (Cerilliant Co., Round Rock, TX). HMOs
were extracted from human breast milk using established procedures. 200 µL of milk was centrifuged
at 9,000 rpm for 20 mins at 4 °C to remove lipids. After the top layer was removed, 400 µL of ethanol
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was added and centrifuged at 9,000 rpm for 10 mins at 4 °C and the supernatant collected. The
ethanol was removed by vacuum centrifuging and reconstituted in water to different concentrations
before analysis using the assay and validation of relative abundance carried out using LC-MS/MS.
We used an Agilent Technologies 1100 Series HPLC system coupled to an Agilent Technologies Mass
Selective Trap SL detector (Agilent Technologies, Santa Clara, CA) equipped with an electrospray
ion source (ESI) and controlled by ChemStation A.10.02, including data acquisition and processing.
Both MS and MS/MS spectra were acquired in the negative-ion mode with an acquisition rate of 1s
per spectrum over ranges of m/z 300 to 2,000 (for MS) and m/z 50 to 2,000 (for MS/MS). Precursor-
ion selection was performed automatically by the data system based on ion abundance. Three
precursors were selected from each MS spectrum to carry out product-ion scanning. Products were
analyzed on a Prevail Carbohydrate ES (250 mm × 4.6 mm id; 5 µm; Alltech Associates, Deerfield,
IL). The mobile phase consisted of water (aqueous solution containing 5 mM ammonium acetate)
and acetonitrile (AcN containing 5 mM ammonium acetate). The solvent gradient was delivered
at a flow rate of 1ml/min and consisted of an initial linear increase from 85% to 50% AcN over 10
min, held at 50% AcN for 2 mins and followed by a linear decrease to starting conditions for 2 min.
The injection volume was 5 µL. The dynamic range and linearity for the quantification of 2’-FL
and 3-FL were evaluated through the use of a series of dilutions as standard curves. To analyze
3-FL, the samples were concentrated in a vacufuge (Eppendorf, Hauppauge, NY). Disparities with
other cited literature may be due to different analytical technique and differences in biochemical
extraction process.
4.4 Results and Discussion
4.4.1 Fucosidases act as linkage-specific detection elements for fucosylated HMOs
To couple reduction of colorimetric dye to the quantification of 2’-FL, we used fucosidases
known in literature [28, 34] to be specific to the carbohydrate linkage to fucosylated molecules.
Free fucose can then be assayed using a redox-coupled reaction in which fucose dehydrogenase
(FDH) oxidizes L-fucose to fuconolactone, creating NADPH, which reduces the formazan dye. To
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confirm that this coupled reaction scheme would produce NADPH, we incubated 2’-FL (Fuc-α-1,2-
Gal-β-1,4-Glc) with commercial purified α-1,2-fucosidase to cleave the fucose and in the presence of
commercial FDH and NADP+. By following the increase in absorbance at 340 nm due to reduction
of NADP+ on a microplate reader, we verified the redox reaction undergone by the cleaved fucose
(Supplementary Figure S.3.5A).
However, the use of two purified enzymes can be expensive. To achieve an efficient, low-
cost detection system, we hypothesized that using a bacterial host as a heterologous system for
the production of high levels of functionally active recombinant enzymes would be cost-effective.
Because it efficiently and orthogonally cleaved L-fucose from 2’-FL in the context of a whole-cell
biosensor [28] we chose to express AfcA, an α-1,2-fucosidase from Bifidobacterium bifidum [35] under
a constitutive promoter, to liberate fucose from 2’-FL [28]. Cell lysate from overnight cultures of E.
coli BL21 (DE3) expressing AfcA was added to purified FDH with NADP+ as before. We detected
reduction to NADPH when 2’-FL was added as an analyte but not on the isomeric HMO 3-FL
(Galβ-1,4(Fuc-α-3)Glc) (Supplementary Figure S.3.5A). No background redox activity associated
with the components in the cell lysate itself was observed in an empty vector control over a period
of one hour. This strain served as a control in subsequent experiments, where the background noise
from the crude cell lysate was noted for all measurements.
4.4.2 Tetrazolium dye allows colorimetric detection of fucosylated compounds
Once we confirmed that the sequential reactions of cleavage by fucosidase followed by oxidation
by fucose dehydrogenase generated the reducing co-factor, we added a redox-sensitive dye to make
the assay visible by the naked eye. Tetrazolium salts have been historically used for testing cell
viability, proliferation and cytotoxicity [36, 37]. We chose 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-
phenyl-2H- tetrazolium chloride (INT), which in the presence of the intermediate electron carrier,
5-methyl- phenazinium methyl sulfate (PMS), is reduced to an insoluble formazan. This precipitate
absorbs light at a wavelength of 500 nm and provides a robust signal visible to the naked eye [38].
The generated NADPH, when coupled to INT, forms a stable red formazan (Figure 4.1B) and,
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being stoichiometrically proportional to the fucose concentration allows us to directly quantify the
fucose. We determined the optimum pH and buffer conditions for the enzyme cocktail in the assay
and coupled it with the INT/PMS assay to establish a colorimetric assay protocol.
We first tested the assay to determine free fucose with FDH from cell lysate. An intense color
change was observed with 500 mg/L L-fucose resulting in a 100% increase in absorbance within a few
seconds as read on a plate reader at 500 nm (Figure 4.1C). The reaction contains 2.5 µg of L-fucose
with NADP+ present in excess. In contrast, by measuring the NADPH formation by reading the
absorbance at 340 nm, a 30% increase in absorbance was seen at equivalent L-fucose concentrations,
which is to be expected since the molar extinction coefficient of INT formazan is 18000 M−1cm−1
compared to 6220 M−1 cm-1 for NADPH. Thus, the colorimetric system showed greater sensitivity
than changes in NADPH readout as demonstrated by the slopes in Supplementary Figure S.3.7A.
Notably, minimal background was again observed with the empty vector control. In addition, the
switch to a colorimetric reaction allowed us to scale down the reaction volume to 20 µL.
To demonstrate the utility of the assay in reliably detecting fucosylated molecules, we used the
assay to detect 2’-FL using additional crude cell lysate from cells expressing pAfcA. We titrated the
amount of cell lysate needed for optimum signal. For each 20 µL reaction, 5 µL lysate was added.
This also exhibited strong absorbance, a four-fold increase, with 2’-FL (300 mg/L) at the same
concentration of L-fucose (300 mg/L), containing, as previously tested (Figure 4.1D). The linkage
specificity was validated by the lack of significant increase in absorbance when tested with its isomer
3-FL, indicating that the α-1,3 linkage was not defucosylated. Similarly, we went on to demonstrate
that this method can be extended to the detection of α-1,3 linked fucose as well by using lysate of
cells harboring plasmid pAfcB expressing α-1,3-fucosidase under identical experimental conditions.
We observed a 1.4-fold change in absorbance with 3-FL but no color change was observed with 2’-FL
(Supplementary Figure S.3.5B). Similar to our previous biosensors, this assay also demonstrated
linkage specificity and the ability to distinguish between isomeric HMOs.
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4.4.3 Fabrication of paper-based platform
Once the colorimetric assay was developed, we focused on translating it to a paper-based assay
to a. Paper-based devices are fabricated from cellulose because it has advantages of being low-
cost, abundant, lightweight, biodegradable and biologically compatible [39, 40]. In addition, its
porosity and hydrophilicity offers wicking properties due to capillary action that can handle small
volumes of liquid with no external pumping [41]. To create our device, we used Whatman Grade 3
chromatography paper which is thicker and sturdier than the commonly used Whatman Grade 1
paper and defined the hydrophilic area using wax-printing method owing to its ease of printing using
commercially available printers. The design layout for the paper corresponded to the dimensions
of a standard 96-well plate [42]. We chose this to accommodate distinct test zones for independent
reactions that can be carried out in parallel, also allowing for the use of multi-channel pipettors for
rapid assaying. Once printed, we melted the wax in an oven. To ensure fully formed barriers, we
observed the bottom side of the paper. Prior to heating, no pattern is visible at the back. Upon
heating, the wax melts and vertically penetrates through the porous fiber network [43], which
becomes visible on the bottom. This allows for the aqueous sample and reagents to be contained
within spatially separated hydrophilic zones. There is also some lateral diffusion of the ink which
reduces the diameter of the detection zone, but this was taken into account during the design to
ensure appropriate dimensions. We designed the template with each well having a line thickness
of 1 mm and internal diameter of 5 mm; after heating, the diameter was reduced to 4 mm. Once
cooled, we further tested the hydrophobic barriers for leaks by addition of colored water and looking
for any sort of bleeding outside of the well. If the liquid failed to contain, the paper was heated
longer until no bleed-through was visible.
The procedure is illustrated in Figure 4.2 and detailed in the Methods. Once the device was
ready to use, the enzymes were directly applied to the detection zones. A mastermix containing
NADP+ dissolved in Tris-HCl buffer (pH 9.5) was then added to wet the test zones, followed by
the analyte to be tested. Immediately following that, the dye was applied and allowed to dry under
ambient conditions before scanning and analysis (Supplementary Figure S.3.6). In our experiments,
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it took less than 1 min from the addition of the dye for a detectable color change in the test zones
to occur.
4.4.4 Paper-based sensing for distinguishing fucosylated HMOs
Next, we implemented this paper-based colorimetric assay for distinguishing three fucosylated
HMOS: 2’-FL (Fuc-α-1,2-Gal-β-1,4-Glc), 3-FL (Galβ-1,4(Fuc-α-3)Glc) and DFL (Fuc-α-1,2-Galβ-
1,4(Fuc-α-3)Glc). We also tested for GDP-L-fucose, the donor substrate, a key component in the
biosynthesis of fucosylated HMOs [44, 45]. Either synthetic routes for 2’-FL and 3-FL, enzymatic
[46] or microbial via metabolic engineering [44], take place via GDP-L-fucose which can be present
in the final product at different levels. It is imperative that our assay is not sensitive to GDP-L-
fucose for its use in analysis of the products. For the assay we spotted the required enzymes on
to the paper: either no enzyme as control and for background reduction, only FDH for L-fucose
and GDP-fucose detection, FDH and AfcA for 2’-FL detection, FDH and AfcB for 3-FL detection
and combination of FDH, AfcA and AfcB for DFL detection. This was followed by the NADP+
dissolved in the buffer, the respective analytes and the dye. The paper was allowed to dry and for
the color to fully develop for an hour at room temperature before analysis. We first tested if the two
isomers, 2’-FL and 3-FL were distinguishable and if there was any crosstalk. We had established
earlier the lack of substrate promiscuity in AfcA and AfcB in the context of the whole cell biosensor
[28]. No fucose was liberated from 3-FL when AfcA was present (Figure 4.3A). Figure 4.3B shows
a 25-reaction array to distinguish three fucosylated HMOs. The control zones (top row with no
added enzymes and left column with no added substrate) showed no color change and the values
obtained were noted to account for the background signal from the dye and improve the accuracy
of the assay. Notably, no residual activity was observed with the concentrations of cell lysate used.
An intense color change from yellow to red was observed with free L-fucose when FDH was present,
as expected. This served as a positive control, confirming the activity of the FDH. With 2’-FL,
a color change was observed only when AfcA was present to cleave the α-1,2-linked fucose. We
thus obtained a signal only when AfcA or both AfcA and AfcB were present. We obtained similar
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results with 3-FL when AfcB was present. We did not observe any color change with GDP-fucose
implying the lack of enzymatic activity of FDH on GDP-fucose as a substrate (data not shown).
We generated the respective calibration curves by the addition of a series of dilutions of 2’-FL
and 3-FL in range 0-6000 mg/L. We then scanned the paper device using a desktop scanner and
analyzed the digital image on the green intensity channel. We quantified the color change in the
test zones, and converted the color change value into the corresponding concentrations using the
calibration curve for the assay (Figure 4.3C, 4.3D). The experimental data were fitted into a 4-
parameter logistic model (4PL) using MATLAB and the resulting transfer functions revealed the
dynamic range and limits of detection. The calibration curve for 2’-FL showed a wide dynamic
range between 150 and 2500 mg/L of 2’-FL (0.3-5 mM) and the limit of detection (LoD) was found
to be below 20 mg/L (0.04 mM) which satisfies the levels at which these biological molecules are
produced either naturally or via synthesis. For example, Baumgärtner et al. engineered an E. coli
strain to produce 2’-FL at levels of up to 21 g/L [44] and analysis of HMOs in human milk shows
2’-FL to be present 60-4650 mg/L [47, 48], which is well within the limit of our device. Similarly,
we characterized the assay for 3-FL (Figure 4.3D) and the dynamic range of detection was found
to be between 250 and 900 mg/L and the limit of detection below 250 mg/L.
We also measured the absorbance values of the series of 2’-FL concentrations in a 96-well
paper plate on a microplate reader to see the correlation with the values obtained from the paper-
based assay. Supplementary Figure S.3.7B shows the direct correlation of the absorbance values
as measured with a plate reader with the values from the paper-based assay which correlate quite
well.
4.4.5 Stability of paper-based sensor
Since the intrinsic instability of enzymes or proteins in general, makes it challenging for them
to be used for downstream applications, it was important to establish that our assay was functional
over a longer period of time. Different strategies have been developed to produce more stable
proteins and improve storage stability and shelf-life. The most frequently used method, especially
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in the biopharmaceutical industry is drying [49, 50]. We spotted the enzymes on the test zones and
either dried it at room temperature or by lyophilization. We then evaluated the stability of the
enzymes on the cellulose matrix by storage at room temperature or at 4 °C. We performed the assay
for 2’-FL detection under the four different conditions over a period of 45 days and imaged the
wells to confirm expression of the enzymes (Supplementary Figure S.3.7C). The dessicated enzymes
maintained the similar activity over a period of one week, and slowly started to decline. In 5 weeks,
the activity dropped to 50% of the original, under both storage conditions, and to 35% in 45 days.
However, when lyophilized, 70% of its activity was retained after 45 days. It was noticed that
with refrigeration, the decline in activity was slower compared to storage at room temperature. In
solution, the enzyme mastermix loses its activity at room temperature in one day and in less than a
week at 4 °C. Overall, the data demonstrates sufficient stability of the paper-based sensor, especially
under lyophilization. The assay can be stored at room temperature for shorter durations, avoiding
the need for cold-chain. Beyond portability, immobilization of the enzymes enables minimal sample
handling and cost and easy operation, without the need for specialized equipment and skills.
4.4.6 Analysis of fucosylated HMOs in breast milk and maternal/infant urine
There is good evidence showing positive roles played by HMOs in breast milk, especially fuco-
sylated HMOs, on infant health. The α-1,2 fucosyltransferase (FUT2) gene catalyzes the transfer
of α-1,2-linked fucose residue, while the α-1,3/4 fucosyltransferase (FUT3) transfers α-1,3-linked
fucose residues to HMOs. Secretor status (harboring a functional copy of the FUT2 gene) can be
established by profiling of HMOs in breast milk [51]. This variation in the composition of HMOs
in different mothers can provide some infants advantages over others.
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Figure 4.2 Schematic describing the design and process of setting up the paper-based
assay. (A) Layout of the wax printed array. Top panel shows the dimensions
of the wells. Bottom panel shows the printed array before and after heating,
as seen on the top and bottom surface of the paper. (B) Cell lysate containing
recombinantly expressed enzymes is spotted on the wells and immobilized. (C)

































































































































































































































































































































































































































We tested if our assay was capable of detecting and quantifying 2’-FL and 3-FL in human
breast milk to help identify secretors. As a control, we used powdered cow’s milk, reconstituted
to mimic breast milk. We also chose to validate the quantitation using HPLC/MS-MS based on
standard retention times and mass spectrometric analysis. For the human breast milk samples, we
observed a color change indicating a concentration of 5012 mg/L of 2’-FL (Figure 4.4A), which we
confirmed with a series of dilutions. The signal from the paper-based assay indicating higher 2’-FL
concentrations may be attributed to the presence of other α-1,2-fucosylated HMOs, such as lacto-
N-fucopentaoses (LNFP I, II, III and V). The concentration of 3-FL was below the detection limit
of the paper-based assay. However, we observed a color change once the samples were concentrated
five- and ten-fold (Figure 4.4B). 3-FL was found at 138 mg/L which corresponds to values found
in literature. We observed no color change with the cow’s milk samples, validating the robustness
of the assay in measuring fucosylation in biological fluids. Although we were able to get adequate
separation between the 2’-FL and 3-FL peaks, there was overlap. The peaks were fully resolved
by utilizing differences in m/z ratios of the deprotonated negative ions (MS) in conjunction with
the difference in retention time (HPLC) to resolve the isomers (Supplementary Figure S.3.8). To
confirm the identity of the peaks, we also carried out an exoglycosidase (α-1,2-fucosidase or α-1,3-
fucosidase) digest. Treatment with either α-1,2-fucosidase or α-1,3-fucosidase resulted in removal
or major reduction of the expected peaks (Supplementary Figure S.3.9). HMOs have also been
detected in the serum and urine of mothers, with 2’-FL at the highest concentrations in secretors
(20 mg/L) [52]. Studies have also shown high resemblance of HMO profiles in infant urine to
mother’s breast milk, as some are absorbed and reach the systemic circulation and excreted in
urine [53]. These samples can serve as excellent indicators of availability of fucosylated HMOs
to infants, allowing for supplementation when needed. We spiked non-biological urine containing
constituents that mimic human urine with 2’-FL within a physiologically relevant concentration
range. The levels of 2’-FL in urine have been shown to correspond to levels in the milk. Goehring
et al. found the urine of breast-fed babies of secretor mothers to contain 2’-FL in the range of
35-191 mg/L [54]. The assay responded to both low (20 mg/L) and high (200 mg/L) levels of
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2’-FL spiked in Surine (Figure 4.4C). Importantly, we did not see any interference from the urine
constituents with the enzymes in our assay.
4.4.7 Determination of fucosylation in glycoconjugates
Glycoconjugates comprise a complex and diverse group of molecules that play important biolog-
ical roles. Current methods of analysis of these molecules also involve labor-intensive procedures.
We hypothesized that our paper-based scheme would be sufficient to analyze other fucosylated gly-
coconjugates. We targeted the highly fucosylated blood group Lewis antigens, specifically the Type
2 structures: composed of Gal-β(1,4)-GlcNAc, giving rise to Lewisx (Lex), sialyl-Lewisx (Sia-Lex)
and Lewisy (Ley). We also tested the blood group H antigen, which is the fucosyl residue in blood
group antigens. Due to the presence of either one or both of α-1,2/3/4-linked fucose, we took a
combinatorial approach. With antigen H type 2, a colorimetric change was only observed with
AfcA (Figure 4.4D). Similarly, Lex was only detected in the presence of AfcB. With Ley antigen, a
three-fold increase in signal in the presence of two fucosidases was observed. Sia-Lex is sialylated
and we hypothesized that the sialic acid may interfere with the fucosidase activity. To test the
hypothesis, we also introduced an α-2,3-neuraminidase that can cleave the sialic acid bound to the
LacNAc. We observed a two-fold increase in the signal upon removal of sialic acid. Although the
assay is not orthogonal, it allows us to easily distinguish the Lewis Type 2 antigens. This tool
has the potential to determine the composition of HMOs in the milk of mothers as determined
by the Lewis blood group and hence, further aid in the development of more personalized HMO
supplementation. We next sought to determine if our paper-based assay had the capacity to detect
fucosylation in the context of more complex biomolecules like glycoproteins. We targeted two com-
mon glycoproteins that are α-1,3-fucosylated: horseradish peroxidase (HRP) and phospholipase A2
(PLA2) to serve as models. Core α-1,3-Fuc is a common N-glycan modification found frequently
on many plant and insect glycoproteins, but not mammalian ones. Since this core antigen does
not occur in mammals it may be responsible for inducing immunogenic responses in mammals [55].
110
These experiments were consistent with our previous results; we were able to see a strong signal in
the presence of α-1,3 fucosidase with both glycoproteins (Figure 4.4E).
One common mammalian N-glycan modification is core α-1,6 fucosylation. To specifically cleave
α-1,6 fucosylated N-glycans, we produced AlfA from Lactobacillus casei by recombinant expression
in E. coli as described earlier. AlfA is an α-1,6 fucosidase, shown to have specific hydrolytic activity
on α-1,6 linked fucose [56]. The recombinant enzyme was tested and validated on 6’-fucosyl-GlcNAc
and A1F-Glycan. 6’-Fuc-GlcNAc is an important modification of the core glycan in N-glycoproteins.
A1F-Glycan is a monosialo-fucosylated biantennary oligosaccharide, found on different mammalian
glycoproteins including IgG, gamma globulins, and many serum glycoproteins. We observed a
strong color change with both substrates and corresponded well with the amount of fucose in the
molecules (Figure 4.4F). The figures correspond to 0.4 µg and 2 µg of L-fucose in A1F-Glycan and
6’-Fuc-GlcNAc respectively. We also tested for the specificity of AlfA: no signal was seen with
α-1,2/3 linked fucosylated substrates (2’-FL and 3-FL respectively). This indicates that the paper
assay allows for efficient, linkage specific quantification of fucosylation in N-glycans. We attempted
to detect α-1,6 fucosylation in IgG from human serum but did not see any signal, possibly due to
fucose being below the limit of detection. No color change was observed when we tried analyzing
the isolated N-glycans by treatment of IgG with endoglycosidase PNGase A/F.
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Figure 4.4 Paper-based assay enables determination of fucosylation type in biological fluids and gly-
coconjugates. (A) Comparing measurement of concentrations of 2’-FL and 3-FL in human
breast milk using paper-based assay and HPLC/MS. Lipids and proteins were removed before
analysis. To analyze 3-FL, samples were concentrated. Inset shows chromatogram peaks for
2’-FL (black) and 3-FL (red). (B) Arrayed image showing colorimetric output from assay on
breast milk samples. * indicates concentrated samples tested. (C) Testing for 2’-FL in spiked
synthetic urine at levels found in maternal and infant urine. (D) Distinguishing Lewis Type
2 antigens and quantification of their fucosylation. (E) α-1,3-Fucosylation in glycoproteins.
Differences in the means of the test conditions and the controls were analyzed using a t-test (




Glycoscience is regaining attention owing to the colossal biological impact it has and there
is an urgent need for rapid and simple screening platforms for glycan analysis. With increasing
number of glycans being identified as disease biomarkers, glycan analysis is en route to becoming
an important diagnostic tool. For example, fucosylation in serum alpha-fetoprotein can serve as
a marker for early diagnosis of hepatocellular carcinoma. To enable more practical methods of
diagnosis or development of glycoprotein therapeutics, advances in analytical glycomics are needed
to overcome the bottlenecks associated with the state-of-the art technologies. Here we demonstrate
a robust, inexpensive, high-throughput colorimetric assay to quantify fucose in biologically relevant
fucosylated molecules. The main advantage of this assay is easy and quick way to perform it,
enabling in-line detection of multiple samples in parallel. This assay also minimizes the volume
of sample needed for analysis. While this assay can be useful in low-resource settings, it also has
the potential to leverage the metabolic engineering efforts for production of fucosylated glycans by
enabling the high-throughput screening of libraries of mutant variants. This can also provide a new
approach for directed-evolution efforts towards improved fucosyltranferase variants. This platform
demonstrates high specificity, reproducibility and stability, which constitutes a promising approach




Figure S.3.5 Orthogonality of enzymatic assay. (A) Timecourse of 340 nm absorbance
as measured on a micro-plate reader with fucose (red), 2’-FL (blue) and
3-FL (green) in the absence of α-1,2-fucosidase and 2’-FL (yellow) and 3-FL
(purple) in the presence of α-1,2-fucosidase. (B) Test for orthogonality of
fucosidases based on measurement of colorimetric readout of assay.
Figure S.3.6 Colorimetric readout using paper-based assay. (A) Image showing dilutions
of commercial 2’-FL captured within seconds of reaction. (B) Image after the
reactions were dry.
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Figure S.3.7 Testing the robustness of the assay and paper device. (A) Colorimetric read-
out using imaging software in comparison to readouts using a microplate
reader. Based on the Mann–Whitney–Wilcoxon test, the two datasets in the
range 0-75 mg/L, are not significantly different. (B) Sensitivity of tetrazolium
dye (500 nm) in comparison to NADPH absorbance (350 nm). Mean readings
with error bars representing standard deviations of three independent exper-
iments is shown. (C) Viability of paper device after 45 days under different
enzyme immobilization techniques and storage conditions.
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Figure S.3.8 Quantification of fucosyllactose isomers using HPLC-MS. (A) (top to bottom)
Extracted ion chromatograms of 2’-FL (m/z 523); specific ion profile for 2’-FL
from MS; a standard curve was created by LC-MS/MS analysis with varying
levels of commercial 2’-FL. (B) (top to bottom) Extracted ion chromatograms
of 3-FL (m/z 523); specific ion profile for 3-FL from MS; a standard curve
was created by LC-MS/MS analysis with varying levels of commercial 3-FL.
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Figure S.3.9 Validation of isomer peaks by exofucosidase digestion. (A) Peaks before and
after treatment with α-1,2-fucosidase to digest 2’-FL (B) Peaks before and
after treatment with α-1,3-fucosidase to digest 3-FL.
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CHAPTER 5. A RAPID, ENZYMATIC ASSAY FOR ANALYSIS OF
SIALYLATED GLYCANS
Fatima Enam1, , Andrea Alvarez-Acosta1, Thomas J. Mansell1
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5.1 Abstract
Rapid sensing of biological molecules is an emerging application. Sialic acids are a diverse
family of monosaccharides found commonly in glycoconjugates of mammalian cells. These sialy-
lated glycans particularly play key roles in cell communication, fertilization, adhesion and cancer
metastasis. Traditional methods for detecting sialylation are costly, time-consuming, and require
extensive infrastructure and technical expertise that may not be readily available, especially in
resource-limited settings. We developed two assays that provide a simple and rapid method for
detection and quantification of sialylated glycans in various biological samples, both simple glycans
and glycoconjugates, down to below 40 µM sialic acid. The output can be fluorometric or colori-
metric and obtained in less than 30 mins. This work guides towards a new platform to facilitate
the detection and quantification of glycosylation in a wider array of biological molecules.
5.2 Introduction
Glycan biodiversity is one of the most complex features in all biological systems that occurred
over millions of years of evolution [1]. Glycans are as universal in nature as nucleic acids, proteins
and lipids [2] and essential to the existence of life [3]. However, unlike the genome and proteome,
the glycome is not template-driven. In addition to that, another level of complexity arises from
their structurally diversity and rapidly evolving nature. This makes glycans inherently challenging
to study and very little is still known, leaving plenty to be explored.
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Of these glycans, sialic acids are a diverse family of sugar units with a nine-carbon backbone
that are typically found attached to the outermost ends of these chains. Given their location and
ubiquitous distribution, sialic acids can mediate or modulate a wide variety of physiological and
pathological processes [4]. Due to their negative charge and hydrophilicity, sialic acids have many
structural or physical roles, for example in neural plasticity, glomerular filtration or blood cell
charge repulsion and also serve as components of binding sites for various pathogens and toxins
[4–8]. Sialic acids also serve as ligands for intrinsic receptors such as Siglecs and factor H [9–11].
Changes in sialic acid expression are seen in many pathological states and measurements of body
fluids have been used to predict disease risk [12, 13]. Microbial pathogens decorate themselves with
sialic acids, assisting in evasion of host immunity. Sialylation of bacterial protein in Campylobacter
jejuni is believed to play an important role in the pathogenesis of Guillain–Barré syndrome (GBS),
an autoimmune neuropathy [14]. Also an overall general increase in sialic acid content has been seen
in tumor cells [15]. If we turn the synthesis of therapeutic glycoproteins where sialylation is key for
functionality, different parameters can affect the sialic acid content of recombinant glycoproteins
and result in inconsistent sialic acid content of the proteins. These variations in sialic acid are
exceedingly important and emphasis needs to be placed in adequately and rapidly analyzing the
degree of sialylation in a high-throughput method.
One major technical hurdle with deciphering this glyco-code is the difficulty in analyzing the
glycan structures. Conventional methods of glycan structure analysis involve chromatography and
mass spectrometry, which do not give complete information [16, 17]. These methods are still limited
by the quantity of the glycan and isobaric structures of monosaccharides are difficult to identify.
Fragmentation of glycans can convey additional information [18], but NMR analysis is needed for
determination of glycan sequence, branching, and linkage and isotopic labeling for quantification
[19]. Affinity-based methods exist that use lectins to specifically bind glycans [20], but the lack of
stringent specificity makes it difficult to distinguish glycans [21]. Metabolic labeling and chemical
ligation have been developed for in vivo imaging of sialylated proteins expressed on the cell surfaces
of organisms [22, 23]. Metabolic oligosaccharide engineering (MOE) is an alternative approach
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for labeling and detecting sialylated and fucosylated glycans by harnessing the glycan metabolic
machinery to incorporate unnatural monosaccharide substrates that is imaged downstream [24, 25].
However, this method cannot be used to detect higher order glycans or to determine linkage [26].
One high-throughput strategy developed for linkage-specific detection and quantification involved
using whole-cell biosensors that express an array of specific glycosidases for analyzing glycans with a
lactose core [27]. Different colorimetric, enzymatic, fluorescence and chromatographic methods have
been developed that either requires derivatization or chromatographic purification for glycoproteins
[28]. Another high-throughput method developed by Markely et al. that measures fluorescence still
relies on chemical derivatization of sialic acid by malononitrile [29].
Here we describe a rapid enzymatic method for the quantification of free sialic acid in hu-
man milk oligosaccharides (HMO) and screening of sialic acid in glycoproteins using a fluorescent
dye. We further demonstrate a colorimetric assay for a simple, rapid, low-cost sensing system for
sialylated biomolecules. The fluorescence intensity/color change is proportional to the concentra-
tion of sialic acid released from the oligosaccharides or glycoproteins. This assay can provide a
high-throughput screening platform for the simultaneous screening of multiple glycans.
5.3 Experimental Methods
5.3.1 Bacterial strains and plasmids
E. coli NEB 5-alpha (New England Biolabs Inc., Ipswich, MA) was used for routine cloning
and E. coli BL21 (DE3) was used for protein overexpression. Primers and synthetic DNA were
purchased from Integrated DNA Technologies (IDT). Construction of plasmid pNanH2 is reported
in our previous work [27]. Plasmid pNanH2 comprises of a constitutive promoter and the sialidase




































































































































5.3.2 Chemicals and reagents
All reagents used were of analytical grade. 10 mM phosphate buffer (pH 5.5) was used as
the buffer solution. Sodium phosphate dibasic, sodium phosphate monobasic, NAD+ were pur-
chased from Fisher Scientific (Fisher Scientific International, Pittsburg, PA). Sialic acid aldolase
from Escherichia coli, pyruvate dehydrogenase from porcine liver, neuraminidase from Clostridium
perfingens, diaphorase from Clostridium kluyveri and fetuin were purchased from Sigma Aldrich.
Luria-Bertani (LB) culture medium and carbenicillin were obtained from Sigma-Aldrich (Millipore
Sigma, St. Louis, MO). 3’-sialyllactose (3’-SL) and 6’-sialyllactose (6’-SL) were purchased from
Carbosynth (Carbosynth, Berkshire, UK). Neuraminidase Assay Kit was purchased from Sigma-
Aldrich (Millipore Sigma, St. Louis, MO). All assay reagents were stored at -20 °C. Unless otherwise
indicated, all assays were carried out at room temperature.
5.3.3 Enzyme isolation
The recombinant sialidase enzyme expressing strain was cultured in 50 mL of LB medium at
37 °C at 250 rpm, overnight with appropriate antibiotic (carbenicillin, 50 ug/ml). The culture
was then incubated at 37 °C in a rotary shaker (250 rpm) for 16 hr. The overnight culture was
washed and resuspended in 2 mL water, and lysed by sonication (10 min, 30 s pulse, 30 s off,
30% amplitude). Debris was removed from lysate by centrifugation at 5,000 xg for 30 mins and
the supernatant stored at 4 °C. One unit of α-1,2-L-sialidase activity was defined as the amount
of enzyme required to release one mmol of sialic acid per minute from 3’-SL (2 mM) in sodium
phosphate buffer (10 mM), pH 5.5 at 30 °C.
5.3.4 Enzymatic assay
The enzymatic reactions were carried out in 384-well plates. A mastermix containing all the
reagents and enzymes was prepared. The lysates containing the enzymes were spotted at the center
of the detection zones and allowed to dry. Table 5.1 shows a full listing of volumes of reagents
required per reaction. Each 30 µL reaction system contains 18 µL PB buffer, 1 µL TPP (18 mM),
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10 µL Coenzyme A (0.72 mM), 1.5 µL NAD+ (2.5 µM), 0.5 µL PDH, 0.5 µL NanA, 0.6 µL MgCl2
(1 mM), 1.8 µL DTT (0.3 mM) and 4.5 µL of either resazurin/PMS or INT/diaphorase dye (70
µM). The reactions were initiated by addition of the samples/standards, immediately followed by
the addition of the dye reagent. The kinetics of the fluorescent reaction were then monitored on
a microplate reader (excitation wavelength: 540 nm; emission wavelength: 590 nm) for 30 mins.
In the presence of sialic acid, the blue dye gets reduced to pink fluorescent resorufin. Background
activity was measured in a control reaction with no substrate, which was subtracted from all
measurements. For the colorimetric assay, the mastermix was spotted onto the paper device before
the analytes were added. The reactions were incubated in the dark at room temperature. Once
dry, the paper was scanned using an Epson Perfection V800 Photo Scanner. All measurements
were performed in triplicate. To evaluate the limit of detection and generate a standard curve, a
series of dilutions of 3’-SL/6’-SL were made and analyzed. Data were fit via non-linear regression
analysis using MATLAB.
Table 5.1 Procedure for running assay for determination of sialylation
Reagent Standard Blank Sample
PB Buffer 18 µL 23 µL 18 µL
Triphenylphosphine Dichloride 1 µL 1 µL 1 µL
CoA 10 µL 10 µL 10 µL
NAD+ 1.5 µL 1.5 µL 1.5 µL
Pyruvate Dehydrogenase 0.5 µL 0.5 µL 0.5 µL
Aldolase 0.5 µL 0.5 µL 0.5 µL
Magnesium Chloride 0.6 µL 0.6 µL 0.6 µL
5.4 Results and Discussion
5.4.1 Heterologous sialidases as detection elements for sialylated HMOs
We started by determining if sialidases cleaved sialic acid from sialylated molecules that can be
detected and quantified. We tested this using a commercial Neuraminidase Assay Kit. Towards
achieving an efficient, low-cost system, we hypothesized that using a bacterial host as a heterologous
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system for the production of high levels of functionally active recombinant enzymes would be an
efficient system. We also hypothesized that with specific sialidases, the bond hydrolysis would be
orthogonal. We chose the pNanH2 plasmid from our previous work, expressing α-1,3/6-sialidase
under a constitutive promoter, to liberate sialic acid from 3’-SL and 6’-SL. This plasmid was
transformed into E. coli BL21 (DE3) and cultures grown overnight. We measured the sialidase
activity in the cell lysate using the commercial kit on 3’-SL and 6’-SL. We detected activity on
both substrates. To determine if there was any background activity associated with the components
in the cell lysate itself, we prepared cells with an empty vector and carried out the same experiment
with 3’-SL. No significant change in absorbance was observed over a period of one hour.
5.4.2 Detection of sialic acid using enzymatic assay
Next, we designed an enzymatic pathway that can be expressed in native/heterologous hosts
and would allow us to quantify sialic acid in a high-throughput manner. In the first step of
the enzymatic assay, NanH2, an α-2,3/6-sialidase, cleaves N-acetylneuraminic acid from sialylated
molecules. A sialic acid aldolase then catalyzes the conversion of the liberated N-acetylneuraminic
acid into N-acetyl-D-mannosamine and pyruvate. The pyruvate molecule then gets oxidized by
pyruvate dehydrogenase (PDH) to produce acetyl CoA, in the presence of coenzymeA. During this
process, NADH is generated and the oxidation reaction is coupled with the reduction of resazurin
to resorufin by NADH. Resazurin is a blue dye that produces a pink fluorescence when reduced
in the presence of phenazine methosulfate, an electron mediator. We determined the optimum pH
that would allow this enzyme cocktail to function. As a proof-of-concept, we validated the high-
throughput assay for analyzing sialic acid content of HMOs. The reaction mechanism is shown in
Figure 5.1, reaction A, with 3’-SL as an example. The total volume for each reaction was 45 µL.
The fluorescence is a function of glycan concentration and hence, quantification of the sialic acid
content in the glycans can be accomplished. To test the ability of the assay to reliably detect sialic
acid in simple biological molecules, we tested on two sialylated HMOs, 3’-SL and 6’-SL. Highly
fluorescent signals were measured indicating the sialylation in the molecules. We generated the
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respective calibration curves by addition of a series of dilutions of 3’-SL and 6’-SL in range 0-3000
mg/L (Figure 5.2). The limits of detection were below 50 mg/L for both HMOs. The dynamic
range for 3’-SL and 6’-SL were 100-2000 mg/L.
Figure 5.2 Limits of detection and transfer functions. Dose response curves for determi-
nation of limits of detection for (A) 3’-SL and (B) 6’-SL. The data was fit with
a Hill model. Mean readings with error bars representing standard deviations
of three independent experiments is shown.
5.4.3 Detection of sialic acid in glycoproteins using fluorescent enzymatic assay
Protein glycosylation is one of the most important post-translational modifications. The glycan
moieties linked to these proteins greatly influence their structure and activity, and hence glycan
profiling has significant implications in the diagnostic and therapeutic aspects. This makes gly-
comics an emerging strategy in biomarker discovery, drug development and clinical applications
[30, 31]. As more evidence emerges, indicating importance of glycans to pathological mechanisms,
disease diagnosis, transfection, and therapy, there is a clear demand for more details about glycan
structures and concentration levels in samples belonging to different populations and disease de-
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velopment stages. and a highly sialylated glycoprotein, fetuin. Fetuin is a glycoprotein with high
levels of glycosylation, found in abundance in fetal bovine serum. Fetal bovine fetuin contains three
N-linked complex glycans and five O-linked glycans (Figure 5.3A) with the N-glycans accounting
for 79% of the total glycans by mass [32]. The known O-glycans on the protein include a disia-
lylated core-1 O-glycan, a monosialylated core-1 O-glycan and a disialylated hexasaccharide. We
obtained commercial fetuin that contains 8.7 wt% sialic acid, most of which is in the bound form.
We used our assay to determine the sialylation in fetuin. We tested controls with no silaidase to
account for any free sialic acid that gave background signal. Figure 5.3B shows the dose-response
curve for dilutions of fetuin in the range 0-10 g/L. The limit of detection is 500 mg/L of fetuin that
corresponds to lower than 50 mg/L sialic acid.
Figure 5.3 Determination of glycoprotein sialylation in fetuin. Dose response curves for
determination of limits of detection in fetuin, composed of 8.7 % (wt.) sialic
acid. The data was fit with a Hill model.
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5.4.4 Colorimetric detection of sialic acid in human milk oligosaccharides using tetra-
zolium dye
While we were able to detect sialylation down to very low limits of detection in a high-
throughput manner with the fluorescent assay, we also wanted to develop an assay that exhibited
high simplicity and required minimum instrumental investment. In our previous work, we demon-
strated a simple colorimetric assay on a paper-based device that allowed us to analyze fucosylation
in various fucosylated biological molecules [33]. Paper is a common, low-cost, and user-friendly
material that can be used for a simpler, inexpensive, and rapid assay.
In our previous work, the reduction of NADP+ was coupled to a colorimetric assay based
on INT tetrazolium dye, that forms a stable red formazan in the presence of the intermediate
electron carrier, 5-methyl- phenazinium methyl sulfate (PMS), when reduced. We tested to see
if we could replace resazurin with INT/PMS and get the same response. We observed no color
change. We tested further with other tetrazolium dyes, including 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), 2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-tetrazolium-
5-carboxanilide (XTT) and nitroblue tetrazolium chloride (NBT) but no color change was seen.
We hypothesized that the intermediate hydrogen carrier here, PMS, was unable to adequately
transfer the reducing equivalent to the final acceptor tetrazolium salts. We substituted PMS for
another well-known electron carrier, diaphorase, which belongs to a ubiquitous class of flavin-
bound enzymes that show NADH dehydrogenase activity. The detection principle follows the same
enzymatic pathway but the pyruvate oxidation step is now coupled to a tetrazolium dye in the
presence of diaphorase, as shown in Figure 5.1, reaction B. A strong signal was observed with
INT. Similar changes were observed with MTT, XTT and NBT (data not shown). Following this
established colorimetric detection of sialic acid, we tested this assay on the paper device.
We generated a calibration curve for 3’-SL by the addition of a series of dilutions of 3’-SL in
range 0-6000 mg/L (Figure 5.4B). Here, we created the mastermix of all the reagents and added it
to the wells. Once the analytes and the dye were added, we waited for the paper to dry. It took less
than 30 mins to observe a color change. We then scanned the paper device using a desktop scanner
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and analyzed the digital image. The experimental data were fitted into a 4-parameter logistic model
(4PL) using MATLAB and the resulting transfer functions revealed the dynamic range and limits
of detection. The calibration curve for 3’-SL showed a wide dynamic range between 200 and 2000
mg/L (0.3-5 mM) and the limit of detection (LoD) was found to be below 50 mg/L (0.04 mM).
Figure 5.4 Development of a colorimetric sialylation assay. (A) Colorimetric output with
two intermediate electron carriers, PMS (left) and diaphorase (right). (B)
Transfer function for sensing 3’-SL. Response curve depicts mean color intensity
(analyzed in triplicate). The dose-response curve was fitted with a 4PL model,
shown by the line. The top shows a capture of the signal expression from
increasing concentrations of 3’-SL. The data was fit with a Hill model.
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5.5 Conclusion
In this work, we demonstrate a strategy for designing a simple, one-pot, high-throughput as-
say for sialic acid in biological molecules. While there are commercial kits available for analyzing
sialylated compounds, they require sample preparation and cannot directly measure sialic acid in
glycoconjugates. We demonstrate here a rapid fluorometric assayfluorescence assays using spec-
trophotometry has proven to be an accurate and fairly simple, it is not the ideal method in terms
of cost and resource availability and most definitely demand power to function. Building off of
previous work, we demonstrated a colorimetric paper-based assay for sialic acid using the same
principles. Reproducing the reaction in a paper-based assay is a feasible method of analyzing sia-
lylated glycans for use as a diagnostic device. The use of this paper technology complements the
fluorometric assay, making it a more robust platform. This avoids complex construction and need
for modern laboratories including personnel with the requisite technical training. We demonstrated
detection of sialylation in 3’-SL and 6’-SL, key HMOs in human breast milk, and can be applied
towards other biologically important sialylated conjugated glycans and biomarkers. The end goal
is to develop a platform for the detection of glycans based on a barcoding strategy. This can be
combined with the previously discussed assay for fucosylated glycans and they can be integrated
into a single device, either paper or microplate, to identify clinically relevant glycans. This enabling
technology can lead towards a sensitive, high-throughput, and low-cost platform for point-of-care
diagnostics.
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CHAPTER 6. ENGINEERING INTERACTIONS IN MICROBIAL
COMMUNITIES USING HUMAN MILK OLIGOSACCHARIDES
Fatima Enam1, Logan Ryerson1, Thomas J. Mansell1
1. Department of Chemical and Biological Engineering, Iowa State University, Ames, IA 50011
6.1 Abstract
The human gut microbiota is a complex ecosystem of microorganisms that play key roles in
host physiology and prebiotics like human milk oligosaccharides (HMO) have been used as dietary
interventions to modulate the composition [1]. Access to hydrolytic enzymes allows microbes to
break down complex carbohydrates, giving them a competitive advantage. Here we engineered
bacterial strains to test different ecological theories of competition. We show how synthetic com-
munities engineered to hydrolyze HMOs can be modulated by different HMOs. Cross-feeding was
simulated where the strain that was not able to degrade the HMO could grow on lactose released
by the other strain during HMO breakdown. Probiotics have great potential to modulate changes
in the host gut microbiome. We demonstrated how HMOs can serve as a route through which
engineered butyrate producing Escherichia coli Nissle 1917 can be modulated across communities.
These results showing experimental manipulation of complex communities can provide insights into
the fundamental biology of microbial interactions and help to harness the power of the microbiome
and can be further expanded towards fine-tuning of therapeutic probiotics.
6.2 Introduction
Complex communities of microbial species are connected via intricate interactions and are in
constant competition with their neighbours for space and resources [2]. In their natural habitat, mi-
crobes exist as members of complex communities composed of multiple taxa, known and unknown,
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and these consortia are being adapted for biotechnological applications [3]. This is due to the
advantages that consortia have over monocultures, for example, lower metabolic burden, higher
metabolic capabilities and robustness to external perturbations or competition from indigenous
microbes [4] and inter-species communication [5], including metabolic interactions with varying
degrees of reciprocity. However, these consortia incorporate large complexities, posing a challenge
to fully understand these systems. An improved understanding of these microorganisms and their
interactions can aid in interpreting the role and importance of each microorganism in a specific
community and environment, and can have multitudes of useful applications in biotechnology [6].
Although both top-down and bottom-up approaches can be taken to study these systems, much
has been learned through metagenomic studies that offers a comprehensive insight into the com-
munity as a whole. Other –omics analysis like transcriptomics, proteomics, metabolomics and flux
analysis are being used to elucidate all interactions in communities [7]. Bottom-up approaches
can offer a cornucopia of information relating to single species but the method can be challeng-
ing owing to the recalcitrance to cultivation and difficulties involved in isolating many microbes.
This led to the designing of synthetic communities, communities of model organisms engineered
to model interactions to address fundamental questions and understand the dynamics of the com-
plex functions that these communities perform. Engineers have employed synthetic biology to
model different behaviors within populations, undertaking communication and differentiation of
function in designing the synthetic consortia, for example, cell-cell communication via bacterial
quorum sensing components [8, 9], metabolite dependence via auxotrophy [10], etc. These tools
have facilitated the assembly and control of interactive synthetic microbial consortia and allows for
the detailed study of its components under controlled and reproducible conditions, facilitating the
establishment of causal links between genotypes and phenotypes. Another advantage lies in the
ability to add, eliminate or substitute at all levels, where individual strains, species or functions
can be specifically removed or added. Consequences of any perturbations can also be monitored
at different levels, enabling us to understand the roles of individual microbes in the context of a
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community. These myriad of relationships between members can be neutral, positive or negative,
including competition, commensalism, mutualism and parasitism [11].
The increasing recognition that the gut microbiota plays a central role in human health suggests
that the manipulation of microbial taxa through diet may provide a means to achieve a beneficial
outcome for the host in a reproducible and consistent manner. Nutritional interactions play a
large role in a microbe’s metabolic capacity and in determining its predominance, in some cases,
survival within a microbial community [12]. HMOs, for example, have been shown to play a
major role as a prebiotic, in shaping the gut microbiome and a key component in developing the
immune system and preventing infectious diseases. HMOs are the third most abundant class of
biomolecules found in human breast milk after lactose and lipids [13]. They are composed of five
different monosaccharides (glucose (Glc), galactose (Gal), N-acetyl-glucosamine (GlcNAc), fucose
(Fuc), and sialic acid (Neu5Ac)) that link together in different orientations, forming more than two
hundred unique oligosaccharides ranging in complexity [14]. HMOs in the infant diet are resistant
to host-mediated hydrolysis due to lack of hydrolytic enzymes and serve as a carbon source for the
distal gut microbial community. With increasing evidence of their benefits from in vitro and in vivo
studies, companies have started to supplement 2’-FL to infant formula [15]. A microbe’s exclusive
access to limiting nutrients can give it a competitive advantage in a community but often times they
may engage in cooperative behaviors as well [16]. Metabolites secreted by one microorganism can
induce cross-feeding that can favor growth of other organisms but may also promote the emergence
of social cheaters that benefit not only from capitalizing on these molecules but also lower metabolic
burden [17].
Complex carbohydrates, including prebiotics, continue to receive attention as a dietary interven-
tion that can benefit the host through mechanisms that include altering the intestinal microbiota
[18, 19]. We previously showed orthogonal and dynamic regulation of growth of specific strains in
mixed cultures, using prebiotic compounds [20]. We used human milk oligosaccharides (HMOs)
as a modulator of bacterial population in cocultures, selectively favoring the growth of the strain
with the ability to metabolize the HMO of interest. We demonstrated that the selective pressure
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exerted by a single carbon source was able to promote controlled colonization, which mirrored
natural strategies exhibited by probiotic bacteria. Although this helped capture the dynamics in
a coculture with two populations, it ignored controlled composition and behavior of higher-order
mixed cultures and any interactions between populations. Here, we describe engineering strate-
gies we took to develop and control synthetic consortia that effectively perform desired functions
and exhibit ecological interactions. We also demonstrate here cross-feeding, where the primary
prebiotic substrate, 2’-fucosyllactose (2’-FL) or 3’-sialyllactose (3’-SL) is converted to accessible
lactose by one population that can be metabolized by the other populations. We not only demon-
strate modulation of microbial population but also modulation of synthesis of molecules within
the communities. This simplified synthetic consortia will allow us to study elementary ecological
interactions in isolation.
6.3 Experimental Methods
6.3.1 Bacterial strains and plasmids
The plasmids and strains used in this study are listed in Table 6.1. E. coli NEB 5-alpha (New
England Biolabs Inc., Ipswich, MA) were used for routine cloning. Plasmids were constructed using
Gibson assembly. The plasmid pET28:GFP was a gift from Matthew Bennett (Addgene plasmid
60733). pET28:GFP is the pET28b expression vector with GFP downstream of the T7-specific
promoter PT7/LacO, which contains binding sites for the lactose repressor, LacI [21]. Plasmid
pET28:mCherry was constructed as described by Enam and Mansell [20], by replacing the GFP
with mCherry on plasmid pET28:GFP. Plasmids pAfcA, pAfcB, pNanH2 and pBnaG, as described
by Enam et. al. [20], comprises a constitutive promoter, ribosome binding site, periplasmic signal
sequence and glycosidase open reading frame cloned into G9m-2 vector. pYebF-AfcA and pYebF-
NanH2 were derivatives of their pelB variants. To construct these, yebF from E. coli was PCR
amplified and cloned as an N-terminal fusion to the glycosidase. The sequences of all plasmids
constructed in this study were confirmed by DNA sequencing.
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Escherichia coli Nissle 1917 (EcN) was kindly provided by Dr. Milton Allison (Iowa State Uni-
versity College of Veterinary Medicine). This strain was engineered using CRISPR/Cas9 to produce
butyrate: ∆frdA ∆ldhA ∆adhE ∆pta-PL-hbd-crt-ter. Both the wildtype EcN and engineered EcN
were transformed with the plasmids described above, in all combinations, one glycosidase harboring
plasmid and another reporter plasmid.
Table 6.1 Strains and plasmids used in this study
Plasmid Description Reference or
source
pAfcA AmpR, pG9-m2 vector with B. bifidum afcA under pJ23110
with N-terminal PelB signal sequence
Enam and
Mansell, 2018
pYebF-afcA pAfcA with N-terminal fusion of E. coli YebF replacing N-
terminal signal sequence
This study
pAfcB pAfcA with afcA replaced by B. infantis afcB Enam and
Mansell, 2018
pNanH2 pAfcA with afcA replaced with B. infantis nanH2 Enam and
Mansell, 2018




pBnaG AmpR, pG9-m2 vector with L. paracasei bnaG under con-




pET28:GFP KanR, pT7/LacO:GFP Shis and Ben-
nett, 2013
pET28:mCherry KanR, pT7/LacO:mCherry Enam and
Mansell, 2018




fhuA2 [lon] ompT gal (λ DE3) [dcm] ∆hsdS λDE3 =




E. coli NEB 5-
alpha
fhuA2 ∆(argF-lacZ)U169 phoA glnV44 F80 ∆(lacZ)M15
gyrA96 recA1 relA1 endA1 thi-1 hsdR17
New England
Biolabs
EcN E.coli Nissle 1917, wild type Laboratory
stock




6.3.2 Bacterial culture and growth
For studying population behavior in mixed cultures, competent BL21 (DE3) cells were co-
transformed with pET28:GFP and either pAfcA, pYebF-AfcA, pAfcB, pNanH2, pYebF-NanH2 or
pBnaG by electroporation. After transformation and recovery, single colonies of the transformed
cells were grown in Luria-Bertani (LB) media (1% tryptone, 0.5% yeast extract, 1% NaCl) con-
taining appropriate antibiotics at 37 °C in a shaking incubator. Media was supplemented with
antibiotics at the following final concentrations: 50 mg/ml carbenicillin and 30 mg/ml kanamycin.
Overnight cultures were used to inoculate fresh M9 minimal media (M9 salts, 2 mM MgSO4, 0.1
mM CaCl2 and 0.1% thiamine) and grown to mid-log phase. These cultures were washed by cen-
trifuging and resuspending in M9 media, ensuring that the OD600 were the same for all cultures.
The cultures were used to inoculate fresh M9 minimal media supplemented with the carbohydrate
source. 2’-FL was added to a final concentration of 0.3%, 6’-SL to a final concentration of 0.4%
or lactose to a final concentration of 0.2%. All oligosaccharides were kind donations from Glycom
(Glycom A/S, Denmark). All oligosaccharide concentrations are molar equivalents to 0.2% lactose.
These cultures were then incubated at 37 °C in a rotary shaker (250 rpm) for 24 hr.
6.3.3 Visualizing populations
For visualizing the behavior of the mixed cultures after being challenged with a sole carbon
source, the cultures were diluted in LB and plated onto LB agar plates supplemented with car-
benicillin, kanamycin and isopropyl-β-thiogalactopyranoside (IPTG). The plates were visualized in
a light box illuminated by blue light and imaged using a phone camera under an orange filter.
Experiments with butyrate producing EcN
For monocultures, individual colonies were selected from Luria Broth (LB) plates, inoculated
into 5 ml of LB liquid medium at 37 °C, 250 rpm overnight for seed-culture preparation. The
following day, fresh LB media was inoculated with the seed-culture and grown to mid-log phase
(optical density at 600 nm (OD600), 0.5). The OD600 was measured using the Nanodrop. The
cultures were washed with M9 media to remove residual LB and reconstituted in M9 media. This
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culture was used to inoculate 500 uL fresh M9 minimal media at 1% supplemented with either
0.2% (w/v) glucose, 0.2% (w/v) glycerol, 0.2% lactose, 0.3% 2’-FL or 0.4% 3’-SL. The cultures
were grown in standard microfuge tubes. For mixed cultures, care was taken to ensure the OD’s
of all the monocultures were the same. During inoculation of M9 media with the desired carbon
source with mixed cultures, the final concentration of cells was kept constant.
6.3.4 Butyrate extraction and detection by GC-MS
500 µL of the culture was harvested and 62.5 µL 10% (w/v) NaCl, 62.5 µL acetic acid was added
into the sample. Then 10 µL internal standard (25 g/L valeric acid in ethanol) was added into the
sample followed by 250 µL ethyl acetate. The mixture was then vortexed for 30 s and centrifuged at
14,000 rpm for 10 min. Next, 125 µL of the top organic layer was transferred into a fresh glass tube
and 1.125 mL ethanol:hydrochloric acid (30:1, v/v) was added, vortexed again and then incubated
at 55C for 1 h. Upon completion, additional 0.625 mL ddH2O and 0.625 mL hexane were added and
the mixture was vortexed for 30 s then centrifuged at 2,000 g for 2 min. Finally, the top hexane
layer was collected and then analyzed by GC-MS (Supplementary Figure S.5.7). The butyrate
produced was analyzed on a DB-5MS separation column (30 m, 0.25 mm ID, 0.25 µm, Agilent).
The temperature for GC-MS analysis was initially held at 50 °C for 2 min, ramped up to 200 °C
at 25 °C/min, held for 1 min, and then raised to 315 °C at 25 °C/min, held for 2 min. Helium was
used as a carrier gas and the flow rate was set at 1 ml/min. Standards and samples were analyzed
in triplicate and standard curves were created from 4 different concentrations. Identification of
butyrate by mass spectrometry was completed by comparison with internal standard.
6.4 Results and Discussion
6.4.1 Engineering microbial interaction in two-member synthetic consortia
To demonstrate competition in a two-member system, we introduced two engineered Escheischia
coli strains with different metabolic capabilities to serve as models for two species (Figure 6.1A):
one expressing a phenotype capable of breaking down 2’-FL labeled with a red fluorescent protein
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(mCherry) and the other capable of breaking down 3’-SL labeled with a green fluorescent marker
(GFP). This system, albeit artificial, mimic the features of natural environments. HMOs are the
third most abundant component in human breast milk, with 2’-FL being the most abundant HMO
and 3’-SL being the most abundant acidic oligosaccharide and play a major role in shaping the
infant gut microbiota [13]. These strains can be grown as monocultures only in the presence of the
substrates they can metabolize owing to the harboring of orthogonal glycosidases that cleave the
decorative moieties on HMOs to liberate lactose (Supplementary Figure S.5.5). These E. coli strains
can utilize lactose as a substrate but cannot metabolize the nondigestible 2’-FL or 3’-SL without
the respective glycosidases, fucosidase and sialidase. This simulates the infant gut microbe, B.
infantis, that import HMOs and degrade them intracellularly, unlike B. bifidum or some B. longum
species that degrade them extracellularly [22].
To test how they behaved in a community, the two strains were washed free of any carbon
source and subsequently mixed to form a coculture, and subjected to either 2’-FL or 3’-SL. We
hypothesized that competition for resources in the same niche would force the strain possessing
the ability for consumption to dominate the population i.e., the RFP labeled strains expressing
fucosidase would outcompete the GFP labeled strains due to their ability to hydrolyze the complex
carbohydrates. The two strains were mixed in equal proportions based on OD600 measurements.
As a control, we grew the coculture in lactose and observed a nearly 50/50 distribution of red and
green colonies (Figure 6.2, top panel). When we subjected the coculture to 2’-FL, the colonies were
predominantly red, with only 7% being green. To prove that our results were robust under different
conditions, we repeated the experiment by altering the carbon source that favored the other strain







































































































































































































































































































































We next investigated whether we could demonstrate cooperation. Microorganisms are able to
utilize complex carbohydrates as long as they have the means to transport and hydrolyze them.
Recent studies showed increased cooperativity in microbial communities that helps the population
coexist [23, 24]. This is achieved by external degradation of substrates by microbes that have the
hydrolyzing ability which cross-feeds others lacking the ability to hydrolyze the complex substrate
[25]. We designed a simple community, again composed of two strains, one of which takes up
a substrate to produce a by-product that the second strain can metabolize. In this community
YebF-AfcA/RFP was engineered to secrete the fucosidase to the extracellular media by fusing a
secretion tag to allow for the breakdown of the substrate (2’-FL) ex vivo, making lactose available
to the other strain and acting as a helper (Figure 6.1B). Upon growing the co-culture in 2’-FL,
the altruistic behavior was verified by the emergence of green colonies (Figure 6.2, middle panel).
Here the release of the lactose in the extracellular medium was associated with the ability of the
disadvantaged strain to populate. This mode closely mimics the foraging mechanism of B. bifidum
in infant gut.
Another interesting phenomenon was observed upon long-term culturing of the coculture, a
laboratory analog of a natural system: the rise of social cheaters (Figure 6.1C). We tested the
hypothesis that the beneficiary strains that were benefiting from the altruism of the helper strains
were consuming metabolites without their expenditure of energy or resources, giving them a fitness
advantage. We allowed the coculture consisting of the altruistic and beneficiary strain to grow
for up to 4 days before plating. With increasing time, the green population started to dominate
(Figure 6.2, bottom panel). The cheaters benefited from the hydrolytic activity of the glycosidases
that were secreted by their neighbours without having to expend the energy required to produce
and secrete the enzymes themselves. This strain displacement with the trajectory pointing to fewer
and fewer red colonies from prevailing, was evidence pointing to social cheating.
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Figure 6.2 A summary of the various metabolic interactions demonstrated by the synthetic
communities. (top) With an accessible nutrient like lactose, either strain has
equal probability of colonization and we see a 50/50 distribution. When 2’-FL
is introduced only strains harboring the fucosidase are able to thrive, biasing
the red population; (middle) Culturing in 3’-SL allows the strain harboring a
sialidase (red) to outcompete others. An altruistic strain is capable of extracel-
lular secretion of the sialidase that makes lactose available to the community,
as seen by the emergence of the green population; (bottom) Social cheaters.
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Figure 6.3 Enrichment of target strains in higher order systems. Synthetic communities of
varying orders were grown in lactose or 2’-FL. N=2: AfcA/RFP vs. AfcB/GFP;
N=3: AfcA/RFP vs. AfcB/GFP and NanH2/GFP; N=4: AfcA/RFP vs.
AfcB/GFP, NanH2/GFP and BnaG/GFP. Dotted lines represent expected ra-
tios of unbiased growth, i.e., 1:1 for N=2, 1:2 for N=3 and 1:3 for N=4. Error
bars represent standard error from triplicate measurements.
6.4.2 Engineering higher-order synthetic consortia
The above results indicate that the synthetic communities can be modulated using HMOs ow-
ing to the specificity of glycosidases. We next sought to expand to a system of n>2 strains to
evaluate higher-order interactions. The 2’-FL metabolizing strain was labeled with RFP and the
remainder of the strains harboring other distinct glycosidases were labeled with GFP. For cocul-
tures with n=3 strains, we seeded them at an initial ratio of 1:1:1, and as predicted theoretically,
approximately1/3rd of the population was red when grown in lactose (Figure 6.3). In 2’-FL, the
community was again dominated by the red population. When the altruistic strains were intro-
duced, cooperativity was observed with the appearance of green colonies. This trend was observed
in communities with up to n=4 strains (Figure 6.3).
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6.4.3 Modulation of metabolic pathways using synthetic consortia
Short-chain fatty acids (SCFAs) are major end products of bacterial fermentation in the gut
and play important roles in host health [26]. Butyrate in particular is important for maintenance of
the colonic epithelium, immune regulation and offers protection against diseases, including colorec-
tal cancer and inflammatory bowel disease [27]. Although butyrate is typically produced by gut
microbiota, the levels produced can be greatly affected by a diet that is low in fiber [28]. Studies
have been carried out to stimulate butyrate-producing bacteria through prebiotic approaches [29–
31]. Despite enhancement in butyrate levels, no effect was observed on the population of butyrate
producers, implying different mechanisms of production like cross-feeding on metabolites or inter-
mediate complex carbohydrate breakdown products [32, 33]. To mimic these natural interactions
in engineered communities, we used a previously engineered butyrate producing probiotic strain, E.
coli Nissle 1917 (EcN) (Supplementary Figure S.5.6). We first integrated the ability to hydrolyze
2’-FL into these EcN strains and analyzed for its ability to metabolize 2’-FL to produce butyrate.
As a control, the strains were grown on equimolar amounts of glycerol or galactose. The butyrate
titer from breakdown of 2’-FL was comparable to levels produced from simple carbon sources, 130
mg/L compared to 190 mg/L (Figure 6.4A). No growth was observed in 3’-SL.
We next introduced a second strain, wild-type EcN harboring a sialidase, to form a coculture.
There was no significant drop in the butyrate titers (Figure 6.4B). In this coculture, only the
dominant strain possessed the ability to utilize the carbon source. Some leakage of metabolites
may occur that can allow the competing strain to grow to some extent. When this coculture was
grown in 3’-SL, no butyrate was detected as expected, since the non-butyrate producer harbored
the sialidase. To demonstrate the mechanisms by which probiotic bifidobacteria and prebiotic
administration influence gut metabolism and promote butyrate production, we introduced the
secretion tag to the sialidase on the non-producer. The coculture was grown in 3’-SL and butyrate
was detected (Figure 6.4B). Our results point to mechanisms of synergy that may take place
between these two strains in which the butyrate producer is able to use the lactose produced by
the non-producer thereby promoting butyrate formation.
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Figure 6.4 Engineered prebiotic-probiotic pair. (A) A probiotic E. coli Nissle engineered
to produce butyrate harboring a fucosidase (green) can break down 2’-FL to
produce butyrate, with similar titers when utilizing simple carbon sources like
glycerol or galactose. No butyrate detected when sole carbon source cannot
be hydrolyzed. (B) When mixed with a wildtype non-butyrate producer, the
titers do not drop significantly. No butyrate detected when sole carbon source
(3’-SL) cannot be hydrolyzed, even in the presence of a hydrolyzer. External
degradation of 3’-SL by neighboring microbes cross-feeds the butyrate producer.
6.4.4 Conclusions
With the human microbiome emerging to be a crucial factor in human health status, it is impor-
tant that the microbes, the key players be more amenable. This allows for a deeper understanding
and better targeted strategies towards modulating health and diseases via the microbiome and
nutrition. The overarching goal of synthetic biology is to apply engineering principles to biological
systems to make the outcomes of these manipulation more predictable and as this field matures it
can help translate to better control of the microbiome, nutrition, and host. Natural microbiomes
consist of species with unknown interactions and unpredictable ecological dynamics, and although
the number of organisms are orders of magnitude higher than what we simulated, a bottom-up ap-
proach like this can help understand microbial interactions that drive the dynamics and functions
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of microbial communities. Due to the intimate association between carbohydrate structure and the
specificity of enzymes for carbohydrate linkages, a coupled system as demonstrated here can be
applied to systems with higher levels of carbohydrate complexity or microbial resolution.
6.5 Supporting Information
Figure S.5.5 Growth kinetics of engineered monocultures on HMOs. Growth of pAfcA
on 2’-FL (red) and 3’-SL (yellow) and pNanH2 on 3’-SL (blue) and 2’-FL
(green).
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Figure S.5.6 Genomic integration of butyrate pathway in E. coli Nissle 1917. The genes
frdA, ldhA, adhE and pta were knocked out. Genes atoB, hbd, crt, ter and
atoDA were integrated into the EcN genome.
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Figure S.5.7 Quantification of butyric acid from producer EcN strain. (A) Extracted ion
chromatograms of butyrate (m/z 117), shown at 3.62 mins and internal stan-
dard (valerate) at 4.14 mins. The peak at 117 m/z units is ethyl butyrate.
Different dilutions of the standard and the samples are shown. (B) A stan-
dard curve was created by LC-MS analysis with varying levels of commercial
butyric acid. Error bars represent standard deviations from triplicate mea-
surements.
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CHAPTER 7. CHEMICAL SYNTHESIS OF BIOINSPIRED 2’-FUCOSYL
ISOPROPYL-β-D-THIOGALACTOPYRANOSIDE (2’-FIPTG) AS A NOVEL
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7.1 Abstract
Different chemical and biochemical routes have been taken to synthesize novel inducer molecules.
Here we demonstrate the synthesis of 2’-fucosyl isopropyl-β-D-thiogalactopyranoside (2’-FIPTG), a
close mimic of HMO, 2’-fucosyllactose, using batch and continuous-flow processes. Using genetically
encoded biosensors, we can detect and quantify the substrate, down to millimolar levels. We also
demonstrate the control of protein expression of engineered strains. Such chemical interventions
offer in situ validation tools and has potential as novel inducer molecules and ability to modulate
synthetic communities.
7.2 Introduction
Advances in synthetic biology has allowed us to design and build microorganisms with ex-
ceptional functionalities. This has enabled us to extend these design strategies towards engi-
neering microbial communities which can be more challenging. As emerging biotechnology ap-
plications demand the need for microbial consortia to perform complex functions, approaches to
facilitate single-strain level control need to be developed. Small inducer molecules like isopropyl
β-D-thiogalactopyranoside (IPTG) is ubiquitous for heterologous protein production in inducible ex-
pression systems. This is most commonly associated with the Escherichia coli T7 RNA polymerase
dependent expression system whose expression is tightly controlled by the lac promoter [1]. Another
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example of regulation of gene expression in natural systems is the response of infant-associated bi-
fidobacteria to human milk oligosaccharides (HMOs). HMOs are the third most abundant class of
biomolecules found in human breast milk [2], composed of five different monosaccharides (glucose
(Glc), galactose (Gal), N-acetyl-glucosamine (GlcNAc), fucose (Fuc), and sialic acid (Neu5Ac))
that link together in different orientations, forming more than two hundred unique oligosaccharides
ranging in complexity [3]. Fucosylated HMOs have been shown to inhibit infections by bacteria and
viruses by binding to pathogens themselves or inhibition of binding to cell-surface glycan receptors
[4, 5], with the most widely studied molecules being the histo-blood group antigens or Lewis-like
antigens and 2’-fucosyllactose (2’-FL), the most abundant HMO. Recent studies have demonstrated
the effects of oral supplementation of 2’-FL in altering the composition of intestinal microbiota and
shaping of the intestinal milieu towards resistance to inflammatory diseases like necrotizing ente-
rocolitis and inflammatory bowel disease (IBD) [6, 7]. It is the selective utilization of HMOs by
beneficial gut bacteria that promotes the enrichment of particular species [8]. HMOs are resistant
to enzymatic hydrolysis but the remarkable ability of certain species like bifidobacteria can be
attributed to expression of glycosyl hydrolases like fucosidases, sialidases and hexosaminidases [9],
and oligosaccharide transporters [10].
Earlier, we demonstrated the regulation of growth and protein expression of engineered strains
in mixed cultures using HMOs as inducers. We hypothesized that by emulation of the chemistry
behind “protection” of these molecules against hydrolysis, we could synthesize a novel molecule to
promote selective induction. Inducer release from the enzymatic cleavage of a protected molecule
would enable selective induction of engineered strains. Lactose or IPTG which is a galactose analog,
induces expression of the lac operon in E. coli by inhibiting the action of the lactose repressor LacI,
inducing lac operon transcription [11]. Despite IPTG being a structural mimic of lactose, the
carbon-thiol bond cannot be broken down which keeps the IPTG concentration constant, making
it a more useful inducer than lactose itself, which can be acted upon by ββ-galactosidase.
Here we report the synthesis of a 2’-fucosyllactose analog, with IPTG in place of lactose. This
protected inducer molecule serves as a dormant IPTG: as long as the fucose moiety is bonded, 2’-
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FIPTG cannot bind to the lac repressor and no target gene is expressed. Upon defucosylation by
the fucosidase expressed in engineered strains, IPTG is released and can act as an inducer. Here we
monitored fluorescence of the green fluorescent protein (GFP) under the control of a T7 promoter
for characterization of induction with 2’-FIPTG. One challenge associated with understanding the
structure-function relationship is the gram scale production, separation and analytical identifi-
cation of the molecule. As a result of these challenges, an automated continuous-flow platform
was developed to enable production of sufficient material amenable for high-throughput biological
analyses.
7.3 Results and Discussion
7.3.1 Synthesis of 2’-fucosyl-isopropyl β-D-thiogalactopyranoside
Our primary motivation was to establish a building block strategy and an automated continuous-
flow approach for the production of this target. Synthetic challenges for this strategy included the
target molecule containing key regioselective and stereoselective features, which are the beta iso-
propyl thiol at the anomeric position of galactose, the regiochemistry of the fucose monosaccharide
at the O2 position, and the alpha glycosyl linkage that links together the galactose and fucose
building blocks.
To overcome these challenges, a proper protecting group strategy was implemented for the
successful synthesis of the target. Observing the retrosynthetic analysis, the fucose and galactose
building blocks contain benzyl ether protection, which are orthogonal to multiple chemical con-
ditions used in the synthesis of the building blocks and protected target molecule. The synthetic
strategy also allows for a one-step global deprotection of the benzyl ethers, introduction of other
protecting groups would result in more deprotection steps. In executing this synthetic strategy, we
first turned our attention to the construction of the fucose donor. Propane thiol installation was
performed on the known compound 1, followed by deacylation under the Zemplen conditions and
benzylation to produce compound 3 (Supplementary Figure S.6.3). The benzyl ether protected
fucose thiol donor can also be used for glycosylation. Thiol donors’ wide range of stability under
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acidic and basic conditions make them ideal for synthesis along with their ability to be activated
under various conditions. Penta benzylated fucose donors are known to be more reactive and sta-
ble under glycosylation conditions compared to other protected fucose derivatives. The acyl fucose
donor was also prepared using NBS for thiol removal followed by acylation.
In the construction of the acceptor monosaccharide, the known compound 8 was synthesized
followed by the isopropyl thiol installation and deacylation providing compound 10 (Figure 7.1).
In the construction of the protected disaccharide, multiple attempts were made to link together
the acceptor with the thiol fucose building block using the pre-activation approach. Pre-activation
glycosylation is a very powerful synthetic tool in which a thiol donor can be activated using a
thiophilic reagent followed by glycosylation of a thiol acceptor. This technique takes advantage of
the donor and acceptor thiol reactivity, in which the most reactive thiol (the donor) is activated in
the presence of the thiol acceptor or followed by addition of the thiol acceptor, without the acceptor
becoming activated. As a result, the coupling of the thiol donor with the thiol acceptor can happen
selectively without homocoupling of the acceptor. Using this approach, degradation of the fucose
donor was witnessed before coupling can occur, indicating that the fucose donor was too reactive.
As a result, the acyl fucose donor derivative was explored and coupling was witnessed between
the donor and acceptor with poor yields (8%). Hypothesizing that the Lewis acid BF3·OEt2 is a
poor promoter for activation of acetyl donors; attention was turned to trichloroacetimidates fucosyl
donors. Highly reactive, the tricholoroacetimidate donor reaction gave multiple side reactions and
decomposition of donor. N-phenyl trifluoroacetimidate donors are known for their high stability and
less side products in the course of glycosylation in comparison to tricholoacetimidate donors. As a
result of this, our working hypothesis was that N-phenyl trifluoroacetimidate fucose donor would
give better reaction performance resulting in less side products and better yield than the acetyl
and tricholoracetimidate donor. In the preparation of 6 (TFA fucose donor), initial reactions were
performed using catalytic amount of DBU and excess of N- phenyltrifluoroacetimidoyl chloride in
anhydrous dichloromethane (Figure 7.1B). Noticing sluggish reaction performance, NaH was used
as an alternative base which resulted in better reaction performance. Under further exploration,
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others have noticed poor reaction performance with milder bases only in the preparation of N-
phenyl trifluoroacetimidate fucose donors.
Glycosylation with N-phenyl trifluoroacetimidate fucose donor and IPTG derivative acceptor
resulted in better performance but not satisfactory (40% yield). Longer reaction time resulted
in degradation of product, which could be due to the acid sensitive O-glycosidic fucose bond.
Homo-coupling of the fucose donor was also observed when N-phenyl trifluoroacetimidate is at the
anomeric position, and increased when 3.0 equiv of BF3·OEt2 was used. Under the glycosylation
conditions without the presence of donor, the acceptor fully decomposes when 0.2 equiv of TM-
SOTf is used at -40 °C. With homo-coupling of donor and short-lived acceptor under the reaction
conditions could explain the low yield performance.
With the target synthesis in batch of compound 11, continuous-flow process seemed promising
(Figure 7.1B). Recent continuous-flow process explored in the Pohl research group showcased key
protecting group transformations to produce an advanced monosaccharide building block in two
synthetic steps. Building upon our knowledge of continuous-flow process and automation, a new
continuous-flow platform was built containing Raspberry Pi, HPLC pumps, and self-documenting
MechWolf program that allows for remote operation of the flow system from a computer. We
first sought out to investigate the deprotection of compound 9 under Zemplen conditions using 25
wt% of NaOMe (Supplementary Figure S.6.4). Noticing the viscous nature of 25 wt% NaOMe,
the first hypothesis was faster flow rates should result in better reaction performance due to an
increased turbulence resulting in adequate mixing. Performing the reaction under various flow
rates to determine minimal residence time for full conversion, a trend was notice in which faster
flow rates gave poor reaction performance, resulting in incomplete consumption of compound 9.
This evidence suggests that an increase in residence time (decreased flow rate) is needed for full
conversion (0.1 mL/min, 30 min). When a PTFE helical static mixer (HT-40-1.70-10-PTFE) from
StaMixCo LLC was incorporated, better reaction performance was observed (76.5% vs 48.4% at
























































































































































































Figure 7.2 Detection of 2’-FIPTG using genetically encoded biosensor. (A) 2’-FIPTG is
uptaken by the bacteria and converted to IPTG owing to cleavage by het-
erologous fucosidase. The IPTG activates the LacUV5 promoter in E. coli
BL21 (DE3), producing T7 RNAP, which transcribes GFP under the T7 pro-
moter leading to fluorescent protein expression. (B) Fluorescent detection of
2’-FIPTG. Cells containing pET28:GFP and either pAfcA (green) or an empty
vector control (blue) were induced for 16h with no inducer, IPTG or 2’-FIPTG.
(C) Promoter engineering to improve heterologous fucosidase expression. Five
promoters of varying strengths from the Anderson Promoter collection were
selected and cloned preceding the fucosidase. The fluorescence was measured
after overnight induction at 500 mg/L of 2’-FL. (D) Fluorescent detection of
2’-FIPTG with improved biosensor. Bars depict mean fluorescence (measured
in triplicate by flow cytometry).
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Glycosylation is an important transformation in carbohydrate chemistry and have been widely
explored by the synthetic community. Developing new and approved promoters to activate various
donors have been of continuous research interest. Establishing robust glycosylation conditions with
the potential of scalability is very valuable to the field in order to obtain gram scale quantities
of complex oligosaccharides. With little research performed in the field on glycosylation reactions
under continuous-flow conditions, we sought out to explore the transformation of the batch glyco-
sylation under the newly develop automated continuous-flow platform.
At -40 °C acceptor 10 and donor 6 was streamed together with TMSOTf at a flow rate of 0.4
mL/min for 7.5 min to give 25% of the target 11 (Figure 7.1C). Experiencing the same side reactions
as the batch process, continuous-flow under these conditions did not prove to be advantageous.
Ultimately, a redesigned donor or synthetic approach will be needed for adequate yields of the
protected product.
Removal of the benzyl protecting groups is traditionally performed using Pd/C or Pd(OH)2/C
under H2 pressure. The presence of thiol functionality in the target makes global deprotection
under this condition very challenging due to poisoning of the Pd catalysis resulting in inefficient
deprotection. As a result of this, we set out to explore global deprotection of a test trial substrate
under a continuous-flow process using an H-Cube ProTM Hydrogenation ThalesNano system and
20% Pd(OH)2/C catalysis cartridge. Given the challenges of global benzyl ether deprotection in
the presence of thiol functionality in batch, we wanted to determine if continuous-flow would result
in global deprotection without poisoning the catalysis due to less prolong time interaction of the
substrate with the catalysis. Under various flow conditions, the reaction outcome showed some
consumption of the test substrate with cleavage of the benzylidene ring. When the output was
cycled for multiple passes through the catalysis cartridge to help deprotect the substrate fully,
no additional product formation was witnessed via TLC which could indicate poisoning of the
catalysis. Due to the poor performance of benzyl ether deprotection using the H-Cube ProTM
Hydrogenation ThalesNano system for the test substrate, we set out to investigate other conditions
in batch. Difficulties of benzyl ether deprotection in the presence of thiols and amines due to
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poisoning of the catalysis have been reported. Some researchers took advantage of benzyl ether
deprotection difficulties and found ways to selectively deprotect napthyl protecting groups in the
presence of benzyl ethers and thiols.
As a result of these difficulties, other ways to deprotect benzyl groups have been explored or
avoided all together. One classic approach for benzyl ether deprotection is the Birch reduction.
When Crich and coworkers discovered that Pd/C and Pd(OH)2/C was inefficient at deprotecting
their benzyl ether thiol substrates even under forcing conditions, they turned to ammonia (l) and
sodium and obtained deprotection in high yields. As a result of this, we turned to the Birch
reduction for our test substrate giving rise to 98% of product. Deprotection was obtained to
produce the target molecule 15, which was identified by LCMS and HRMS (Figure 7.1C).
7.3.2 Detection of 2’-fucosyl-isopropyl β-D-thiogalactopyranoside
In our previous work, we reported the detection of 2’-FL using a genetically encoded whole-cell
biosensor: the method uses heterologous expression of AfcA, an 1,2-α-L-fucosidase that is highly
specific to α-1,2 fucose linkages, which upon cleavage generates lactose that can be detected by the
lac operon. A reporter plasmid consisted of GFP under control of the T7 promoter (pET28:GFP).
When lactose entered the system and induced the lac operon, T7 RNA polymerase was transcribed
and expressed GFP. We hypothesized that since IPTG activates the lac operon, we could detect
2’-FIPTG upon defucosylation.
We first tested to see if AfcA was capable of hydrolyzing our molecule of interest to liberate
IPTG and fucose (Figure 7.2A). We grew our biosensing cells to mid-log phase and incubated them
overnight with either no inducer, IPTG or 2’-FIPTG, added at the same molar equivalents to 0.2%
(w/v) IPTG. As a control, we used biosensing cells harboring an empty vector. All cultures were
then analyzed for GFP fluorescence by flow cytometry. Figure 7.2B shows the mean fluorescence
from each induction condition. As expected, IPTG induction led to very high fluorescence with
and without expression of AfcA. In contrast, cells harboring the pAfcA plasmid induced with
only 2’-FIPTG showed over six-fold higher signal than cells not expressing pAfcA. To test for
166
the α-1,2-fucose linkage specificity, we also induced cells expressing AfcB, an α-1,3-fucosidase, that
is responsive to 3-FL. No response was seen upon induction with 2’-FIPTG (data not shown),
confirming the α-1,2-fucose linkage in the synthesized molecule. However, the response of our
biosensor to 2’-FIPTG was not as robust as that of the fucosylated HMO. We hypothesized that
this was a result of inadequate enzyme expression. To overcome this, we created a library of
promoters to regulate the AfcA expression. The gene encoding AfcA is transcribed under the
control of a constitutive promoter from the Anderson promoter library, pJ23110. We selected four
other unique promoters from the library and cloned the transcriptional fusion of AfcA with the
different promoters using Gibson Assembly. We subsequently tested the biosensor by culturing the
transformants at varying induction levels with 2’-FL (0-1000 µM) (Supplementary Figure S.6.5).
Expectedly, the biosensor exhibited improved responsiveness (Figure 7.2C).
However, we did not notice a predictable improvement in the responsiveness as the strength
of the transcriptional promoters increased (Figure 7.2C). To confirm the improved ability of the
biosensor, we induced the culture with 2’-FIPTG. The redesigned sensor was substantially more
responsive compared to the original. We observed a 35-fold increase in fluorescence compared to
the control. Although the signal still was not as strong as with 2’-FL, we saw a major improvement.
These observations raised valid questions regarding the catalytic efficiency and affinity of AfcA
towards this mimic of 2’-FL. This particular fucosidase was identified from intestine-colonizing
bifidobacterial strains for their ability to break down 2’-FL as a substrate [12]. Nagae et al.
performed structural and biochemical analyses to determine the catalytic reaction mechanism of
AfcA which is unique in belonging to GH family 29, but having an inverting mechanism rather
than a retaining one [13]. Inverting enzymes utilize two enzymatic residues that act as acid and
base respectively, while retaining glycosidases utilize a two-step mechanism with a retention of
stereochemistry of the products. The study revealed that although the molecular recognition of
2’-FL by the AfcA catalytic domain is primarily mediated by interactions with the L-fucose and
galactose moieties, but also forms weak hydrogen bonds with the glucose moiety. The O6 hydroxyl
group of glucose forms a weak hydrogen bond with the NH2 of an arginine residue (677) in the
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catalytic site. 2’-FIPTG lacks the glucose moiety resulting in the formation of a limited hydrogen
bonding network that can affect the affinity of the substrate. Interestingly, they also found the
kcat/Km value for 2’-FL to be 7.7-fold higher than that for 2-fucosylgalactose (2FG), that lacks
the glucose moiety at its reducing end. This further explains the lower observed enzyme specificity
for 2’-FIPTG in comparison to 2’-FL.
7.4 Conclusion
In summary, we have demonstrated a platform for synthesis and detection of 2’-FIPTG, a novel
molecule for induction of protein production. This work not only sets the foundation for future work
in oligosaccharide synthesis using a continuous-flow approach but also highlights the importance of
batch synthesis in some cases. Current protocols in organic synthesis are primarily from a batch
process; we anticipate our approach will be useful for the development of more continuous-flow
methods. We successfully designed an improved biosensor for detecting this molecule which can
be implemented for confirmation of the target during synthesis. In addition to serving as a novel
inducer molecule, this could serve as a powerful tool to elucidate the structure-function relationships
of other fucose-containing synthetic molecules or biological molecules, due to its selective cleavage
of specific fucosyl residues from the targets.
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7.5 Supporting Information
Figure S.6.3 Synthesis of n-propyl-2,3,4-tri-O-benzyl-1-thio-β-L-fucopyranoside and acyl
derivative.
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Figure S.6.4 Deacetylation of 2-propyl-2-acyl-3,4,6-tri-O-benzyl-1-thio-β-D-galactopyranoside
under Zemplen conditions under continuous-flow.
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CHAPTER 8. CONCLUSIONS AND OUTLOOK
Taken together, the engineering strategies developed in this work enable a powerful approach
for high-throughput methods of detecting prebiotics and their utilization in modulation of micro-
bial communities. We have demonstrated a linkage-specific, orthogonal detection of ten abundant
human milk oligosaccharides (HMOs), which allows researchers to analyze HMO structures in less
than 6 hrs. Furthermore, this method is robust against crosstalk, allowing parallel sensing of these
glycan structures. Not only does this method enable the high-throughput detection of HMOs, but it
also provides an intriguing platform for optimizing biotechnological production of these molecules.
It is important to note that this technology is not restricted to the context of lactose backbone
upon which this study was based. Rather, the design rules behind this technology can be extended
towards analyzing other complex structures. Further application of this work may be useful for
the design of optimized glycosyltransferases for the creation of complex high-value products or to
engineer improved linkage-specific glycosidases. This tool can enable directed evolution approaches
for mutagenesis and screening of large mutant libraries in a continuous manner in vivo. This will be
especially important in establishing orthogonal glycosidases for detection of more complex HMOs.
To further accelerate the pace of the Design–Build-Test–Learn (DBTL) pipeline for the op-
timization of biosynthetic pathways, we have developed an enzymatic, paper-based assay for de-
termination of the type of fucosylation in glycans. This approach takes advantage of paper as a
low-cost platform with easy patterning to control fluid flow and immobilizing enzymes for detection
of the analytes of interest. This enabled the analysis of fucosylated glycans and glyco-conjugates
similar in magnitude to those obtained using current state-of-the-art methods using significantly
less effort and negligible costs. We have shown that this approach of utilizing linkage-specific gly-
cosidases is suitable for extension to sialylated compounds as well. While we have demonstrated
the concept on paper with purified enzymes, we expect to improve the flexibility of the assay by
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the use of heterologously produced enzymes that would greatly decrease the cost of each assay, as
demonstrated in the fucosylation assay. The sialylation assay, in its present form, enabled us to
detect sialylation in key biological molecules but this can apply to a broad range of applications
ranging from analyzing glycan displays that play roles in host-microbe interactions to food science,
where high-throughput methods to improve production and detection of important oligosaccharide
groups are important. To make this technology more user friendly, a mobile phone app can be
developed which is calibrated for rapid quantification of the sugars of interest. It is expected that
these strategies mentioned above will enable us to expand the current glycan synthesis and analysis
toolbox by enabling directed evolution-based approaches to glycosyltransferase, glycosidase, and
strain engineering. This technology is very promising for diagnostics where highly sensitive detec-
tion of various biomarkers is essential for early disease diagnosis. This assay has high sensitivity
and paired with a colorimetric readout, ease of fabrication and stability can allow identification of
various glycan targets, taking the form of a glyco-barcode assay.
Next, we demonstrated the engineering of communities in which the building blocks are not
gene modules but mixtures of cell populations, to produce a self-regulating, mutually reinforcing,
robust system that performs a given function. It still remains a key challenge in microbial ecology
to predict microbial community assembly and dynamics and hinges upon our understanding of
how organisms compete and cooperate, as they degrade complex carbohydrates. We constructed
an engineered system that enables dynamic regulation of growth and protein expression in mixed
cultures to help understand the dynamics of microbial communities. Our prebiotic strategy offers
a mechanism of orthogonally modulating growth and production of small molecules via prebiotic
supplementation. Excitingly, this synergy between prebiotics and probiotics opens the door for
engineered probiotic strains whose proliferation can be dynamically controlled by the addition of
tailored prebiotics in the context of the gut microbiome.
Lastly, this work has emphasized that unique molecules, either carbohydrate sources or chem-
ically synthesized inducers, can provide a niche for an engineered strain to fill, based upon their
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functional modularity of degradation. This is again due to the tight correspondence between car-
bohydrate structure and the specificity of enzymes for carbohydrate linkages that we have.
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APPENDIX A. STRUCTURES OF GLYCANS




Figure A.2 List of other glycans listed in thesis
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APPENDIX B. DETAILED PROTOCOL FOR DETECTION OF HMOS
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B.1 Abstract
Human milk oligosaccharides (HMOs) are important prebiotic complex carbohydrate compo-
nents of human breast milk. However, optimization of their biotechnological synthesis is limited by
the relatively low throughput of monosaccharide and linkage analysis. Currently, glycans are ana-
lyzed by chromatographic/mass-spectrometric methods with throughput on the order of hundreds
of samples per day without automation. To enable high-throughput screening of HMO structures,
we constructed a whole-cell biosensor that uses heterologous expression of glycosidases to generate
linkage-specific, quantitative fluorescent readout for a range of lactose-core HMOs. The presence of
lactose in milk or in biotechnological processes could lead to false positives, so we demonstrate the
reduction of signal from lactose using different strategies. The throughput of this technique allows
for optimization of manufacture of HMOs, as many reaction conditions or bioreactor parameters
could be assayed in parallel in a matter of hours.
B.2 Introduction
Human milk oligosaccharides (HMOs) are lactose-derived oligosaccharides, usually comprising
three to eight sugar monomers. They have a lactose (Galβ1-4Glc) reducing end and are further elon-
gated by glycosidic links (β1-3- or β1-6-) to glucose (Glc), galactose (Gal) or N-acetylglucosamine
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(GlcNAc). In addition, fucose (Fuc, α1-2- or α1-3-) or sialic acid (Sia or NeuAc, α2-3- or α2-6-)
residues are often added.
Current analysis of oligosaccharides and other carbohydrates is limited in throughput and scope
by the need for chromatographic/mass spectrometric technology, which can take roughly an hour
per sample, not to mention the necessity for expensive equipment, specialized columns and deriva-
tizing agents, and expertise on the operation of these equipment. Rapid optimization of synthesis
of these oligosaccharides is thus limited by the throughput of this slow analytical step.
In this paper, we demonstrate detection of trisaccharide lactose-based HMOs, focusing on 2’-
fucosyllactose (2’-FL), using genetically encoded E. coli biosensors with a limit of detection at
4 mg/L for 2’-FL. An important feature of this biosensor is its ability to distinguish between
isomeric trisaccharides. The design principle is based on the expression of specific glycosidases
in Escherichia coli that liberate lactose from HMOs, the presence of which is detected by the
lac operon, which in turn generates a fluorescent signal. We do this by building a two-plasmid
system, one harboring the linkage-specific glycosidase and the other a fluorescent reporter protein.
This biosensor platform is suitable for high-throughput screening by flow cytometry or micro-
plate reader. We also demonstrate the utilization of the biosensor in detecting 2’-FL produced
by an engineered strain. Within this manuscript, we present three strategies on selective removal
of lactose which can result in false positive signal from the biosensor, given that the engineered
producer strain is grown on lactose. Within a mixed microbial population, the strain capable of
hydrolyzing the carbohydrate source outcompetes the others. We demonstrate here the control
and manipulation of the mixed culture population by exploiting the hydrolyzing phenotype of the
biosensing cells in media with a defined carbohydrate source.
Taken together, the genetically encoded biosensors allow us to detect and quantify HMOs as
well as modulate a mixed population. Due to its high throughput and ease of use, this method




B.3.1 Cell culture and induction conditions
In our experiments, we use three strains: E. coli BL21 (DE3) with an empty vector, E. coli
BL21 (DE3) with plasmids pAfcA and pET28:GFP/RFP, E. coli BL21 (DE3) with plasmids pAfcB
and pET28:GFP/RFP. All strains are grown in Luria-Bertani (Miller) broth (LB) or M9 minimal
media with appropriate antibiotics. Prepare stock solutions of 1,000x kanamycin (50 mg/mL) and
carbenicillin (100 mg/mL) in DI water.
B.3.1.1 Media preparation
3.1.1.1. Prepare LB media by mixing 25 g of LB powder stock with 1 L of deionized (DI) water
and autoclaving the solution at 121 °C for 20 min to sterilize. To prepare LB plates, add 15 g agar
to the LB media before sterilization. When preparing LB media/agar that includes an antibiotic
for selection, wait until the sterilized LB media temperature is below 60 °C, and then add 1 µL of
antibiotic stock for every 1 mL of LB media/agar.
3.1.1.2. For M9 minimal media, prepare separate solutions of 1 M MgSO4 and 1 M CaCl2.
Sterilize the solutions using a 0.22 µm filter. Mix M9 media broth powder with 1 L of DI water.
Autoclave the M9 solution at 121 °C for 15 min. Cool the solution down to 50 °C and add 2 mL
of MgSO4 and 100 µL of CaCl2.
B.3.1.2 Media preparation
3.1.2.1. Prepare LB media by mixing 25 g of LB powder stock with 1 L of deionized (DI) water
and autoclaving the solution at 121 °C for 20 min to sterilize. To prepare LB plates, add 15 g agar
to the LB media before sterilization. When preparing LB media/agar that includes an antibiotic
for selection, wait until the sterilized LB media temperature is below 60 °C, and then add 1 µL of
antibiotic stock for every 1 mL of LB media/agar.
3.1.2.1. For M9 minimal media, prepare separate solutions of 1 M MgSO4 and 1 M CaCl2.
Sterilize the solutions using a 0.22 µm filter. Mix M9 media broth powder with 1 L of DI water.
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Autoclave the M9 solution at 121 °C for 15 min. Cool the solution down to 50 °C and add 2 mL
of MgSO4 and 100 µL of CaCl2.
B.3.1.3 Carbohydrate inducers
3.1.3.1. Stock solutions of the carbohydrate inducers are made at molar equivalents to 20 g/L
of lactose: 29 g/L of 2’-FL and 3-FL.
3.1.3.2. Induce 200 µL of cells with 2.0 g/L final concentration of lactose or 2.9 g/L final
concentration of 2’-FL/3-FL. Incubate at 37 °C with continuous shaking and let cultures grow
overnight.
B.3.1.4 Cell culture
3.1.4.1. The day before the experiment seed 5 mL of medium supplemented with appropriate
antibiotics from a fresh bacterial colony, using sterile technique.
3.1.4.2. Incubate all cultures at 37 °C with agitation at 250 rpm and grow the cultures overnight.
3.1.4.3. Transfer 50 µL of overnight culture into 5 mL fresh LB/M9 media with appropriate
antibiotics.
3.1.4.4. Incubate at 37 °C with continuous shaking and grow until culture has reached OD600
0.5–0.7. At this mid-log phase, the cells can be induced.
NOTE: The genetic circuit contains two parts: a glycosidase gene, afcA or afcB, driven by
a J23110 promoter resulting in constitutive expression cloned into pG9m-2 vector with a signal
sequence of pelB encoded upstream of the glycosidase gene to facilitate periplasmic export, as
well as a fluorescent reporter system containing the T7 promoter driving expression of GFP or
mCherry. The first part is expressed on plasmid pAfcA and the second reporter system on plasmid
pET28:GFP. All cloning was executed in a commercial competent E. coli strain. The final construct
was transformed into E. coli BL21 (DE3). All primers were purchased commercially.
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B.3.2 Measurement of fluorescence and limits of detection
B.3.2.1 Preparation of cells for flow cytometry
3.2.1.1. Transfer the overnight cultures to 1.5 mL tubes and centrifuge at 13, 000 rpm for 1
min.
3.2.1.2. Discard supernatant and re-suspend the pellet in 500 µL of phosphate-buffered saline
1x (PBS) to prepare a single cell suspension and transfer the single cell suspension to 5 mL flow
cytometry tubes.
3.2.1.3. Keep the cells in the dark at 4 °C until running the sample. Run the samples on a flow
cytometer. For best results, analyze the cells on the flow cytometer as soon as possible.
3.2.1.4. Select 488 nm laser to excite GFP and mCherry. Collect FITC and mCherry fluores-
cence levels with a 525/50 nm and with a 610/20 nm bandpass filter respectively.
NOTE: In our representative results, we used a BD FACSCanto Plus RUO (San Jose, CA)
flow cytometer with a solid state 488 nm/20 mW (nanometer/milliWatt) blue laser. We gated cells
for forward and side scatter to avoid aggregated cells and debris. We carried out measurements of
fluorescence for three independent biological replicates maintained under identical conditions. For
each culture, 25,000-40,000 events were collected.
B.3.2.2 Calibrating the biosensor
3.2.2.1. To make a calibration curve, make dilutions of the standard 2’-FL or 3-FL in the range
0-2500 mg/L.
3.2.2.2. Incubate the biosensing cells as described previously in section 1.3. Carry out three
biological replicates for each dilution.
3.2.2.3. Determine the limit of detection (LOD) by plotting the fluorescence output against the
oligosaccharide concentration.
NOTE: Given the variability of arbitrary fluorescence units across experiments, each experi-
ment should include a negative control: biosensing cells that have not been induced.
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B.3.3 Detection of 2’-FL in a producer strain
B.3.3.1 Cultivation of producer strain
For making minimal media, prepare separate solutions of 1 M K2HPO4, FeSO4.7H2O, sodium
citrate and 1 M thiamine. Sterilize the solutions using a 0.22 µm filter. Mix M9 media broth
powder with 1 L of DI water. Autoclave the M9 solution at 121 °C for 15 min. Cool the solution
down to 50 °C and add MgSO4, CaCl2, K2HPO4, FeSO4.7H2O, sodium citrate and thiamine to
final concentrations of 2 mM, 0.1 mM, 12 g/L, 7.5 g/L, 100 g/L and 7.5 µg/L respectively.
3.3.1.1. Start a culture of 2’-FL producing strain, JM109 gwBC-F2, under desired conditions
and let it grow overnight, as described in Baumgartner et al.
3.3.1.2. Subculture at 1% as described earlier in 250 mL of minimal media.
3.3.1.3. To this minimal media add glycerol to a final concentration of 10 g/L and incubate the
culture at 37 °C.
3.3.1.4. When the culture reaches an OD600 of 0.5—0.7 add IPTG to a final concentration of
0.5 mM and lactose to a final concentration of 2 g/L.
3.3.1.5. Incubate at 37 °C with continuous shaking and let cultures grow for 24 hrs.
B.3.3.2 Extraction of 2’-FL
3.3.2.1. Transfer the overnight cultures to 50 mL Falcon tubes and centrifuge at 3500 rpm for
15 min.
3.3.2.2 Discard supernatant and resuspend the pellet in DI water. Repeat the wash step three
times to remove residual lactose and finally re-suspend in 5 mL DI water.
3.3.2.3. To lyse the cell suspension, use a sonicator at 30% power, in 30 s pulses. Keep the cells
on ice at all times.
3.3.2.4. Centrifuge the lysed cells for 25 mins at 5100 rpm. Remove the supernatant, pass it
through a sterile (e.g., 0.22 µm) filter and store it at 4 °C until analysis.
NOTE: The experiment can be paused here by storing the lysate at 4 °C.
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B.3.3.3 Determination of 2’-FL concentrations
3.3.3.1. Determine the concentration of 2’-FL in the cell lysate using HPLC-MS. HPLC analysis
is performed on Agilent Technologies 1100 Series HPLC system coupled to an Agilent Technologies
Mass Selective Trap SL detector using a Luna C18 reversed phase column.
3.3.3.2. Make dilutions of the standard 2’-FL stock solution and the cell lysate samples and run
the LC-MS.
3.3.3.3. Determine peak areas on the chromatograms for each standard and the unknown
samples and create a calibration curve using known concentrations of the diluted standards.
3.3.3.4. Calculate the unknown 2’-FL concentrations of the cell lysate, taking into account the
dilution factors.
B.3.3.4 Validation with biosensor
3.3.4.1 Grow up a culture of 2’-FL biosensing cells and at mid-log phase, induce with cell lysate
equivalent to concentrations of 2’-FL used to make the calibration curve.
3.3.4.2. Run the reactions with cell lysate and standard 2’-FL in parallel.
3.3.4.3. Run the samples on a flow cytometer. Generate a dose-response curve by plotting
the fluorescence output against the oligosaccharide concentration. Compare the response of the
standards to the cell lysate.
NOTE: Strain JM109 gwBC-F2 was obtained from the Sprenger Lab capable of producing
2’-FL at levels of up to 21 g/L using lactose as a substrate. For control, extract cell lysate from
strain JM109 gwBC, which has the fucosyltransferase futC genes deleted. The lysate is passed
through a filter to prevent clogging of the chromatographic column during analysis.
B.3.4 Selective removal of lactose
The biosensing cells are sensitive to lactose and it is desirable for the biosensor to selectively
detect HMOs over lactose. One strategy would include washing of cells as described in 3.2. Three
other strategies are described below:
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B.3.4.1 Treatment with commercial purified β-galactosidase
3.4.1.1 Dissolve lyophilized β-galactosidase to 1000 (FCC lactase) units/mL, in 1 mM magnesium
chloride or use commercial β-galactosidase in solution.
3.4.1.2 To determine the optimum concentration of enzyme needed, grow an inoculum of 2’-FL
biosensing cells and induce with 2 g/L lactose and 2.9 g/L 2’-FL at mid log phase.
3.4.1.3 To 100 µL cultures, add variable amounts of β-galactosidase and let the cultures grow
overnight.
3.4.1.4 As described earlier, measure the fluorescence and calculate the optimum units of enzyme
needed by determining the minimum enzyme concentration to achieve desired attenuation of signal.
3.4.1.5 To 2’-FL producing cells grown for 24 hrs, add optimum units of β-galactosidase and
incubate overnight. Continue with the protocol for determining the 2’-FL titer as described in
section 3.
B.3.4.2 Pre-treatment with LacZ+ Strain
3.4.2.1 Start a 25 mL culture of 2’-FL producing strain and once induced at mid-log phase,
incubate it for 24 hrs.
3.4.2.2 Inoculate an E. coli BL21 (DE3) culture in LB, grow it to mid-log phase and add 50
mL of the culture (2:1) to the 24 hr culture.
3.4.2.3 Incubate at 37 °C for 3 hr. Proceed with the protocol for determining the 2’-FL titer as
described in section 3.
B.3.4.3 Lactose precipitation with ethanol
3.4.3.1 Start a 25 mL culture of 2’-FL producing strain and once induced at mid-log phase,
incubate for 24 hrs.
3.4.3.2 Add two volumes of 100% ethanol to the culture, shake well and incubate for 4 hr. 4.3.3
Centrifuge the suspension at 3500 rpm for 15 min.
3.4.3.4 Collect the supernatant and incubate overnight at 4 °C. This step precipitates the lactose.
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3.4.3.5 Remove the precipitated lactose by passing the solution through a filter paper. The
filtrate is the cell lysate containing the 2’-FL which can be quantified by following step 3.4.
NOTE: The final concentration of ethanol in the cell lysate added to the biosensing cells range
from 0-2 % (v/v), not considering the losses due to evaporation.
B.4 Discussion
We present a new strategy for the linkage-specific detection of human milk oligosaccharides. This
was accomplished by building whole cell biosensors by genetically engineering E. coli which upon
induction with specific glycans respond with a fluorescent signal. The protocol also details on how
the biosensor can be used to detect and quantify HMOs in a metabolically engineered bacterial
strain. Our protocol offers advantages over alternative methods due to its high throughput in
addition to its linkage-specificity compared to chromatographic/MS methods. The low limit of
detection and broad dynamic range allows for the direct measurement of HMOs. Critical steps in
this protocol occur in the preparation of the cell lysate. For ensuring maximum titer of 2’-FL, it
is crucial to provide the optimum conditions. Variabilities in batches may arise due to sonication
parameters or induction times. Care should be taken during characterization of the biosensor. It is
also recommended to run proper controls for all steps in the experiment to ensure consistent results.
One limitation of our protocol is its reliance on lactose for induction which becomes a bottleneck
when lactose naturally present, as in breast milk, or used as the substrate in biotechnological
production of HMOs. We have addressed this with clever strategies to remove the signal to noise
ratio so that the biosensor can selectively detect HMOs over lactose. The genetically encoded
whole cell biosensor presented here will allow optimization for the manufacture of HMOs, as many
reaction conditions or bioreactor parameters can be assayed in parallel in a matter of hours.
